



[Click for updates](#)

Critical Reviews in Food Science and Nutrition

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/bfsn20>

Impact of diet composition on blood glucose regulation

Wendy R. Russell^a, Athanasia Baka^b, Inger Björck^c, Nathalie Delzenne^d, Dan Gao^e, Helen R. Griffiths^f, Ellie Hadjilucas^g, Kristiina Juvonen^h, Sampo Lahtinenⁱ, Mirian Lansink^j, Luc van Loon^k, Hannu Mykkänen^h, Elin Östman^c, Gabriele Riccardi^l, Sophie Vinoy^m & Martin O. Weickertⁿ

^a Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen, UK

^b ILSI Europe a.i.s.b.l., Brussels, Belgium

^c Lund University, Lund, Sweden

^d Université catholique de Louvain

^e Beckman Research Institute of City of Hope

^f Life and Health Sciences, Aston University

^g Coca-Cola Europe, Scientific and Regulatory Affairs Department, Brussels, Belgium

^h University of Eastern Finland, Institute of Public Health and Clinical Nutrition, Kuopio, Finland

ⁱ Danisco A/S Health and Nutrition, Kantvik, Finland

^j Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands

^k Maastricht University, Maastricht, The Netherlands

^l University Federico II, Naples, Italy

^m Kraft Foods, R&D Centre, Nutrition Department, Saclay, France

ⁿ University Hospitals Coventry and Warwickshire and Division of Metabolic and Vascular Health, University of Warwick, Coventry, UK

Accepted author version posted online: 12 Nov 2013.

To cite this article: Wendy R. Russell, Athanasia Baka, Inger Björck, Nathalie Delzenne, Dan Gao, Helen R. Griffiths, Ellie Hadjilucas, Kristiina Juvonen, Sampo Lahtinen, Mirian Lansink, Luc van Loon, Hannu Mykkänen, Elin Östman, Gabriele Riccardi, Sophie Vinoy & Martin O. Weickert (2013): Impact of diet composition on blood glucose regulation, Critical Reviews in Food Science and Nutrition, DOI: [10.1080/10408398.2013.792772](https://doi.org/10.1080/10408398.2013.792772)

To link to this article: <http://dx.doi.org/10.1080/10408398.2013.792772>

Disclaimer: This is a version of an unedited manuscript that has been accepted for publication. As a service to authors and researchers we are providing this version of the accepted manuscript (AM). Copyediting, typesetting, and review of the resulting proof will be undertaken on this manuscript before final publication of the Version of Record (VoR). During production and pre-press, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal relate to this version also.

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and

are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

Impact of diet composition on blood glucose regulation

Wendy R. Russell¹, Athanasia Baka², Inger Björck³, Nathalie Delzenne⁴, Dan Gao⁵, Helen R. Griffiths⁶, Ellie Hadjilucas⁷, Kristiina Juvonen⁸, Sampo Lahtinen⁹, Mirian Lansink¹⁰, Luc van Loon¹¹, Hannu Mykkänen⁸, Elin Östman³, Gabriele Riccardi¹², Sophie Vinoy¹³ and Martin O. Weickert¹⁴

1. Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen, UK; **2.** ILSI Europe a.i.s.b.l., Brussels, Belgium; **3.** Lund University, Lund, Sweden; **4.** Université catholique de Louvain; **5.** Beckman Research Institute of City of Hope; **6.** Life and Health Sciences, Aston University; **7.** Coca-Cola Europe, Scientific and Regulatory Affairs Department, Brussels, Belgium; **8.** University of Eastern Finland, Institute of Public Health and Clinical Nutrition, Kuopio, Finland; **9.** Danisco A/S Health and Nutrition, Kantvik, Finland; **10.** Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands; **11.** Maastricht University, Maastricht, The Netherlands; **12.** University Federico II, Naples, Italy; **13.** Kraft Foods, R&D Centre, Nutrition Department, Saclay, France and **14.** University Hospitals Coventry and Warwickshire and Division of Metabolic and Vascular Health, University of Warwick, Coventry, UK

Correspondance: **ILSI Europe a.i.s.b.l.**

Avenue E. Mounier 83

Box 6 – 1200 Brussels

Belgium

Fax: +32 27620044

Email publications@ilsieurope.be

Abstract

Nutritional management of blood glucose levels is a strategic target in the prevention and management of type 2 diabetes mellitus (T2DM). To implement such an approach it is essential to understand the effect of food on glycaemic regulation and on the underlying metabolic derangements. This comprehensive review summarises the results from human dietary interventions exploring the impact of dietary components on blood glucose levels. Included are the major macronutrients; carbohydrate, protein and fat, micronutrient vitamins and minerals, non-nutrient phytochemicals and additional foods including low-calorie sweeteners, vinegar and alcohol. Based on the evidence presented in this review, it is clear that dietary components have significant and clinically relevant effects on blood glucose modulation. An integrated approach that includes reducing excess body weight, increased physical activity along with a dietary regime to regulate blood glucose levels will not only be advantages in T2DM management, but will benefit the health of the population and limit the increasing worldwide incidence of T2DM.

Keywords: postprandial glycaemia, diabetes, human dietary intervention, insulin resistance, insulin sensitivity

Abbreviations: PPG, postprandial glycaemia; PPI, postprandial insulinaemia; T2DM, type 2 diabetes mellitus; GI, glycaemic index; GL, glycaemic load; GP, glycaemic profile; DF, dietary fibre; HSH, hydrogenated starch hydrolysates; RS, resistant starch; SFA, saturated fatty acid; PUFA, polyunsaturated fatty acid; MUFA, monounsaturated fatty acid; TFA, trans fatty acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; GG guar gum; SCFA short chain fatty acid; IGT, impaired glucose tolerance; IFG impaired fasting glucose; GLP, glucagon-like peptide, GPR G-protein couple receptor

Introduction

Around 366 million people world-wide have diabetes and this is projected to reach 552 million by 2030 (Whiting *et al.* 2011). Diabetes is a leading cause of death in developed countries and is predicted to become epidemic in newly industrialised nations. Additionally, poorly controlled diabetes is a major factor in several serious disorders including macrovascular disease, vision loss, renal failure, neuropathy and amputations (Diabetes Control and Complications Trial Research Group, 1993; Ohkubo *et al.* 1995; UK Prospective Diabetes Study Group, 1998; Huxley *et al.* 2006; Haffner *et al.* 1998; Niskanen *et al.* 1998). Nutritional management of blood glucose dysregulation is a strategic target, as there is mechanistic evidence to suggest that elevated blood glucose levels contribute towards development of type 2 diabetes mellitus (T2DM) (Blaak *et al.* 2012). Moreover, high blood glucose levels, including values that are below the cut-off for the diagnosis of diabetes, have been shown to be associated with an increased risk of cardiovascular events. This relationship applies not only to fasting values but also to other markers of glucose homeostasis, which reflect blood glucose control in the postprandial period (after a glucose load or meal) or in a longer time frame, including both fasting and postprandial conditions over a prolonged period (glycated haemoglobin; HbA1c) (Heianza *et al.* 2011). Adoption of a nutritional approach could deliver a cost-effective T2DM prevention and management strategy, applicable across the population. However, to implement a successful strategy and provide clear guidance, it will be essential to understand the effect of food on the underlying metabolic derangements. Particular foods are implicated with increased or reduced incidence of T2DM and their macro-, micro- and not-nutrient composition along with

their energy content are all considered to be contributors to glucose homeostasis (Figure 1). This comprehensive review will focus on the evidence from human dietary interventions, demonstrating that particular food components have significant and clinically relevant effects on blood glucose regulation.

Search strategy

A systematic and comprehensive review of the literature was undertaken using the highest quality data from the following bibliographic databases: MEDLINE (PubMed) and Web of Knowledge (or Science). These databases were searched for intervention trials investigating the effect of nutrients in postprandial hyperglycaemia in T2DM patients or obese or control subjects with an explicit strategy for identifying data for extraction and summarizing the data. The search was conducted by combination (using Boolean operators) of the search terms of: “postprandial” + “specific macronutrient or other substance” and further refined by adding: “glucose” or “hyperglycaemia” or “insulin sensitivity” or “insulin resistance”. Outputs were restricted to those completed studies only published in English. Terminology and quality of evidence was assigned according to guidelines from Oxford Centre for Evidence Based medicine available at <http://www.cebm.net/?o=1116>. Strategy for identifying data for extraction and summarizing study findings are detailed in Tables 1-9 and include: Type of Study, Food source (including physical characteristics and delivery), Control, Population Group, Methodology, Study Duration, Primary and Secondary Outcomes and References. In addition to inclusion of data regarding PPG, outputs considering impact of dietary components on blood glucose regulation were also

included, as this was considered to be relevant. The **search** exclusion criteria were type 1 diabetes mellitus (T1DM), gestational diabetes, diabetes insipidus, infants and paediatric studies, **although reference has been made to these studies for discursive purposes.**

Impact of macronutrients on blood glucose levels

Dietary carbohydrates and glycaemic control

By promoting sub-clinical inflammation, chronic hyperglycaemia is a major contributor to endothelial damage, providing a link between diabetes and cardio-vascular disease (Ceriello 2004). It has been suggested that oscillatory postprandial glycaemic fluctuations are particularly detrimental in relation to interleukin 6 expression, indicating that foods which release their carbohydrates at a slow rate to the blood are to be preferred. Available intervention studies regarding the impact of dietary Glycaemic Index (GI), or Glycaemic Load ($GL = GI \times \text{the amount of carbohydrates per portion}$) on glycaemic control in subjects with diabetes was compiled in an extensive Cochrane review in 2009 (Thomas and Elliott 2009). Data from 11 intervention studies lasting four weeks or longer were included and subjected to meta-analysis. The over-all conclusion was that low GI diets improved diabetic control and reduced HbA1c to an extent that was comparable to that seen following medication in newly diagnosed T2DM subjects. It was also put forward that a low GI diet may improve whole body peripheral insulin sensitivity (Rizkalla *et al.* 2004), and reduce the number of hypoglycaemic events (Gilbertson *et al.* 2001). Of interest in this context, is that hypoglycaemia may be an additional risk factor for cardio-vascular disease in children with type 1 diabetes, independently of HbA1c (Pena *et al.*

2012). Consequently, carbohydrate foods that promote low but sustained blood glucose levels may be considered advantageous with regard to metabolic control of diabetes and possibly reduce risk of future cardio-vascular events.

One potential point for criticism of the GI concept is that the glycaemic impact of foods may be markedly affected by certain meal components. This has been shown in healthy subjects when adding e.g. certain proteins or lipids to mixed meals (Wolever and Bolognesi 1996). Consequently, adding whey and/or certain amino acids to a meal may substantially reduce the glycaemic excursion in healthy and T2DM (Frid *et al.* 2005; Nilsson *et al.* 2007; Gunnerud *et al.* 2012). However, for foods and meals rich in carbohydrates it appears as if the GI of mixed meals can be predicted from the component foods in healthy subjects indicating that for carbohydrate-rich meals the effects of additive components of GI are minor. This has also been demonstrated in T2DM subjects (Järvi *et al.* 1995; Robert and Ismail 2012). The authors concluded that generally, the single foods were ranked similarly to the mixed meals, supporting the utility of the GI concept also for mixed meals in T2DM (Robert and Ismail 2012).

The GI of foods is influenced by the type and amount of dietary fibre (DF). In a study by Järvi and co-workers (Järvi *et al.* 1999), a four-week intervention was performed in T2DM subjects comparing a high vs. low GI diet, using a cross-over design. The differences in GI of the diets were achieved by manipulating the food structure, thus essentially maintaining the same food composition- including that of the DF, but with different rates of digestion and absorption of the available carbohydrates. It was concluded, that the low GI diet with slow release carbohydrates

lowered the glucose and insulin responses throughout the day and improved the lipid profile and capacity for fibrinolysis, suggesting a therapeutic potential of such a diet in diabetes.

The impact of carbohydrate foods on blood glucose levels is affected by a range of food factors e.g. the type of carbohydrate, the food form, type and amount of DF and the presence of certain food components capable of interfering with the digestive and/or absorptive mechanisms. As for the roles of sugars on glycaemic regulation in diabetic subjects, Wheeler and Pi-Sunyer published a review in 2008, which is still valid (Wheeler and Pi-Sunyer 2008). One of their messages was that adding an amount of sugar up to 10% of total energy to the diet did not negatively influence glycaemic regulation as measured by HbA1c. Another message put forward by the same authors was that high-fructose corn syrup should be considered as sucrose rather than fructose when included in the diabetic diet, since it most often consist of half glucose and half fructose (Wheeler and Pi-Sunyer 2008). Regarding the effects of fructose on glycemic control in diabetes, Cozma *et al.* recently published a meta-analysis (Cozma, Sievenpiper *et al.* 2012). Their aggregated analyses of short-term controlled feeding trials revealed that isocaloric fructose replacement of other carbohydrates (mainly starch and/or sucrose) resulted in clinically significant improvements in glycemic control, without significant effects on insulin, when including both type 1 and type 2 diabetic individuals. In stratified analysis, however, the reduction in glycated albumin and/or haemoglobin was only significant in people with type 1 diabetes. There are certainly trends towards positive outcomes on glycaemia regulation also for individuals with T2DM, but larger and longer trials of higher quality are warranted to establish such associations (Cozma, Sievenpiper *et al.* 2012). However, it should be taken into account

that a higher intake of sucrose or fructose should not be recommended to people with diabetes or other conditions of impaired blood glucose regulation, in view of a potential detrimental impact on body weight, insulin sensitivity and blood lipids (Johnson *et al.* 2009; Stanhope *et al.* 2009).

Effect of carbohydrate structure and properties

Chemical composition as well as the degree of gelatinization may play a role for glycaemic responses to starchy foods. Most of the knowledge concerning the differences in PPG to carbohydrates and carbohydrate foods stem from studies in healthy subjects. Information regarding the GI features of carbohydrate foods is available in the international GI tables (Atkinson *et al.* 2008), where studies in diabetic subjects are presented.

Amylose-amylopectin ratio in starch: In a study of parboiled rice of a high-amylose (27%) variety, it was suggested that a combination of the high-amylose rice and formation of stable amylose-lipid complexes of the complex II type were responsible for substantial lowering of GI (Larsen *et al.* 2000). Furthermore, the results indicated that the severity of processing during parboiling may be an important tool to reduce the GI of rice. In bread products, the use of wheat (Hallstrom, Sestili *et al.* 2011), barley (Liljeberg, Åkerberg *et al.* 1996) and corn (Granfeldt, Drews *et al.* 1995) varieties with elevated amylose contents have been reported to have increased contents of resistant starch (RS). In addition to the formation of an enzyme-resistant starch fraction in bread with elevated amylose content, a slowly digestible starch fraction appears to be formed, as judged from decreased PPG in healthy subjects. When combining the use of cereal varieties with elevated amylose contents with baking at pumpernickel conditions (low

temperature-long time), the formation of RS is promoted even more (Hallström *et al.* 2011). Some suggested mechanisms behind the increased RS-formation are: a compact structure that results in restricted starch swelling and gelatinization, formation of amylose-lipid, or amylose-protein complexes, or encapsulation of gelatinized starch between layers of RS.

Native vs. gelatinized starch: Processing by heat is common in the manufacturing of cereal products. During heat treatment the starch is more or less completely gelatinized. However, although the degree of gelatinization may be rather low, the rate of amylolysis and thus the glycaemic response appear to increase rapidly. This has been shown for e.g. oat flakes in healthy subjects (Granfeldt, Hagander *et al.* 1995; Granfeldt, Eliasson *et al.* 2000). A possibility to lower the glycaemic response to starchy food is by using native starches, rather than gelatinized or partly gelatinized forms. The use of uncooked corn starch to prevent nocturnal hypoglycaemia in diabetic children is one example of how glycaemic features of a food product can be optimised by a conscious choice of ingredients. Thus, in a study by Kaufman and Devgan (1996), the frequency of nocturnal and before breakfast hypoglycaemic episodes was significantly reduced in type 1 diabetic subjects after having uncooked corn starch included in an evening snack, compared with their normal snack without such starch.

Chemically modified starch: Hydrogenated starch hydrolysates (HSH) are used as bulking and non-reducing sweetening agents in for example, candy and gums. When comparing the glycaemic response to glucose and two varieties of HSH in both insulin- and non-insulin dependent diabetic subjects as well as healthy individuals, the glycaemia was significantly

reduced after the HSH-meals (Wheeler, Fineberg *et al.* 1990). Furthermore, when combining all the subjects, a difference in glycaemic responses between the two HSH-varieties could be detected, pointing in favour of the HSH with shorter hydrogenated saccharide chains (HSH 5875).

Intact botanical structure or physical form: As mentioned above, studies in T2DM subjects have clearly indicated the importance of food structure on PPG (Järvi *et al.* 1995). In an earlier study (d'Emden *et al.* 1987) the glycaemic responses to equi-carbohydrate portions of bread made from either white wheat or semolina, respectively, or spaghetti made from white and whole grain wheat, respectively were tested in a group of non-insulin dependent diabetic subjects. No differences were found in glycaemic response between either forms of bread, or either type of spaghetti, but both bread products showed higher glucose responses than the spaghetti meals. Thus, it was concluded that the physical form of the food was a major factor influencing the glycaemic response. Similarly, maintaining the botanical structure of cereal kernels (Liljeberg *et al.* 1992) as well as rice (Panlasigui and Thompson 2006) intact has been shown to reduce PPG. The importance of botanical structure has recently been investigated in two semi-acute studies in healthy subjects (Nilsson *et al.* 2008a; Nilsson *et al.* 2008b). Interestingly, it was revealed that the semi-acute benefits of barley kernels on daylong glycaemia was lost when the kernels were milled into flour and consumed as porridge (Nilsson *et al.* 2008a). On the other hand, by mimicking the content of DF and RS in barley kernel bread, a flour based bread product improved glucose tolerance in an overnight perspective study (10 hours), compared with a white wheat bread (Nilsson *et al.* 2008b). The benefits observed on semi-acute glucose tolerance are

mediated by mechanisms emanating from colonic fermentation of the indigestible carbohydrate fraction.

In an earlier attempt to investigate the potential of depletion and disruption of dietary fibre, Haber *et al* (Haber *et al.* 1977) compared the postprandial blood glucose levels in healthy subjects after intake of apples, fibre-disrupted apple purée and fibre-free apple juice. The results showed that plasma glucose rose to the same extent after all three meals, but there was a substantial difference in the rebound fall with the apple juice causing a marked hypoglycaemia between approx. 60-120 min after the meal. The postprandial glucose response after intact apples did not fall below the fasting level at any time point. In addition to its detrimental effect on glucose regulation, the disruption and removal of fibre also favoured faster and easier ingestion, which may promote over-eating of such products.

Course of glycaemia: After reviewing the literature regarding effects of available carbohydrates on blood glucose levels in diabetic patients we conclude that there are surprisingly few studies focusing on carbohydrate foods. However, as reported in the International tables of glycaemic index (Atkinson, *et al.* 2008), there is a high correlation between GI-values derived from studies performed in healthy and diabetic subjects, respectively. Therefore, much of the information on the glycaemic response of different foods gained in healthy people may be relevant also to predict the impact of these foods on blood glucose levels in diabetic patients. Another important aspect to consider when discussing acute and semi-acute glycaemia is to acknowledge not only the GI-value of a food product but the course of glycaemia. In 2009, the concept of glycaemic

profile (GP) was introduced and is defined as the duration of the incremental postprandial blood glucose response divided by the blood glucose incremental peak (min mM^{-1}) (Rosen *et al.* 2009). Rye products generally produced high GI-values despite low insulin indices. When examining the course of glycaemia after rye products, there was a sustained blood glucose increment beyond the 120 min used for GI-calculations, resulting in a higher than expected GI-value. It has been suggested that GP is more strongly correlated with insulin response (both insulin index and insulin incremental peak) compared with GI (Rosen *et al.* 2009; Rosen, Östman *et al.* 2011). Taking into account also the avoidance of hypoglycaemia after high-GP food, this GP measure describing the course of glycaemia may also be interesting to apply to PPG and glycaemic regulation in diabetic subjects.

Dietary fibre and glycaemic control

Dietary fibre has traditionally been defined as edible plant polysaccharides and lignin naturally occurring in foods, and which are resistant to hydrolysis by human digestive enzymes (Trowell 1976). Later definitions of fibre in nutrition have also included isolated fibres from food raw materials or edible synthetic carbohydrates that are resistant to digestion and absorption in the human small intestine but are partly or completely fermentable in the colon, and display beneficial physiological effects, i.e. improved bowel function, blood cholesterol and blood glucose attenuation (Raninen *et al.* 2011). These beneficial effects, i.e. improvements in metabolic and disease control, are essentially based on the dominant attributes of different fibre types when passing through the gastrointestinal tract.

Types of dietary fibre: Dietary fibre is chemically a heterogeneous group of compounds with variable molecular size and different physicochemical properties, such as water solubility, viscosity, cation exchange properties, organic acid absorption and water-holding capacity (Eastwood *et al.* 1992; Guillon *et al.* 2000). Several classifications for fibre have been established (Slavin *et al.* 2009, Raninen *et al.* 2011) in which the traditional one is based on water solubility dividing fibre into soluble (pectins, gums, mucilages) and insoluble (cellulose, hemicelluloses, lignin) fibre types. Although solubility *per se* is an essential determinant of the physiological responses, viscosity and fermentability are likely to play a more pronounced role in the physiological benefits in humans.

Major dietary sources of DF are whole grain cereals, legumes, vegetables and fruits, which include a wide variety of different types of fibre. The strongest and most consistent effects on reduced risk of developing T2DM are observed with diets high in insoluble and often only moderately fermentable cereal fibre, whereas fruits and vegetables, which are more important sources for soluble/fermentable fibre do not show any protective effect on this outcome in meta-analyses of prospective cohort studies (Weickert *et al.* 2006; Schulze *et al.* 2007; DeMunter *et al.* 2007).

However, most commonly used fibre supplements are primarily soluble fibre types, such as guar gum, glucomannan, xanthan gum, psyllium, pectin, alginate, β -glucan concentrates and various fibre combinations (Vuksan *et al.* 2009, Papathanasopoulos and Camilleri 2010). To date, it has not been investigated in long-term controlled human interventions whether these agents

influence the risk of developing T2DM. Due to the diversity of DF in natural fibre sources it is generally recommended to adhere to these food sources to improve daily DF intake, thereby also assuring the additional nutritional qualities of a healthy diet. Even so, it is usually challenging to meet the recommended DF intake. Therefore, fibre supplements can play an important role in increasing DF intake but also in managing daily glucose levels both in healthy individuals and individuals with impaired glucose metabolism. However, although the potential health benefits of different types of DF are known, there is still no clear consensus about the ideal composition and proportion for the consumption of the major sources of DF.

Amount of fibre: In addition to the type of DF, the amount of DF plays a marked role in acute glycaemic and insulinaemic responses. For example, findings from studies using β -glucan have showed that four grams of soluble β -glucan appear to be a threshold for a significant reduction in postprandial glucose and insulin responses in healthy individuals (Granfeldt *et al.* 2008, Juvonen *et al.* 2011), whereas in T2DM subjects somewhat lower amount may be sufficient (Tapola *et al.* 2005). However, the amount of fibre does not appear to explain the lower postprandial insulin response observed after a meal containing rye bread as compared to white wheat bread (Juntunen *et al.* 2003). Furthermore, the food matrix, i.e. liquid or solid food forms in which fibre is consumed and macronutrient content in mixed meals can markedly affect postprandial glucose and insulin responses, as described elsewhere in the text.

Postprandial trials on fibre foods and supplements: Recently, an obvious reappearance in the research interest on the role of DF in the regulation of glycaemic and insulinaemic responses in

individuals with T2DM has emerged. Until now, a large number of postprandial studies involving different fibre types, either in the form of unprocessed foods or as isolated DF supplements, have been carried out in people with T2DM (Table 1 & 2). Additionally, data is derived from a few longer-term dietary interventions in which either modified total diets or individual fibre products were served to individuals with T2DM for periods from two weeks up to one year (Table 2).

The randomized short-term trials clearly indicate that especially soluble fibres with viscous properties (e.g. glucomannan, guar gum, psyllium, β -glucan) exert acute improvements in glucose and insulin responses in individuals with T2DM (Table 1). Guar gum (GG), an example of such a water-soluble non-starch polysaccharide, has shown both glucose and insulin lowering properties (Ellis *et al.* 1991; Golay *et al.* 1995), and psyllium fibre administered to NIDDM patients immediately before breakfast and dinner lowered postprandial glucose by 14% at breakfast and 20% at dinner compared to placebo. A second meal effect was observed at lunch (served 5 h after breakfast), where glucose was 31% lower compared with placebo. Psyllium's ability to reduce glycaemia was not affected by the patients mode of therapy (diet-treated or on oral hypoglycaemic agents) (Pastors *et al.* 1991).

In the majority of these postprandial studies, relatively high doses of single DF types have been used to produce significant postprandial reduction especially in glucose but also in insulin responses when compared with no or low-fibre test products (Östman *et al.* 2006, Tappy *et al.* 1996, Kim *et al.* 2009). The significant effects of DF on postprandial glucose are not necessarily

accompanied with similar insulin responses which may partly result from the DF type or amount used in these studies. Insoluble cereal fibre is non viscous/gel-forming and therefore, do not directly influence GI. However, cereal fibre has been shown to improve whole-body insulin sensitivity, an effect that can be observed as short as 24 hours after intake i.e. second meal effect (Weickert *et al.* 2005; Nilsson *et al.* 2008). Since many low-GI foods are also rich in insoluble cereal fibre interpretation of the results is often not straight forward (Weickert *et al.* 2009). It is also worth to note that the food matrix in which the fibre is incorporated may actually modulate the postprandial responses (Brennan 2005) so that the effect of the added fibre may be partly masked (Sels *et al.* 1992). These examples highlight the difficulties when trying to investigate the metabolic effects of single components of complex foods (Weickert *et al.* 2012).

Semi-acute effects: The presence of intrinsic DF in certain cereal products has been shown to influence PPG in healthy humans at a subsequent meal, through a mechanism involving gut fermentation (Nilsson *et al.* 2008a,b). Consequently, provision of evening meals based on barley kernel bread significantly lowered blood glucose excursions at a subsequent standardized breakfast compared with an evening meal with white bread. Also, markers of inflammation and insulin resistance were lowered, and the incretin hormone GLP-1 increased at breakfast (Nilsson *et al.* 2008a). In the case of barley, similar benefits on over-night glucose tolerance could be mimicked by adding a similar amount and ratio of barley DF and RS to white wheat bread. In contrast, a flour based whole grain barley evening meal failed to induce benefits the subsequent morning (Nilsson *et al.* 2008c), indicating a role of the combined barley DF and RS in case of the kernel based barley meal. Additionally, ingestion of boiled cereal kernels from rye and barley in

the morning, not only reduced the acute PPG, compared with white bread, but additionally improved PPG at two subsequent standardized meals in healthy subjects. It is clear that cereal products rich in intrinsic DF may improve day-long PPG (Nilsson *et al* 2008b). It is put forward that whereas the benefits of certain kernel based products in the 10 h perspective is related to gut fermentation; benefits from breakfast to lunch are probably mediated by the latent features of the breakfast meal. In contrast to barley, most rye meals are characterized by improved PPG, including both flour based and kernel based products (Rosen *et al.* 2011). Interestingly, in the case of rye, evidence of rapid gut fermentation is present as judged from early postprandial increment in breath hydrogen excretion. Taken together, the botanical structure and intrinsic composition of fermentable substrates seems important for PPG at subsequent meals.

Longer-term interventions: Evidence from longer-term DF interventions in T2DM subjects shows that relatively high fibre levels can be consumed when given as unprocessed foods (legumes, vegetables, whole grain cereals) without causing gastrointestinal problems (Table 2). Both de Natale *et al.* (2009) and Chandalia *et al.* (2000) noticed improved glycaemic control in T2DM subjects after feeding 4-6 weeks of diets supplying 50-53 g of fibre per day. No adverse side effects were reported. Studies lasting 6–12 months with diets containing low-GI foods have produced rather negative results on fibre effects, showing no effect on glycated hemoglobin levels in T2DM subjects (Jenkins *et al.* 2008; Wolever *et al.* 2008).

An 18-week randomised controlled intervention in healthy subjects having increased intake of insoluble cereal fibre, supplemented by cereal fibre extracts twice daily, significantly improved

whole-body insulin sensitivity, as measured using euglycemic-hyperinsulinemic clamps (Weickert *et al.* 2011). A previous intervention by Pereira and colleagues showed comparable results when investigating the effects of whole grain diets on whole-body insulin sensitivity (Pereira *et al.* 2002). Interestingly, the consumption of insoluble resistant starch appears to result in comparable effects on insulin sensitivity in healthy adults (Robertson *et al.* 2003; Robertson *et al.* 2005) and in subjects with metabolic syndrome (Johnston *et al.* 2010). It is worth noting that in some studies different sorts of moderately fermentable insoluble cereal fibre and insoluble resistant starch resulted in comparable improvements of estimated insulin sensitivity 24 hours after consumption of the cereal. Fibre/starch extracts consumed in a second meal test, indicated that colonic fermentation with the production of SCFA was not the key factor conveying improved insulin sensitivity in this setting (Weickert *et al.* 2005). Longer-term studies with isolated fibre products have yielded conflicting results. Schwab *et al.* (2006) gave 24-30 g soluble fibre in the form of sugar beet pectin or synthetic polydextrose mixed with drink for three months to 66 subjects of which 10 were T2DM subjects, the rest having problems with glucose metabolism (IGT, IFG). They found no effect on fasting or on PPG after a standardized breakfast. However, supplemental fructooligosaccharides (FOS), 20 g/d, given to subjects with idiopathic hyperglycaemia reduced the glucose excursions (Sorensen and Johansen 2010).

Possible mechanisms of fibre effects: Soluble viscous fibres play a marked role in managing postprandial glucose and insulin levels via forming viscous gels by absorbing water and thereby reducing gastric emptying (Marciani *et al.* 2001, Darwiche *et al.* 2003, Sanaka *et al.* 2007) and rate of glucose absorption (Dikeman *et al.* 2006). Other suggested explanations why high

viscosity products reduce PPG are altered intestinal motility, slower diffusion rate of starch digestion products and reduced α -amylase accessibility (Leclerc *et al.* 1994). In addition, it has been shown *in vitro* that guar gum inhibits α -amylase in a direct, non-competitive way in the first stage of the enzymatic degradation of starch (Slaughter *et al.* 2002).

The mechanisms underlying the association of increased fibre intake with improved glycaemic control in longer term studies (Hu *et al.* 2001; Schulze *et al.* 2007; Livesey *et al.* 2008) are not fully understood, but may include also colonic effects such as short chain fatty acid production by colonic fermentation and concurrent liberation of phenolic compounds in addition to the above mentioned altered postprandial gastric and small intestinal functions (Lappi *et al.* in press; Vitaglione *et al.* 2008). Improved whole-body insulin sensitivity by insoluble cereal fibre was suggested to be related to interference with the digestion and/or absorption of dietary protein and consequently reduced amino acid induced activation of the mammalian target of rapamycin (mTOR) S6 kinase 1 (S6K1) signalling pathway (Weickert *et al.* 2006, 2011) that directly results in insulin resistance both in animal models and human intervention studies (Krebs *et al.* 2002; Tremblay *et al.* 2005; Um *et al.* 2004). Further mechanisms that may be involved could be cereal-fibre induced binding of bile acids and fibre-induced effects on gut hormones and metabolite profiles but this will need to be investigated in future studies.

Thus, these results suggest that acute consumption of foods rich in soluble fibre or soluble fibre supplements is beneficial especially for the postprandial glycaemic control but also for the insulinaemic response. However, the number of studies investigating the effects of DF on acute

glucose and insulin responses in T2DM subjects is still limited which limits interpretation of the effects. Moreover, the relevance of acute postprandial effects needs to be studied with regard to long-term health outcome; in this context also insoluble dietary fibre seem to play an important role by improving glucose and/or insulin homeostasis (Blaak *et al.* 2012).

Gut microbiota and glycaemic control

The gut microbiota is increasingly considered as a symbiotic partner for the maintenance of health. The human gut harbours vast numbers of bacteria, around 10^{11} bacterial cells per mL of contents (Qin *et al.* 2010, Diamant *et al.* 2010). Specific strains of gut bacteria can be classified upon their sequence analogy into phyla, gender, species and sub-species. More recently, Arumugam *et al.* have “clusterized” the gut microbiota of individuals from different countries and continents into three “enterotypes” identified by the variation at the level of one of the three following genera: *Bacteroides*, *Prevotella* and *Ruminococcus* (Arumugam *et al.* 2011). Long term dietary pattern may influence the proportion of those enterotypes, the *Prevotella* group being associated with carbohydrates and fibre intake (Wu *et al.* 2010). *Bifidobacterium* spp. represents an important and complex group of bacteria whose presence is often associated with beneficial health effects (Boesten and de Vos, 2008, Turrone *et al.* 2009, Delzenne and Cani 2011). The *Bifidobacterium* genus was poorly represented in the faecal samples of diabetic subjects compared with healthy individuals (Wu *et al.* 2010). Another interesting bacterial species is *Faecalibacterium prausnitzii*, which level is found to be decreased in subjects with diabetes compared to non-diabetic obese subjects. Additionally, *F. prausnitzii* is negatively associated with inflammatory markers measured in the serum of obese individuals before and

after roux- and Y-gastric bypass surgery (Furet *et al* 2010). Related to the gut microbiota, components of the bacterial membrane have been incriminated in the development of inflammation and this is associated with lipopolysaccharides (LPS), present in gram negative bacteria (for review, see Cani and Delzenne, 2011). The level of serum LPS is increased approximately two fold in obese subjects and those with diabetes, or fed a high-fat diet. This is considered to involve processes including an increase in chylomicron formation (upon high fat diet feeding), a decrease in gut barrier integrity, and/or a decrease in alkaline phosphatase activity, which is the enzyme responsible for the cleavage of the LPS in the intestine. It is likely that the metabolic function of the gut microbiota could be important in the control of blood glucose, even if much of the data has been mainly obtained in animal studies. The promoting effect of the gut microbiota on intestinal glucose absorption has been suggested in germ free mice colonized with the saccharolytic *Bacteroides thetaiotaomicron*: this effect supports the fact that events occurring upon bacterial fermentation may have an effect in the upper part of the gut, and can modulate digestible carbohydrates availability (Hooper *et al.* 2001). The short chain fatty acids produced upon carbohydrate fermentation in the gut, reach host tissues where they may act as metabolic regulators or substrates. If propionate acts as gluconeogenic substrate in the liver, it is also able, at least *in vitro*, to counteract gluconeogenesis from lactate, thereby decreasing hepatic glucose production. Dietary supplementation of butyrate can prevent and treat diet-induced insulin resistance in mouse. The mechanism of butyrate action is related to promotion of energy expenditure and induction of mitochondria function (Gao *et al.* 2009). On the other hand, the G-protein coupled receptors; GPR43 and 41 are both expressed in endocrine L cells in the colon, and when activated by their physiological ligands, the short chain fatty

acids, they promote proglucagon expression, GLP-1 secretion, and thereby could control insulin secretion and glucose homeostasis (Tolhurst *et al.* 2012).

If the gut microbiota plays a role in the control of glycaemia, it would be interesting to modulate the gut microbiota composition. The transplantation of gut microbiota from diabetic animals to germ free mice transfers the diabetic and obese phenotype, thereby suggesting that the characteristics of the gut microbiota of diabetic individuals *per se* could play a role in the metabolic response to diet, and that gut microbial transfer is effective (for review, Delzenne *et al.* 2011). The proof of this concept has recently been shown in humans. An allogenic faecal transplantation assay was performed from a non lean male donor to individuals with a metabolic syndrome, and this “treatment” was shown to improve glucose tolerance and insulin sensitivity after six weeks. Specific changes in the gut microbiota composition were associated with the improvement of health (Vrieze *et al.* 2012). It is clear that dietary approaches influence the composition of the gut microbiota in humans and for this reason, the following sections will cover the potential interest of prebiotics and probiotics to control blood glucose levels.

Prebiotics and blood glucose regulation

Among dietary fibre, some oligo- and polysaccharides exhibit prebiotic properties, a concept originally described by Gibson and Roberfroid (1996) and recently revisited at the initiative of the ILSI prebiotic task force (Roberfroid *et al.* 2010). This “prebiotic concept” is defined as the selective stimulation of one or a limited number of microbial genus(era)/species/strain(s) in the gut microbiota that confer(s) health benefits to the host. Inulin-type fructans were the first

studied prebiotics that have repeatedly demonstrated the capacity to stimulate the growth of bifidobacteria in both animals and in humans. Even if other bacteria may be promoted or modulated on fructan administration, there is no proof that the bifidobacteria are responsible *per se* for the health effect of fructans, the bifidogenic effect appears as the “microbial signature” of those prebiotics. Other oligosaccharides such as galactans, arabinoxylans and glucans have now been considered as dietary fibres with prebiotic properties (Delzenne *et al.* 2011).

The modulation of gut microbiota by using dietary prebiotics in the control of blood glucose homeostasis has been evaluated in experimental animal models of hyperglycaemia, associated or not with obesity (streptozotocin treatment rats, obese leptin deficient or leptin resistant mice of rats, high fat/ and or high glycaemic index diet). The data have been detailed in a previous paper (Roberfroid *et al.* 2010). A decrease in postprandial or post-oral glucose tolerance test is observed in most of the models. The implication of gut peptides such as an increase in L cell differentiation leading to an increase portal GLP-1 may be involved in this effect, as shown in high fat fed mice or rats (Delzenne *et al.* 2011), or more recently in ob/ob mice (Everard *et al.* 2011). Data obtained in high-fat fed mice treated with fructan-type prebiotics revealed an improvement of hepatic insulin sensitivity and a decrease in fasting insulinemia that correlated with the increase in caecal *Bifidobacteria* (Cani *et al.* 2008). A more detailed genomic analysis of the gut microbiota in ob/ob mice treated with fructans as prebiotics highlighted novel bacteria that could be associated with the improvement of gut endocrine function (L cell number), such as *Faecalibacterium praustnitzii* or *Akkermansia muciniphila* (Everard *et al.* 2011). The increase in GLP-2 by L cells occurring in prebiotic-treated mice could, in turn, reinforce the gut barrier

integrity and thereby decreases inflammation in the liver tissue. This effect also contributes to improved glucose metabolism (Cani *et al.* 2009). However, in the Profimet study whole-body insulin sensitivity (Weickert 2011) was significantly improved independent of various markers of colonic fermentation, SCFA profiles in faecal samples, and dominant groups of the gut microbiota (Weickert *et al.* 2011), indicating that further factors were involved in conveying improved insulin sensitivity upon the consumption of insoluble cereal fibre.

Few papers have been published, which have focused on the influence of prebiotics on glucose homeostasis in humans (Table 3). Luo *et al.* (1996) were the first to show that 20 g of short chain fructans given for four weeks in healthy subjects decreased basal hepatic glucose production, but had no detectable effect on insulin-stimulated glucose metabolism. In T2DM subjects, no significant modification of glucose homeostasis (plasma glucose level or hepatic glucose production) occurred in prebiotic-treated patients (Luo *et al.* 2000). In a similar study conducted in hypercholesterolemic patients, fructan-prebiotics reduced the PPI response, but the clinical relevance of this effect remains unclear (Giacco *et al.* 2004). A two-week supplementation with 16 g/day inulin-type fructans, *versus* the same amount of maltodextrin as placebo, was able to increase GLP-1 production, and to lessen postprandial glucose response after a standardised breakfast (Cani *et al.* 2009a). Increases in gut peptides have also been shown in obese individuals treated with prebiotics. This effect was related to improvement of satiety, but the relation with glucose homeostasis was not reported in this study (Reimer *et al.* 2009). Glycaemia was not significantly modified in obese individuals subjected to low-calorie diet completed with Jerusalem artichoke concentrate containing oligofructose as prebiotic, whereas an improvement

of HOMA-IR was observed in treated obese adult women (Antal *et al.* 2008). If there are some positive effects of a prebiotic intervention, there is a lack of information relating the improvement of glucose response and to changes in gut microbiota composition and/or activity in humans or in diabetic/obese subjects. Those studies are needed to evaluate the relevance of microbiota in the management of glucose homeostasis.

Probiotics and blood glucose regulation

A number of observations have led to speculation that probiotics, defined as “live microbes which, when administered in adequate amounts, confer a health benefit on the host” (Fao/Who; 2002), may have potential benefits in the maintenance of healthy glucose metabolism. However, despite encouraging pre-clinical studies, the clinical research in this field is still only starting to emerge. In this review no human clinical studies assessing the effect of probiotic bacteria specifically on postprandial glycaemia were identified. However, a limited number of clinical studies addressing the effect of probiotics on related outcomes such as fasting glycaemia and insulin resistance were identified.

Some studies have investigated the effect of probiotics on fasting glycaemia. Moroti and co-workers (Moroti *et al.* 2012) reported that consumption of probiotics and fructo-oligosaccharides reduced fasting glycaemia in elderly subjects with T2DM, whereas consumption of a placebo product did not. Similar results on probiotics were reported by Ejtahed and co-workers (Ejtahed *et al.* 2012, Ejtahed *et al.* 2011), but Chang and co-workers (Chang *et al.* 2011) and Schaafsma and co-workers (Schaafsma *et al.* 1998) did not observe reduced glycaemia in their interventions.

Probiotics combined with dietary counseling have also been suggested to improve glucose regulation during pregnancy (Laitinen *et al.* 2009). Probiotics may also regulate glucose by targeting insulin action; Andreassen and co-workers (Andreassen *et al.* 2010) reported an improvement in insulin sensitivity in diabetic and non-diabetic volunteers following consumption of probiotics. A bilberry drink with oatmeal fermented with probiotics has also been suggested to lead to reduced insulin demand upon glycaemic response (Granfeldt and Bjorck, 2011). In addition to human studies, several animal studies have yielded promising results on the efficacy of probiotics in the maintenance of healthy fasting and postprandial blood glucose levels, and related outcomes (Amar *et al.* 2011; Andersson *et al.* 2010; Chen *et al.* 2011).

Dietary protein and blood glucose regulation

High protein diets appear to have beneficial effects on weight loss, body composition and certain blood lipids, at least in the short term (Hesssion *et al.* 2009). Satiating effects of dietary protein, a reduced choice of foods, and an aversion against dietary fat in the absence of carbohydrates have all been attributed to better weight loss with high protein diets (Weickert *et al.* 2005). Lowering the percent protein of the diet from 15% to 10% increases total energy intake (Gosby *et al.* 2011), further indicating that a higher intake of dietary protein may help to reduce energy intake. In a recent review, it is concluded that dietary protein by acting on satiety and energy expenditure in negative energy balance may prevent weight cycling effects (Westerterp-Plantenga *et al.* 2012), indicating a beneficial role on weight regulation. Furthermore, a combination of high-protein and low glycaemic load foods, in a hypo-caloric diet, significantly

increased insulin sensitivity and decreased markers of inflammation in overweight and obese women with polycystic ovary syndrome (Mehrabani et al 2012). Insulin resistance following amino acid infusion has been reported in healthy humans (Tremblay et al 2005). One of the mechanisms of protein-induced insulin resistance appears to be inhibition of glucose uptake through phosphorylation of downstream factors of the insulin signaling cascade by the translation initiation factor serine-kinase-6-1 (S6K1) (Tremblay *et al.* 2005). On the other hand, it has been put forward that branched-chain amino acids (BCAA), in particular leucine, may help to counteract “anabolic” resistance” which may increase availability of AA for muscle protein synthesis, reduce muscle protein breakdown and enhance glucose disposal to help maintain blood glucose homeostasis in T2DM (Manders et al 2012). Recent data on metabolomic profiling in obese adults has suggested associations between BCAA and future risk of T2DM (Newgard *et al.* 2009), whereas the opposite has been found in youth (Michaliszyn et al 2012). In fact in youth increased plasma AA concentrations were positively associated with beta-cell function. In animal models particularly the intake of BCAA appears to lead to unfavorable metabolic effects including insulin resistance, although in rodents the background of a high fat diet is required to promote these negative effects (Newgard *et al.* 2012).

Longer term intake of high protein diets in human has been shown to result in whole-body insulin resistance (Weickert *et al.* 2006; Linn *et al.* 2000), associated with up-regulation of factors involved in the mammalian-target-of-rapamycin (mTOR)/S6K1 signalling pathway (Weickert *et al.* 2006; Linn *et al.* 2000), increased stimulation of insulin and glucagon within the endocrine pancreas, stimulation of gluconeogenesis (Weickert *et al.* 2006; Linn *et al.* 2000), and

high glycogen turnover (Weickert *et al.* 2012; Linn *et al.* 2000). Furthermore, protein induced deterioration of insulin sensitivity has been observed in humans under conditions of restricted fat intake (30% of energy intake), both on whole-body and liver level, as measured using euglycaemic hyperinsulineamic clamps combined with stable isotope techniques (Weickert *et al.* 2011). Interestingly, the way of protein administration seems to be of importance, and supplementation of insulin resistant rats with leucine through gavage, that is intermittent feeding, significantly lowered fasting glycaemia compared with continuous administration through the drinking water (Zanchi *et al.* 2012).

In the short-term, these unfavorable effects on insulin resistance could be compensated by high protein diet induced weight loss, and, at least in physically active people, an increase of the lean muscle mass that is also mediated *via* the mTOR/S6K1 pathway. In the Diet, Obesity and Genes (DiOGenes) European multicentre trial with 548 completers, maintenance of weight loss was marginally better with the high protein diet despite controlled conditions, with no significant difference between groups in the full model (Larsen *et al.* 2010). Furthermore, DiOGenes revealed that both a high protein intake or increased intake of high-GI carbohydrates may increase low-grade inflammation (Gögebakan *et al.* 2011), which could be further related to worsening of whole-body insulin resistance (Möhlig *et al.* 2006). In further agreement that high protein-diets may have deleterious effects on glucose metabolism, a recent large prospective cohort with 10-years follow-up revealed that consuming 5% of energy from animal protein, but also from total protein at the expense of fat or carbohydrates increases diabetes risk as much as 30% (Sluijjs *et al.* 2010). Furthermore, low carbohydrate high protein diets, used on a regular

basis and without consideration of the source of proteins or the nature of carbohydrates is associated with increased risk of cardiovascular disease (Lagiou *et al.* 2012), thereby suggesting a link between high-protein Western diets, cardiovascular risk and T2DM. Given these concerns further research is advised before high protein diets should be routinely introduced as a tool in the treatment of patients with T2DM or at risk of developing diabetes. However, in subjects with intact beta cell function protein/amino acid induced insulin resistance may be compensated by the also observed amino acid mediated increase in insulin secretion, as discussed in the next paragraph.

Amino acid induced insulin secretion

In a state of impaired glucose tolerance or T2DM, endogenous insulin secretion shows multiple abnormalities. Secretory defects include an attenuated early insulin secretory response to glucose, reduced ability of the β -cell to fully compensate for the degree of whole-body insulin resistance, impaired glucose sensing ability of the β -cell, and a shift to the right in the dose-response curve between glucose and insulin secretion, all of which are indicative of a progressive insensitivity of the β -cell to glucose (Polonsky *et al.* 1996). These defects involve glucose-sensing and signaling pathways in the β -cell. Even though insulin secretion in response to the prevailing glucose concentration may be blunted in T2DM subjects, insulin secretion in response to other stimuli remains functional (van Loon *et al.* 2003). Besides glucose, amino acids can also act as potent stimuli for the secretion of insulin from the pancreatic β -cell (Newsholme *et al.* 2005). *In vitro* studies using incubated primary islet cells or β -cell lines have described strong insulinotropic properties for arginine, leucine, isoleucine, alanine and phenylalanine (Blachier *et*

al. 1989 Floyd *et al.* 1963, Lajoix *et al.* 2001, Malaisse, 1991, Pipeleers *et al.* 1985, Schwanstecher *et al.* 1998, Sener *et al.* 1981., Xu *et al.* 2001, Salehi *et al.* 2012). The various mechanisms by which these amino acids promote and/or enhance insulin secretion from the pancreatic β -cell are diverse and have not yet been fully elucidated (Newsholme *et al.* 2005). In the presence of glucose, amino acids like arginine seem to be able to stimulate insulin secretion by depolarizing the plasma membrane (Blachier *et al.* 1989). The latter results in the opening of voltage activated Ca^{2+} channels, resulting in the influx of Ca^{2+} , which triggers insulin exocytosis (Newsholme *et al.* 2005). Other amino acids tend to induce their insulinotropic properties by activating the Ca^{2+} channels, through their co-transport with Na^+ (Sener *et al.* 2002). Furthermore, similar to glucose mediated insulin secretion (Dean and Matthews, 1970), intracellular catabolism of the metabolizable amino acids in the pancreatic β -cell will increase the intracellular energy status (ATP/ADP ratio), which closes ATP-sensitive K^+ channels, leading to the depolarization of the plasma membrane. (Brennan *et al.* 2002, Dunne *et al.* 1990, Newsholme *et al.* 2005). In addition, leucine-induced insulin secretion is mediated both through its oxidative decarboxylation, as well as its ability to allosterically activate glutamate dehydrogenase (Newsholme *et al.*; 2005 Xu *et al.* 2001). The latter has also been reported for other amino acids, like phenylalanine (Kofod *et al.* 1986). A simplified overview on some of the proposed mechanisms by which amino acids are likely to stimulate insulin secretion in the pancreatic β -cell is provided in Figure 2.

In accordance with the *in vitro* data on incubated β -cells, *in vivo* studies in humans have shown increased plasma insulin concentrations following the intravenous infusion of amino acids in

both healthy (Floyd *et al.* 1966, Floyd *et al.* 1970) and T2DM patients subjects (Floyd 1968). In line with those findings, nutritional studies in humans already reported the synergistically stimulating effect of the combined ingestion of carbohydrate and protein on plasma insulin concentrations in the 1960s (Pallotta and Kennedy, 1968, Rabinowitz *et al.* 1966), which were later confirmed in both healthy (Nuttall *et al.* 1985) and T2DM subjects (Gannon *et al.* 1998, Gannon *et al.* 1992, Nuttall *et al.* 1984). A series of studies trying to define the *in vivo* insulinitropic potential of the ingestion of various free amino acids and protein in combination with carbohydrate, report a mixture containing a protein (hydrolysate) with the addition of free leucine to be most potential (van Loon *et al.* 2000a, van Loon *et al.* 2000b). The latter was later shown to allow a 2-4 fold greater increase in postprandial insulin release in both healthy and T2DM subjects when compared with the ingestion of carbohydrate only (Manders *et al.* 2008, Manders *et al.* 2006, Manders *et al.* 2005, van Loon *et al.* 2003). Reduction in PPG was observed following intake of whey and soy protein with or without supplementation with amino acids (isoleucine, leucine, lysine, threonine and valine) in healthy volunteers. This reduction was mediated by an early postprandial insulinaemia (PPI) response and correlated with presence of plasma GLP-1 (Gunnerud *et al.* 2012). Increased plasma amino acid concentrations was also shown to be positively associated with β -cell function relative to insulin sensitivity in adolescents (Michaliszyn *et al.* 2012)

The insulinitropic properties of amino acids, and leucine in particular, may be of relevance as a means to stimulate endogenous insulin release and, as such, to improve postprandial glycaemic control in T2DM subjects (Manders *et al.* 2006, van Loon *et al.* 2003). In agreement, various

studies have reported lower postprandial glucose concentrations in both healthy, normoglycemic and T2DM subjects following co-ingestion of protein (concentrate/hydrolysate) and/or free amino acids (Gannon *et al.* 1998, Gannon *et al.* 1992, Gannon *et al.* 2001, Nuttall *et al.* 1985, Nuttall *et al.* 1984; Frid *et al.* 2005). The greater postprandial insulin response following protein and amino acid co-ingestion has been proven functional, stimulating blood glucose uptake, and reducing post-prandial hyperglycaemia in T2DM subjects (Manders *et al.* 2005). Co-ingestion of a small amount of protein hydrolysate and leucine with each main meal can be applied to improve 24 h glycemic control by reducing the prevalence of postprandial hyperglycaemia (Manders *et al.* 2006) despite a higher energy intake. Protein and/or amino acid ingestion strongly stimulates postprandial insulin release in both healthy and T2DM subjects and, as such, can strongly affect postprandial glycaemic control. Dietary intervention strategies to improve PPG should not only consider the glycemic load of a meal, but should also consider the protein/amino acid content of the meal.

Dietary fatty acids and blood glucose regulation

A significant positive correlation exists between circulating free fatty acid level and insulin resistance in tissues. Twenty years ago, Storlien *et al.* (Storlien *et al.* 1991) reported that high saturated fat fed rats developed insulin resistance; whereas those fed with diets high in n-3, with a low n-6/n-3 ratio, maintained insulin action at normal levels. Subsequent studies of platelet membrane phospholipid fatty acid content in Indian Asians who are at increased risk of metabolic syndrome showed a greater proportion of n-6 polyunsaturated fatty acid (PUFA) linoleic acid, and arachidonic acid in combination with a reduced proportion of the n-3 long

chain (LC)-PUFAs, eicosapentanoic acid (EPA), and docosahexaenoic acid (DHA) in Indian Asians than in whites (Lovegrove *et al.* 2004). These effects have variably been attributed to PUFA-mediated alterations of the membrane phospholipid characteristics, such as fluidity (Rustan *et al.* 1997) or through the saturated fatty acid (SAFA)-driven accumulation of ceramide and diacylglycerol, which inhibit Akt/PKB activation. Latterly, an increase in ceramide content in skeletal muscles of obese insulin resistant humans (Adams *et al.* 2004) and in subjects who showed insulin resistance after lipid infusion (Strackowski *et al.* 2004) ends further support to its role, possibly through alterations in lipid raft formation and stability (Xu *et al.* 2001) or increased reactive oxygen species (ROS) generation from mitochondrial uncoupling. In vitro experiments have confirmed that the presence of the monounsaturated fatty acid, oleate, can divert palmitate away from ceramide synthesis and prevent ceramide accumulation and insulin resistance (Gao *et al.* 2009, Gao *et al.* 2012) Since dietary fat and the resulting plasma fatty acids profiles are co-related, dietary intervention is predicted to influence insulin resistance.

A systematic analysis of the literature for studies reporting on the impact on blood glucose and insulin of interventions on fatty acid intake in the diet of adult humans with either obesity or T2DM has been undertaken here. We have identified 20 relevant studies for inclusion in systematic review, of which three considered fatty acid length and degree of esterification (Scalfi *et al.* 1991, Li *et al.* 2008) four examined n-3 PUFAs (Zambon *et al.* 1992, West *et al.* 2005, Brady *et al.* 2004, Kelly *et al.* 2012) three studies examined PUFAs generally (Li *et al.* 2010, Madigan *et al.* 2000, Jans *et al.* 2012); 14 investigated effects of cis-MUFA (West *et al.* 2005, Li *et al.* 2010, Madigan *et al.* 2000, Thomsen *et al.* 2003, de Natale *et al.* 2009, Sloth *et al.* 2009,

Paniagua *et al.* 2007, Manning *et al.* 2004, Piers *et al.* 2003, McCargari *et al.* 1998, Christiansen *et al.* 1997, Lefevre *et al.* 2005, Lopez *et al.* 2011, Lerman-Garber *et al.* 1994, Jans *et al.* 2012) three considered trans-MUFA (de Natale *et al.* 2009, Christiansen *et al.* 1997, Lefevre *et al.* 2005) with seven describing effects of SAFA (Thomsen *et al.* 2003, Manning *et al.* 2004, Piers *et al.* 2003, Christiansen *et al.* 1997, Lopez *et al.* 2011, Devaraj *et al.* 2008, Rivellese 1996). In total, dietary effects on post-prandial glucose or insulin were reported in 689 participants. Key features of these studies are reported in Table 4. Overall, there was no effect of varying triacylglycerol, diacylglycerol or chain length on insulin resistance in study participants although some benefits for lipid metabolism were noted. In contrast, closer examination of PUFA intervention studies showed mixed results; one study reported a decrease in PPI concentration (n=10, 12 weeks PUFA intervention) whereas a second reported no benefit (n=18, US T2DM subjects, single PUFA meal) a third (n=11, T2DM subjects in Ireland, two weeks PUFA intervention) reported higher PPI concentrations after compared with post-MUFA diets and a fourth reported improved AUC over 6 hours for glucose and insulin after PUFA and MUFA compared to SFA (n=10, Dutch insulin resistant, single meal). The variability in duration of dietary change may be significant in determining effect, with benefit being observed in the study with longest intervention. In the two studies that described an investigation of trans-MUFA, one did not show any significant difference to MUFA in outcomes and the second showed comparable effects to a saturated fatty acid diet. This is consistent with a review by Thompson *et al.* (Thompson *et al.* 2011) that there is very little convincing evidence that habitual exposure to dietary trans-fatty acid as part of a standard western diet has a significant contribution to risk of diabetes or insulin resistance. However, studies in FABP2Thr54 carriers (at increased risk for

T2DM complications) have shown increased postprandial glucose following trans-MUFA challenge compared to non-carriers of this allele (Lefevre *et al.* 2005). The majority of studies identified systematically in this present review have described cis-MUFA interventions on insulin resistance involving 277 subjects in 12 studies. Only 24 subject interventions showed no significant benefit, with the remaining 10 studies of 253 participants describing significant reductions in either post-prandial glucose and/or insulin compared to control diets. Taking the systematic analysis of dietary fatty acid modulation together strongly supports the benefit of replacement of fats with MUFAs in the diet of T2DM or obese insulin-resistant subjects for the improvement of their glucose/insulin metabolism.

Impact of micronutrients on blood glucose levels

Dietary vitamins and glycaemic control

Micronutrients are nutrients required in small quantities for a whole range of physiological functions, but which the organism itself cannot produce. Micronutrients include dietary trace minerals, which are generally less than 100 mg day⁻¹ and vitamins. Vitamins, organic molecules that are vital for normal physiology in any organism, are known to improve health when supplemented during specific deficiency states. However, less is known of the clinical value for supplementing to improve the outcomes of diseases that are associated with lower plasma vitamin levels. Concerns exist that vitamin supplementation for health benefit may be distributed according to a bell-shaped curve, where deficiency contributes to disease but excessive vitamin intake may also have adverse health outcomes for some individuals. However, the association

between vitamin E and all cause mortality is now disputed (Gerss J, 2009). A number of clinical trials are registered presently that are investigating vitamin supplementation in early diabetic states to prevent onset of T2DM, or in T2DM subjects to improve outcome measurements such as HbA1c level. A limited number of studies have completed which describe vitamin effects on PPG or PPI and these are summarised and discussed.

The complex of B vitamins serves as cofactors principally associated with metabolism and circulating plasma levels of B vitamins are reduced in some diabetic populations (Page *et al.* 2011, Mitri *et al.* 2011). Thiamine (vitamin B1) is an essential coenzyme for the transketolase enzyme and the dehydrogenase complexes for pyruvate, α -ketoglutarate and branched-chain keto acids which is at lower plasma concentration in T2DM (Page *et al.* 2011). Benfotiamine, a lipid-soluble allithiamine derivative that has better intestinal absorption and improved bioavailability than thiamine, has been shown to afford postprandial benefit on vascular function following meals rich in advanced glycation end-products in T2DM. Plasma glucose levels were lowered in the benfotiamine supplemented group but not significantly in the postprandial period after and AGE meal (Stirban *et al.* 2006), but the effects of benfotiamine on PPG were significant after a cooked meat meal (Stirban *et al.* 2007). The pharmacologic effects of niacin (nicotinic acid; vitamin B3) on cholesterol lowering were first reported in 1955 (Altschul *et al.* 1955). It is potent in lowering fasting triglycerides and postprandial triglycerides, however, extended-release niacin increased postprandial insulin concentrations by 54% by 2 h after a high-fat meal indicating a decrease in insulin sensitivity (Plaisance *et al.* 2008). Nevertheless, there remain some significant benefits of niacin for management of cardiovascular complications and the most

recent summarised evidence suggests that the cardiovascular benefit outweighs the reduction in glycaemic control (Goldberg *et al.* 2008, Bays *et al.* 2011). However, it was observed that treatment with high dose, extended-release niacin did not reduce the risk of cardiovascular events (including heart attacks and stroke) in people with heart and vascular disease receiving intensive statin therapy (Boden *et al.* 2011). The cofactor, biotin (vitamin B7) works in synergy with insulin and independently increases the activity of glucokinase. No studies meeting the inclusion criteria for this review were identified using biotin supplementation alone. However, in moderately obese subjects with T2DM and with impaired glycaemic control supplemented with chromium and biotin combination for four weeks, glucose levels decreased at 1 hour and 2 hours and glucose area under the curve and fructosamine level were significantly decreased (Geohas *et al.* 2007).

As a lipid soluble vitamin whose levels are expected to correlate to an extent with lipid levels, the interpretation of the association that exists between plasma vitamin D and diabetes is complicated (Muscogiuri *et al.* 2011). Nevertheless, daily intake of a vitamin D-fortified yogurt drink (500 IU vitamin D3), either with or without added calcium, improved glycemic status in T2DM patients measured as HOMA-IR (Nikooyeh *et al.* 2011). In contrast, supplementation with cholecalciferol did not improve glycaemic control in T2DM whose serum 25-hydroxyvitamin D levels were in the normal range at baseline (Jorde *et al.* 2009). Similarly, non-T2DM subjects with lower than normal plasma vitamin D levels did not show any difference in glucose homeostasis post glucose tolerance test (Tai *et al.* 2008). Using ^2H NMR analysis of monoacetone glucose (MAG) after tracer administration to understand what effect vitamin D3

may have on hepatic glucose metabolism revealed no changes in the percentage contribution of glycogenolysis (O'Sullivan *et al.* 2011). At present there is a lack of evidence to support any intervention with vitamin D on PPG was compounded by the early termination of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial due to concerns over increased cardiovascular events with rosiglitazone (Punthakee *et al.* 2012).

High plasma and cellular nutrients promote the formation of reactive oxygen species (ROS) from membrane NADPH oxidase and mitochondria. It has been proposed that ROS play an important role in insulin resistance and therefore vitamins as dietary antioxidants may act as important mitigants of metabolic stress, promoting glucose and fatty acid utilisation. Antioxidants frequently act in concert, at least in vitro, each operating within defined redox couples and transferring radicals to yield less reactive/damaging products. The principal dietary antioxidants include a number of vitamins (C-ascorbate, E-tocopherols and A-carotenoids) which are essential for human health, and phytochemicals such as lycopene. Recently, we have undertaken a meta-analysis and shown that HbA_{1C} levels were significantly reduced by antioxidant supplementation, suggesting that antioxidants may have some benefit in protecting against the complications of T2DM (Akbar *et al.* 2011). Our analysis showed that vitamin C or E supplementation did not affect plasma glucose or insulin levels, and here we have supplemented these studies by examining the effect of antioxidant vitamins on postprandial glucose/insulin.

Four studies (Evans *et al.* 2003; Carroll and Schade 2003; Nappo *et al.* 2002; Neri *et al.* 2005) were identified that met inclusion criteria for the study investigating antioxidant effects in 77 subjects with all studies incorporating vitamin C, three also including vitamin E and one also including N-acetyl cysteine. Summary information is shown in Table 5. Supplement duration varied from immediately prior to the test fatty meal up to 14 days of supplementation prior to meal test. None of the studies reported any benefit on plasma glucose excursions in the postprandial period following antioxidant intervention. More recent interest in vitamin E has been directed towards gamma tocopherol as the active constituent which is reported to have anti-inflammatory and gene regulatory effects. (Masterjohn *et al.* 2012) have investigated effects of vitamin E supplementation enriched with (500 mg day⁻¹) gamma tocopherol on PPG in 12 healthy, normoglycaemic, college students. They did not see any benefit for AUC glucose or insulin following five-day ingestion of a supplement enriched in γ -tocopherol

Dietary minerals and blood glucose regulation

Deficiencies of several dietary minerals (such as chromium, magnesium, and zinc) have been reported in T2DM subjects. As there is no evidence of beneficial effects of mineral supplementation on diabetic subjects without underlying deficiencies, the following review will be focused on the evidence of three most reported micronutrients on glucose control (Table 5).

Chromium. Chromium is a trace mineral which plays an important role in whole body glucose homeostasis by enhancing the binding of insulin to insulin receptor (Cefalu and Hu, 2004).

Beneficial roles of chromium supplementation on glucose metabolism have been demonstrated in T2DM subjects. For example, chromium supplementation (500 µg/d chromium picolinate) for four-months in T2DM subjects showed a significant reduction of fasting and postprandial glucose levels (Anderson *et al.* 1997; Cheng *et al.* 1999) and this beneficial effect existed after chromium supplementation for a ten-month period. Moreover, an acute chromium supplementation at 400 µg and 800 µg to a white bread meal showed a substantial reduction in PPG in young, apparently healthy adults compared with the white bread meal supplemented with a placebo (Frauchiger *et al.* 2004).

Magnesium. Magnesium is a mineral which plays important roles in glucose transport and therefore blood glucose metabolism. A reduced plasma magnesium levels has been often reported in subjects with T2DM. A previous study in young diabetes subjects in Bangladeshi showed that more than half the subjects were hypomagnesemic (Khan *et al.* 1999). Furthermore, a recent cross sectional study showed lowered mean magnesium intake, urine magnesium, plasma magnesium and erythrocyte magnesium in T2DM subjects with poor glucose control (Sales *et al.* 2011). However, because the lack of randomised interventional studies, the role of magnesium in hyperglycaemia in T2DM subjects is not clear and future studies are required.

Zinc. Zinc is a mineral plays important roles in the synthesis and insulin sensitivity (Roth *et al.* 1981; Park *et al.* 1986; Brun *et al.* 1995). Previous studies have shown that plasma and tissue zinc concentrations in humans and animal models with T2DM are lower than in non-diabetic

subjects due to the increased urinary zinc excretion by uncontrolled diabetes (Kinlaw *et al.* 1983). Supplementation of zinc is found to be beneficial in alleviating the hyperglycaemia of *ob/ob* and streptozotocin-induced diabetic mice models (Chan *et al.* 1998; Chen *et al.* 2000). Also, a randomised study evaluated the effect of zinc with other antioxidants on blood glucose in human diabetic subjects on long-term follow-up. They showed that oral zinc sulfate (22 mg/day) supplementation with a multivitamin/ mineral preparation (vitamin A, vitamin D3, vitamin E, magnesium, manganese, copper, and selenium) for a four-month period significantly reduced both fasting and postprandial glucose levels in previously diagnosed (for at least two years) subjects from Sri Lanka with T2DM compared to the placebo group (Gunasekara *et al.* 2011). Another study in *ob/ob* mice also showed that administration (by gavage) of arachidonic acid plus zinc significantly increased glucose disposal in *ob/ob* mice and effectively decreased blood glucose levels in obese mice from acute treatment (30 min; 3 h) to up to 14 days prolonged treatment (Hwang *et al.* 2002). Further human studies are required to fully evaluate the effect of zinc supplementation alone on glucose metabolism in diabetic subjects.

Impact of phytochemicals on blood glucose regulation

Phytochemicals are plant secondary metabolites broadly classified according to the pathway from which they are derived. Very few studies have directly attributed specific phytochemical as to having an effect on PPG. Much of the data discussed concerns the observation that a phytochemical-rich food has been effective in modulating the glycaemic response and the foods include; berries, nuts, soy, cinnamon, seaweed, tea, ginseng, beans, chocolate and the herbal

extract 'salacia' (Tables 6-8). The phytochemicals associated with fibre are an important and likely effective group and this has been discussed above. The most widely studied phytochemical rich foods studied for their effect on postprandial metabolism are berries, nuts, cocoa and beverages (tea and coffee). This is due to their strong epidemiological association of these products with cardiovascular health.

The compounds that appear to be of particular importance are phenylpropanoid-derived and comprise predominantly the flavonoids and phenolic acids (Table 6). Many preclinical and *in vitro* studies have shown these molecules can attenuate the postprandial glycaemic response, improve acute insulin secretion and insulin sensitivity and these have been extensively reviewed (Hanhineva *et al.* 2010). No human studies to date have demonstrated a direct effect of the flavonoids or phenolic acids on PPG. However, resveratrol, a phenylpropanoid-derived stilbene found in grape skins has been shown to reduce plasma glucose and improve insulin resistance in volunteers with T2DM, when administered in a capsule (Brasnyo *et al.* 2011). The seed extract of grapes also had an effect on blood glucose regulation by lowering fructosamine in T2DM volunteers (Kar *et al.* 2009). In this study an improvement in endothelial function, antioxidant status and C-reactive protein (CRP) was described. Other soft fruits found to decrease plasma glucose levels were fig (Serraclara *et al.* 1998), sea buckthorn berries (Lehtonen *et al.* 2010) and mixed puree containing blackcurrant, bilberry, cranberry and strawberry (Torrönen *et al.* 2010). Again, no direct effect of an individual phytochemical could be attributed. Few humans studies have explored vegetables as a potential source of phytochemicals which could effect PPG. A Flaxinius species extract was found to have an acute effect postprandial glucose levels in healthy

male volunteers (Visen *et al.* 2009). Another particularly phytochemical rich plant source found to effect PPG in healthy volunteers was seaweed (Goni *et al.* 2000). Seaweed is also a rich source of vitamins, minerals and amino acids and the causative effect needs further investigation.

Of the foods containing these phytochemicals, flavan-3-ol rich chocolate and tea are widely studied. In healthy and IGT volunteers (with no symptoms of diabetes) chocolate had an effect on blood glucose levels when in response to an OGTT (Grassi *et al.* 2005, 2008), although no effect was observed on insulin sensitivity measured by the glucose clamp method in mild-moderate hypertensive volunteers (Muniyappi *et al.* 2008). Tea is the second most commonly consumed beverage worldwide after water (Table 8). Results of epidemiological studies have suggested that consumption of tea (mainly green tea) could lower the risk of T2DM (Iso *et al.* 2006) as well as cardiovascular risk through decrease of CRP (Rebello *et al.* 2011, Steptoe *et al.* 2007), serum amyloid A and haptoglobin (de Baquer *et al.* 2006). Maki and coauthors did not confirm the link between tea consumption and CRP, but daily users of green tea represented more than 80% of the sample, and they others were potentially coffee drinkers (Maki *et al.* 2010). So, it is difficult to see the clear link with CRP in a population where tea and coffee are consumed daily. Animal studies showed a clear effect of green tea extracts on the improvement of glucose tolerance either in induced diabetic rats or in genetic models of rodents with T2DM (Sae-tan *et al.* 2011). Despite preclinical evidence (Tsuneki *et al.* 2004), green tea, when consumed as a beverage had no effect on postprandial glucose or insulin response when consumed within a meal or one hour prior to a meal in healthy human volunteers (Josic *et al.* 2010, Louie *et al.* 2008). Green tea has been particularly studied for health interest because of its

high content on polyphenolic compounds (especially catechins). Consumption of an epigallocatechin gallate (EGCG; > 97%) enriched extract by overweight volunteers also showed no change in glucose levels, insulin sensitivity or secretion (Brown *et al.* 2009). However, there was some correlation of green-tea phenolic intake and insulin levels in healthy humans (Fukino *et al.* 2005) and a catechin-rich green tea increased insulin levels in volunteers with T2DM subjects (Nagao *et al.* 2009). Another cross-sectional study linked green tea consumption to the lowering of fasting blood glucose and fructosamine (Maruyama *et al.* 2009). In a longer term study it was demonstrated that daily supplementation of green tea-extract powder (as an equivalent of 456 mg of catechins daily) for two months lowered the HbA1c levels in subjects with borderline diabetes (Fukino *et al.* 2008) and green tea was inversely associated with plasma C-reactive protein concentrations (Rebello *et al.* 2011). Some potential mechanism of action of the catechins could be the modulation of certain glucose metabolism enzymes in the liver (increase of glucokinase expression and decrease phosphoenolpyruvate carboxykinase), as well as lipid metabolism enzymes in the liver and adipose tissue (acyl-CoA oxidase-1 and carnitinepalmitoyl transferase-1), and potentially on some adipose and muscle glucose receptors (GLUT-4 mRNA or translocation) (Sae-tan *et al.* 2011). Other types of tea are less well studied (ie, dark tea, Oolong tea). However, it was observed that black tea exhibited a late phase plasma glucose response in healthy humans with a corresponding increase in insulin (Bryans *et al.* 2007). In conclusion, controversial results have been obtained on the consumption of tea and its impact on glucose metabolism. Discrepancy of results may be due to type of tea. However, the interest of phenolic compounds present in green tea seems to be associated with a positive impact of glucose metabolism.

Coffee is among the most widely consumed beverages in the world (Table 8). Knowledge on both the positive and negative health effects of coffee has been shown and it has been extensively studied in relation to various diseases (Van Dam *et al.* 2005). Several systematic reviews associated the habitual consumption of caffeinated or decaffeinated coffee with a substantially lower risk in T2DM (VanDam *et al.* 2005, Tunnicliffe *et al.* 2008, Floegel *et al.* 2012). Higher consumption of coffee was consistently associated with a lower prevalence of newly detected hyperglycaemia, particularly postprandial hyperglycaemia (Van Dam *et al.* 2005). Some interesting additional inverse associations were found between coffee consumption and inflammatory markers; CRP, Tumor Necrosis Factor alpha (TNF- α) (Williams *et al.* 2008; Maki *et al.* 2010) and some interleukins (Wedick *et al.* 2011). The potential beneficial chronic effects of coffee may be related to antioxidant compounds including chlorogenic acid (Tunnicliffe Shearer 2008, van Dam 2006, Johnston *et al.* 2003). However, no direct link has been established so far. The acute effect of coffee may be different if consumed within a meal or before the meal, and if it is decaffeinated or caffeinated coffee. It has been shown that caffeinated coffee elicited acute insulin insensitivity when ingested around one hour before a carbohydrate meal compared to decaffeinated coffee (Moisey *et al.* 2008). Additionally, co-ingestion of caffeinated coffee with a high carbohydrate meal increased the blood glucose response, without modifying postprandial insulin response. Three hours later, an OGTT showed decreased insulin sensitivity after the caffeinated coffee compared to water or decaffeinated coffee (Moisey *et al.* 2010). Based on the current knowledge, the controversy between deleterious acute effect and

beneficial chronic effect of caffeinated coffee has not been clarified. However, decaffeinated coffee could be another alternative to provide a beneficial impact on the glycaemic response.

Nuts in general contain very little available carbohydrate and therefore, contribute little to the postprandial glycaemic response. Addition of nuts (almonds, pistachios and mixed nuts) to carbohydrate rich foods has been shown to blunt the glycaemic response (Jenkins *et al.* 2006) in a dose dependent manner (Josse *et al.* 2007, Kendall *et al.* 2011a, Kendall *et al.* 2011b) up to 55% (90 g) in healthy people (Table 8). Also, in T2DM subjects, mixed nut intake decreased the PPG response dose dependently, although the effect was half of the effect seen in non-diabetic subjects (Kendall *et al.* 2011a). In another study in T2DM subjects ingestion of 28 g almonds before a high-starch meal lowered PPG by 30%, but did not demonstrate this response in healthy volunteers. In contrast to the former studies, in this study, the control meal contained added fat (butter), and the amount of butter was reduced to compensate for the fat content of the almonds in the treatment meal. In impaired glucose tolerant adults, incorporation of whole almonds into a breakfast meal containing 75 g of carbohydrate also resulted in a lower PPG response and blunted the glucose levels throughout the day. The mechanism of action of nuts on PPG may be due to a reduction in gastric emptying rate as a consequence of the additional energy from fat and protein. However, when the energy and fat contents of meals were controlled, a reduction in PPG was observed (Cohen and Johnston, 2011). Alternatively, the phytochemicals in nuts (phytates and phenolics) could play a role by reducing amylase activity, the enzyme that hydrolyzes starch. Addition of nuts to meals resulted in decreased (Jenkins *et al.* 2006) (healthy volunteers) or unchanged (Cohen and Johnston, 2011, Mori *et al.* 2011) (IGT, DM2) insulin

response and increased insulin levels after a second meal (Mori *et al.* 2011) (IGT). Furthermore, addition of nuts to a meal may result in less oxidative protein damage (Jenkins *et al.* 2006). Only a limited number of longer term trials with nuts on glycaemic control have been conducted in people with T2DM. Three relatively small and short-term studies have generally not found significant improvements in markers of glycaemic control with nut consumption (for overview, see, Kendall *et al.* 2010). However a recent pilot trial in which ingestion of one serving of almonds 5 days week⁻¹ resulted in a 4% reduction of HbA1c (Cohen and Johnston, 2011). In addition a very recent well-powered study of 117 subjects with T2DM, consumption of mixed nuts (73 g/d) for 12 weeks significantly reduced HbA1c levels and improved blood lipid risk factors for CHD (Jenkins *et al.* 2011). Although, no compounds could be individually attributed to the effects observed, nuts are rich sources of phenolics and phytosterols, as well as macro- (e.g. MUFA) and micronutrients (e.g. α -tocopherol). More studies are required to make definite conclusions on the role of nuts in glycaemic control.

With reference to more specific phytochemicals, various herbal extracts have been shown to be effective. This includes Ginseng, both Asian (*Panax ginseng*) and American (*Panax quinquefolius*) and Korean Red (*Panax ginseng*; heat treated) species (Table 8). The two most popular types of ginseng, namely *Panax quinquefolius* L (American ginseng) and *Panax ginseng* CA Meyer (Asian ginseng) are most widely studied with respect to their hypoglycaemic effects. In a series of randomized, placebo controlled studies, American ginseng has been shown to reduce PPG by up to 39% in healthy volunteers (Dascalu *et al.* 2007), Vuksan *et al.* 2000a, Vuksan *et al.* 2001, Vuksan *et al.* 2000b) and up to 22% in T2DM subjects (Vuksan *et al.* 2000,

Vuksan *et al.* 2000c). In one study with healthy volunteers, only a trend for hypoglycaemic effects was found (Sievenpiper *et al.* 2000) and one study did not find any effects of American ginseng on PPG (Sievenpiper *et al.* 2003a). The effects of Asian ginseng are mixed, with some studies showing increasing (Sievenpiper *et al.* 2000, Sievenpiper *et al.* 2003a), no (Sievenpiper *et al.* 2000, Sievenpiper *et al.* 2003a, Sievenpiper *et al.* 2003b, Reay *et al.* 2009, Reay *et al.* 2006) or decreasing effects up to 29% (Sievenpiper *et al.* 2006, De Souza *et al.* 2011) on indices of PPG in healthy volunteers. The high variability in efficacy on PPG may be secondary to the variability in the ginseng source (species, batch, preparation, part of the plant and variety) and its composition, as represented by the measured ginsenoside profile. For example, Korean red ginseng rootlets have been shown to decrease PPG (Vuksan *et al.* 2008), while the root body has not (Sievenpiper *et al.* 2006, De Souza *et al.* 2011). This inconsistency limits the generalisability of the effects from one ginseng source to another and thereby the use of ginseng as a hypoglycaemic agent by subjects with T2DM. However, it has been shown in a so called “acute to chronic testing model” that an acute clinical postprandial model used to select the most efficacious ginsenoside profile, dose and time of administration is able to identify sources of ginseng with safety and efficacy on long term glycaemic parameters in T2DM subjects (Vuksan *et al.* 2000d, Vuksan *et al.* 2003). Two other long term studies in T2DM subjects, with some (methodological) limitations, also showed positive effects of ginseng on glycaemic control (Sotaniemi *et al.* 1995). In 18 healthy volunteers (placebo controlled, double-blind, cross over study), 200 mg *Panax ginseng* extract during eight weeks had no effect on any gluco-regulatory parameter investigated. (Reay *et al.* 2009) The mechanism behind the hypoglycaemic effects of ginseng are unknown but may include modulation of digestion of food and thereby carbohydrate

absorption. Modulation of glucose transport and insulin secretion have also been proposed (Vuksan *et al.* 2000a). It is hypothesised that the ginsenosides may be responsible for the effect, but phytochemicals such as the alkaloids or other plant components may be involved. There have also been various studies on cinnamon with no conclusive results. A recent study where a cinnamon extract was administered to healthy volunteers had no effect on PPG (Markey *et al.* 2011). However, several human studies with the herbal extract of *Salacia oblonga* have demonstrated significant decreases in postprandial glucose levels in both healthy and T2DM subjects (Heacock *et al.* 2005, Collene *et al.* 2004 and Williams *et al.* 2007). The mechanism of action is considered to be through competitive inhibition of α -glucosidase activity and two bioactive phytochemicals kotalanol and salacinol have been isolated (Matsuda *et al.* 2005).

The mechanism of action of non-nutrients on PPG is mostly unknown due to poor classification of the phytochemical composition of the foods studied. Potential mechanisms are mostly based on *in vitro*, pre clinical and human *ex vivo* data. Some general mechanisms that have been proposed include: inhibition/retardation of carbohydrate digestion, modulation of glucose release, uptake and absorption, stimulation of insulin secretion (pancreatic β -cells), activation of receptors, modulation of signalling/gene expression, inhibition of lipolysis, decrease in oxidative stress and inflammation. It may be that the level required of certain plant products may be too high to tolerate. For example some interventions have been shown to be ineffective at sustainable product levels (Clegg; 2011, Josic; 2010) and the food may have to be provided as a purified extract. For this reason, herbs, spices and certain plant extracts (with high phytochemical content) are likely to be more effective. There is also little consideration regarding the

phytochemicals associated with fibre and protein rich plants such as cereal crops and soya. Phytochemicals bound to these fractions can be released within the gastrointestinal tract and influence PPG, but few studies address their metabolism and bioavailability. It is clear that phytochemical-rich foods have potential to influence PPG, but in order to understand the impact of individual components on glucose metabolism it will be essential that the bioactive metabolites are identified.

Impact of miscellaneous food components on blood glucose regulation

Low-calorie sweeteners and glycaemic response

People with diabetes need to monitor their carbohydrate intake in order to control blood glucose levels. Low-calorie sweeteners are added to foods, beverages and used as table-top sweeteners to provide sweetness without the calories or carbohydrates. As a caloric sweetener replacement, they are added in smaller quantities; hence, they provide few or zero calories. Low-calorie sweeteners do not affect the glycaemic response and can help control overall carbohydrate intake by substituting for higher energy yielding sweeteners (Fitch *et al.* 2012; Duffy and Sigman-Grant 2004).

A recent review (Fenstrom *et al.* 2012) concluded that ingestion of low-calorie sweeteners by animals and humans does not cause the hypothesized changes in blood glucose or hormone levels. An animal study observed that rats given acesulfame-K, saccharin, stevia or sucralose by

gavage showed no change in blood concentrations of GLP-1, GIP and glucose. Also, low-calorie sweeteners by gavage did not influence the rise in blood glucose during an oral glucose tolerance test (Fujita *et al.*, 2009). The influence of drinking solutions containing acesulfame-K (165 mg), aspartame (165 mg), cyclamate (800 mg) or saccharin (75 mg) on blood insulin and glucose levels in human volunteers over the following 2 h in comparison with sucrose (30 g) or water controls was investigated (Härtel *et al.* 1993). In comparison with the water control, and in contrast to the dose of sucrose, it was concluded that the ingestion of acesulfame-K, aspartame, cyclamate or saccharin (at moderate doses) did not increase blood glucose and insulin over the 2-hour study period.

Further information is available from clinical research on the more recently developed sweeteners such as sucralose and stevioside/rebaudioside A (commonly known as stevia). A high single oral dose of sucralose (1000 mg) given orally to individuals with non-insulin-dependent diabetes mellitus and individuals with insulin dependent diabetes did not influence plasma C-peptide or glucose concentrations (Mezitis *et al.* 1996). A single oral dose of sucralose (10 mg/kg) did not affect the glucose induced changes in blood glucose levels when given with a large test dose of sucrose (100 g) (Roberts 1999). Furthermore, a randomised, double-blind, placebo-controlled study in which 128 subjects with T2DM were given either sucralose (667 mg/d for 13 weeks) or placebo showed no effect on fasting plasma glucose, HbA1c or fasting serum C-peptide, demonstrating no effect of chronic ingestion of sucralose on glucose homeostasis (Grotz *et al.* 2003). A similar effect was observed when the low calorie sweetener,

stevioside/rebaudioside A was consumed in a chronic study by patients with diabetes (Maki *et al.* 2008).

In summary, the above randomised human studies that varied from 1 to 16 weeks in duration found no significant difference between the effects of low-calorie sweeteners and various comparisons (sucrose, starch or placebo) on standard measures of glycaemic and in general did not detect clinically relevant effects (Table 9). Furthermore, in the last two years more data has emerged. Anton and colleagues (2010) looked at the effects of preloads containing stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels in both lean and obese individuals. They concluded that stevia preloads reduced postprandial blood glucose and insulin levels, suggesting stevia may assist with glucose regulation. Raben *et al.* (2011) looked at importance of exchanging sucrose for sweeteners, on risk factors for diabetes development. Healthy overweight subjects were randomised to consume drinks and foods sweetened with either sucrose or sweeteners as supplements to their usual diet. After 10 weeks, a diet rich in low-calorie sweeteners had no effect on postprandial glucose, insulinemia and lipidemia. Lastly, a study by Brown (2012) concluded that drinking diet soda could increase the amounts of a hormone that has been previously shown to be beneficial for people with diabetes when it comes to appetite and insulin secretion. More research, however, is needed to determine if this finding may impact future treatment of individuals with diabetes (Brown *et al* 2012). In conclusion, the use of low-calorie sweeteners and the products that contain them by subjects, with or without diabetes, do not affect blood glucose and are tools to help people reduce and control their caloric intake. Reducing calories could help to attain and maintain a healthy body

weight, and thereby lower the risk of heart disease and diabetes. Leading health groups such as American Heart Association, American Diabetes Association (Gardner *et al.* 2012) and the Academy of Nutrition and Dietetics (Fitch *et al.* 2012) also agree that substituting low-calorie sweeteners for added sugars in beverages and other foods has the potential to help people reach and maintain a healthy body weight and help people with diabetes with glucose control.

Water and glycaemic control

Addition of water to a test meal resulted in a 40% increased glucose response in 12 well controlled T2DM subjects (Table 9). In poorly controlled diabetic subjects, however, no significant effect was found, probably due to the varying fasting glycaemia in these subjects (Torsdottir and Andersson, 1989). In another study in T2DM subjects, similar glucose responses were found to test meals with either 90 or 600 mL of tap water (Gregersen *et al.* 1990).

Alcohol and glycaemic control

Epidemiological studies showed a U-shaped relationship between alcohol consumption and T2DM in western countries (Carlsson *et al.* 2005), showing that moderate alcohol consumption is associated with an increase in insulin sensitivity (Kiechl *et al.* 1995, Facchini *et al.* 1994, Kroenke *et al.* 2003). However, it is also suggested that unhealthy diets which include alcohol consumption are associated to metabolic disease genesis. Alcohol consumption of 10 g was associated with an increase in Low-Density Lipoprotein (LDL) oxidation, which is implicated in the development of cardiovascular disease (Schroder *et al.* 2006). Some inconsistent results may

be attributed to the difference in beverage types, drinking frequency and other dietary factors. The specific interest of phytochemical content in some alcoholic beverages such as wine has been addressed above. In a recent prospective cohort study, moderate alcohol consumption from 0 to 11 g/day of ethanol as beer, wine or liquors has been studied in around 3000 postmenopausal women with T2DM (Rajpathak *et al.* 2010). It was shown that an inverse association between quantity and frequency of alcohol intake in relation to incident CHD (Rajpathak *et al.* 2010), was consistent with previous results obtained with non-diabetic postmenopausal women (Joosten *et al.* 2008). In an acute setting, moderate alcohol consumption (around 20 g of alcohol) may decrease the glycaemic response when consumed within the meal, or before the meal (around 2 h prior to ingestion), independently of the type of beverage (Brand-Miller *et al.* 2007). However, the consumption of moderate alcohol may not modify the glycaemic response of the breakfast when consumed during dinner (Godley *et al.* 2009). One potential mechanism of action is the inhibition of the gluconeogenesis and the decrease of glucose output from the liver, as well as potential inhibition of α -amylase and α -glucosidase. However, this transitory impact of alcohol on glycaemia seems to produce deleterious metabolic and hormonal consequence in the long term. Animal studies showed that chronic alcohol consumption increased plasma glucose and serum leptin, resistin and adiponectin which are involved in insulin resistance genesis (Pravdova *et al.* 2009). Thus, moderate alcohol consumption may have some metabolic interest, including improvement of insulin sensitivity, and the reduction of some cardio-vascular risk factors, but some critical questions are pending regarding the potential beneficial quantity, and which type of alcohol.

Vinegar/acetic acid and glycaemic control

The interest on the effects of vinegar on the glycaemic response has been studied because of the organic acid content, mainly acetic acid. Several years ago, organic acids such as acetic and propionic acids were shown to lower the glucose and insulin responses when added to white bread meals in healthy subjects (Liljeberg and Björck, 1998, Darwiche *et al.* 2001, Östman *et al.* 2005). More recently, addition of vinegar in a carbohydrate rich meal decreased significantly the glycaemic and insulin responses in T2DM subjects only after a high GI meal (Liatas *et al.* 2010). The blood glucose and insulin kinetics were not modified after the low GI meal. A recent paper did not confirm the decrease of glucose response in a sucrose supplemented rice meal with addition of acetic acid (Mettler *et al.* 2009). Although, the authors could not find a clear explanation to justify this result, it may be due to the elevation of glycaemia with rice was not large enough to observe the decremental effect of acetic acid, as some rice have a low GI. The potential mechanism of action proposed for acetic acid to decrease postprandial glucose and insulin responses is by slowing down the gastric emptying phase (Liljeberg and Björck, 1998, Darwiche *et al.* 2001), but this was not confirmed (Hlebowicz *et al.* 2008). Thus, addition of vinegar or acetic acid in carbohydrate rich meal may have a short term positive impact by decreasing the postprandial glucose and insulin responses of high GI meals. There is no information regarding this addition in longer term studies.

Discussion

Lifestyle modifications with the highest impact on the risk of diabetes and on blood glucose regulation in the long term are weight reduction and increased habitual physical activity. As for diet composition, the strongest correlation of a dietary component with reduced risk of developing T2DM is with insoluble and moderately fermentable cereal-based fibre (Hu *et al.* 2001; Schulze *et al.* 2007). Diets rich in fruit and vegetables, which are a good source of soluble/fermentable fibre have also shown a protective effect. However, the evidence is less consistent, particularly if their impact on the risk of T2DM is evaluated independently of their effects on body weight (Cooper *et al.* 2012). Many studies utilize soluble fibre in the context of a healthy diet and these have been shown to potentially play a role in managing daily glucose levels both in healthy individuals and individuals with impaired glucose metabolism. An additional factor, which appears to influence glycaemic and insulinaemic responses in addition to the amount of fibre in the diet, is the food matrix of carbohydrate rich foods. In particular, soluble fibre has been shown to alter the physical food form, structure, and viscosity of test foods (Tappy *et al.* 1996, Kim *et al.* 2009), impacting on the rate of carbohydrate digestion and absorption which in turn is reflected in the postprandial glucose and insulin responses (Juvonen *et al.* 2009, Karhunen *et al.* 2010). The overall glycaemic impact of foods may be markedly affected by the individual meal components. However, when single foods were ranked in relation to their glycaemic index, they showed a similar ranking of blood glucose responses when included in a mixed meal (Robert and Ismail 2012). In general, the results suggest that carbohydrate foods that promote low but sustained blood glucose levels may be considered advantageous with regard to metabolic control of diabetes (Järvi *et al.* 1999), with acute

consumption of foods rich in soluble fibre being beneficial for both postprandial glycaemic control and the insulinaemic response.

Despite encouraging pre-clinical studies demonstrating that control of glycaemia is likely to involve interaction with gut microbes, evidence from human clinical studies is only just starting to emerge. There are some positive effects of including prebiotics in the habitual diet and a limited number of clinical studies addressing the effect of probiotics on related outcomes such as fasting glycaemia and insulin resistance were identified. Amino acids function as nutritional signals regulating various metabolic processes and can stimulate secretion of insulin from the pancreatic β -cells (Newsholme *et al.* 2005), with intravenous infusion of amino acids resulting in increased plasma insulin concentrations (Floyd *et al.* 1966, Floyd *et al.* 1968, Floyd *et al.* 1970). In particular, leucine can strongly stimulate endogenous insulin release and has potential to improve postprandial glycaemic control (Manders *et al.* 2006, van Loon *et al.* 2003). Protein and/or amino acid co-ingestion can improve PPG (Gannon *et al.* 1998, Gannon *et al.* 1992, Gannon *et al.* 2001, Nuttall *et al.* 1985, Nuttall *et al.* 1984). However, it should be noted that longer term intake of high protein diets has been shown to result in whole-body insulin resistance (Weickert *et al.* 2006; Linn *et al.* 2000). Although these unfavorable effects on insulin resistance could be compensated in the short term by high protein diet induced weight loss, anabolic effects resulting in increased lean/muscle mass, and an amino acid induced increase in insulin secretion in subjects with intact β -cell function, a clearer understanding of the impact of protein consumption on blood glucose levels is required. High fat diets are associated with reduced insulin sensitivity, whereas with lower fat intake the impact appears to be dependent on the fatty

acid composition. The data regarding dietary fatty acid modulation strongly supports the benefit of replacement of saturated fats with MUFAs in the diet of T2DM or obese insulin-resistant subjects for the reduction of insulin resistance and improvement of blood glucose levels.

Data regarding the impact of micronutrients on blood glucose regulation is beginning to emerge. Although, there is currently no data supporting the effect of vitamins on blood glucose levels it has been shown that plasma concentrations of B vitamins are reduced in some diabetic populations (Page *et al.* 2011; Mitri *et al.* 2011) and that regular vitamin D intake improved glycaemic control in T2DM subjects (Nikooyeh *et al.* 2011). Reduced circulating levels of minerals such as magnesium and zinc have been observed in T2DM subjects (Kinlaw *et al.*, 1983) and there is some evidence that mineral supplementation can be effective in improving glucose metabolism (Anderson *et al.*, 1997; Cheng *et al.*, 1999; Gunasekara *et al.*, 2011). However, intervention data from human studies is severely limited. There is a large and increasing body of evidence to suggest that phytochemical-rich foods can improve glucose metabolism. Unfortunately, in general these studies suffer from poor characterisation of the phytochemical composition of the foods studied and limited human interventions with single compounds and this decreased the strength of the data obtained.

Based on the evidence presented in this review, it is clear that dietary components can modulate blood glucose levels. Although closely related, fasting and postprandial blood glucose levels are regulated by mechanisms that are to some extent, different. In fact, while postprandial blood glucose concentrations are largely dependent on meal composition, fasting values are only

minimally influenced by the amount and/or rate of glucose absorption during the previous meal, and reflect the rate of glucose production in the liver (the two key processes being glycogenolysis and gluconeogenesis). Among the various dietary constituents, the one with the strongest influence on blood glucose levels in the postprandial period is the amount of digestible carbohydrate in the diet. Digestible carbohydrates include monosaccharides (glucose, fructose), disaccharides (sucrose, lactose) and certain polysaccharides (starch), which are digested and absorbed in the human intestine, thus contributing to the glucose in flow to the blood stream. However, the impact of dietary carbohydrates on glucose metabolism depends not only on the amount consumed, as believed in the past, but also on some specific food properties which can profoundly influence the metabolic effects. Among these, also the food structure and some specific physico-chemical characteristics of carbohydrates present in the food can have a relevant role in modulating blood glucose response. The ratio between mono-, di- and polysaccharides is no longer regarded as important in relation to the effects on postprandial blood glucose since amylase and disaccharidase activities in the human duodenum are sufficient to hydrolyse starch and disaccharides within minutes. The meal content of protein and fat, although able to influence postprandial glucose values, has limited practical significance because the magnitude of these effects is rather small.

More important are all dietary factors able to delay the process of digestion and/or absorption of carbohydrates in the intestine, thus reducing the glycaemic response to carbohydrate-rich food. Although, the overall mechanisms of action are not yet clear, the nature of the effective dietary components suggests that they are likely to include delayed gastric emptying and accessibility of the available carbohydrates (Thomas and Pfeiffer, 2012). As already mentioned, soluble viscous

types of fibre are those with the largest impact on the postprandial glucose and insulin response after a meal. The knowledge of nutritional factors influencing blood glucose metabolism in the fasting state is still not complete. Liver glucose production, the major determinant of fasting glucose levels, is under the control of insulin and therefore not adequately suppressed when insulin resistance is present; thus nutritional factors influencing fasting plasma glucose concentrations are primarily those acting on insulin resistance. The strongest corroboration of efficacy for dietary components improving glucose metabolism in the fasting state is available for non-digestible carbohydrates (i.e. dietary fibre, resistant starch and fructo-oligosaccharides) and MUFAs (as replacement of saturated fat) with weaker but substantial evidence that certain phytochemicals, predominantly phenolic compounds are likely to be effective. Non-digestible carbohydrates escape digestion in the small intestine and are fermented by colonic bacteria in the large bowel generating SCFAs and other metabolites such as phenolic compounds (Lappi *et al.* in press; Vitaglione *et al.* 2008). This may explain the available, albeit mostly preclinical evidence that suggests that the gut microbiota plays an important role in metabolic regulation of glucose metabolism. These metabolites could influence liver glucose production and, thus, the fasting glucose concentration. Moreover, they act as prebiotics influencing the composition of gut microbiota. Finally, alcohol intake also has significant, clinical effects on plasma glucose levels. In fact, alcohol acutely suppresses hepatic glucose production thus lowering plasma glucose levels. Conversely, if habitually consumed in large amounts it impairs insulin sensitivity, thus deteriorating glucose tolerance and increasing plasma glucose levels.

In conclusion, T2DM is a lifestyle illness that can be managed and prevented by reducing excess body weight, increasing physical exercise and modifying diet composition as outlined in this

review. Intensive interventions should be undertaken in individuals at high risk and, in particular, in those with impaired blood glucose regulation, in whom they have proven to be effective. This is especially desirable since high blood glucose levels, even if they are below the diagnostic threshold for diabetes, are also linked with a high risk for CVD. Therefore, lifestyle measures effective in improving blood glucose regulation are useful for prevention of cardiovascular disease as well as of T2DM. New emphasis on prevention might limit the dramatic worldwide increase in the incidence of T2DM expected in the next decades which is also going to impact on health and longevity of the population.

Acknowledgements

This work was conducted by an expert group of the European branch of the International Life Sciences Institute (ILSI Europe). The expert group received funding from the ILSI Europe Metabolic Syndrome and Diabetes Task Force. Industry members of this task force are listed on the ILSI Europe website at www.ilsieurope.eu. For further information about ILSI Europe, please email info@ilsieurope.be or call +32 2 771 00 14.

The Expert Group is grateful to Professor Massimo Massi-Benedetti for his invaluable advice and guidance throughout the project.

The opinions expressed herein and the conclusions of this publication are those of the authors and do not necessarily represent the views of ILSI Europe nor those of its member companies.

Declaration of interest

Ms Athanasia Baka is employed by ILSI Europe.

References

1. Whiting DR, Guariguata L, Weil C, Shaw J. (2011) IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract.* **94/3**: 311-21.
2. Diabetes Control and Complications Trial (DCCT) Research Group. (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med.* **329/14**: 977-986.
3. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S *et al.* (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract.* **28/2**:103-117.
4. UK Prospective Diabetes Study (UKPDS) Group. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet.* **352/9131**:837-853.
5. Huxley R, Barzi F, Woodward M. (2006). Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. *Br Med J.* **332/7533**:73-78.

6. Haffner SM, Lehto S, Ronnema T, Pyorala K, Laakso M. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* **339/4**: 229-234.
7. Niskanen L, Turpeinen A, Penttilä I, Uusitupa MI. (1998) Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. *Diabetes Care* **21/11**: 1861-1869.
8. Blaak EE, Antoine JM, Benton D, Björck I, Bozzetto L, Brouns F, Diamant M, Dye L, Hulshof T, Holst JJ, Lamport DJ, Laville M, Lawton CL, Meheust A, Nilson A, Normand S, Rivellese AA, Theis S, Torekov SS, Vinoy S. (2012) Impact of postprandial glycaemia on health and prevention of disease. *Obes. Rev.* **13/10**: 923-84.
9. Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, Kodama S, Hsieh SD, Mori Y, Shimano H, Yamada N, Kosaka K, Sone H. (2011) HbA1c 5.7-6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. *Lancet.* **9786**: 147-55.
10. Ceriello, A. (2004). Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. *Am Heart J.* **147/5**: 803-807.

11. Thomas, D. and E. J. Elliott (2009). Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. *Cochrane Database Syst Rev*(1): CD006296.
12. Rizkalla, S. W., L. Taghrid, *et al.* (2004). Improved Plasma Glucose Control, Whole-Body Glucose Utilization, and Lipid Profile on a Low-Glycemic Index Diet in Type 2 Diabetic Men: A randomized controlled trial. *Diabetes Care*. **27/8**: 1866-1872.
13. Gilbertson, H. R., J. C. Brand-Miller, *et al.* (2001). "The effect of flexible low glycaemic index dietary advice versus measured carbohydrate exchange diets on glycaemic control in children with type 1 diabetes." *Diabetes Care*. **24/7**: 1137-1143.
14. Pena, A. S., J. J. Couper, *et al.* (2012). Hypoglycemia, but not Glucose Variability, Relates to Vascular Function in Children with Type 1 Diabetes. *Diabetes Technol Ther*. **14/6**: 457-62.
15. Wolever, T. M. S. and C. Bolognesi (1996). "Prediction of glucose and insulin responses of normal subjects after consuming mixed meals varying in energy, protein, fat, carbohydrate and glycaemic index." *J Nutr*. **126**: 2807-2812.
16. Frid, A. H., M. Nilsson, *et al.* (2005). "Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects." *Amer J Clin Nutr*. **82/1**: 69-75.

17. Nilsson, M., J. J. Holst, *et al.* (2007). Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. *Amer J Clin Nutr.* **85/4**: 996-1004.
18. Gunnerud UJ, Heinzle C, Holst JJ, Östman EM, Björck IM (2012). Effects of pre-meal drinks with protein and amino acids on glycemic and metabolic responses at a subsequent composite meal. *PLoS One.* **7/9**: e44731.
19. Järvi, A. E., B. E. Karlström, *et al.* (1995). The influence of food structure on postprandial metabolism in patients with non-insulin-dependent diabetes mellitus. *Am J Clin Nutr.* **61**: 837-842.
20. Robert, S. D. and Ismail A.A. (2012). Glycemic responses of patients with type 2 diabetes to individual carbohydrate-rich foods and mixed meals. *Ann Nutr Metab.* **60/1**: 27-32.
21. Järvi, A. E., B. E. Karlström, *et al.* (1999). Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients. *Diabetes Care.* **22/1**: 10-18.

22. Wheeler, M. L. and F. X. Pi-Sunyer (2008). Carbohydrate Issues: Type and Amount." J Amer Dietetic Ass. **108/4**: S34-S39.
23. Cozma AI, Sievenpiper JL, de Souza RJ, Chiavaroli L, Ha V, Wang DD, Mirrahimi A, Yu ME, Carleton AJ, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Beyene J, Kendall CW, Jenkins DJ. (2012) Effect of fructose on glycemic control in diabetes: a systematic review and meta-analysis of controlled feeding trials. Diabetes Care. **7**: 1611-20.
24. Johnson, R.K., Appel, L.J. Brands, M., Howard, B.V., Lefevre, M., Lustig, R.; Sacks, F., Steffen, L.M., Judith Wylie-Rosett, J. (2009) on behalf of the American Heart Association Nutrition Committee of the Council on AHA Dietary Sugars Intake and Cardiovascular Health A Scientific Statement From the Amer Heart Ass Circulation. **120**: 1011-1020.
25. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozaawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ (2009). Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. **119/5**: 1322-34.
26. Atkinson, F. S., K. Foster-Powell, *et al.* (2008). International tables of glycemic index and glycemic load values. 2008. Diabetes Care. **31/12**: 2281-3.

27. Larsen HN, Rasmussen OW, Rasmussen PH, Alstrup KK, Biswas SK, Tetens I, Thilsted SH, Hermansen K. (2000). Glycaemic index of parboiled rice depends on the severity of processing: study in type 2 diabetic subjects. *Eur J Clin Nutr.* **5**: 380-5.
28. Hallstrom, E., F. Sestili, *et al.* (2011). A novel wheat variety with elevated content of amylose increases resistant starch formation and may beneficially influence glycaemia in healthy subjects. *Food Nutr Res.* **55**: doi: 10.3402/fnr.v55i0.7074.
29. Liljeberg, H. G. M., A. K. E. Åkerberg, *et al.* (1996). Resistant starch formation in bread as influenced by choice of ingredients or baking conditions. *Food Chem.* **56/4**: 389-394.
30. Granfeldt, Y., A. Drews, *et al.* (1995). Arepas made from high amylose corn flour produce favorable low glucose and insulin responses in healthy humans. *J Nutr.* **125/3**: 459-465.
31. Granfeldt, Y., B. Hagander, *et al.* (1995). Metabolic responses to starch in oat and wheat products. On the importance of food structure, incomplete gelatinization or presence of viscous dietary fibre. *Eur Journal Clin Nutr.* **49**: 189-199.

32. Granfeldt, Y., A.-C. Eliasson, *et al.* (2000). An examination of the possibility of lowering the glycemic index of oat and barley flakes by minimal processing. *J Nutr.* **130/9**: 2207-2214.
33. Kaufman, F. R. and S. Devgan (1996). Use of uncooked cornstarch to avert nocturnal hypoglycemia in children and adolescents with type I diabetes. *J Diabetes Complications.* **10/2**: 84-87.
34. Wheeler, M. L., S. E. Fineberg, *et al.* (1990). Metabolic response to oral challenge of hydrogenated starch hydrolysate versus glucose in diabetes. *Diabetes Care.* **13/7**: 733-740.
35. d'Emden MC, Marwick TH, Dreghorn J, Howlett VL, Cameron DP. (1987). Post-prandial glucose and insulin responses to different types of spaghetti and bread. *Diabetes Res Clin Pract.* **4**: 221-6.
36. Liljeberg, H. G. M., Y. E. Granfeldt, *et al.* (1992). Metabolic response to starch in bread containing intact kernels versus milled flour. *Eur J Clin Nutr.* **46**: 561-575.
37. Panlasigui, L. N. and Thompson L.U. (2006). Blood glucose lowering effects of brown rice in normal and diabetic subjects." *Int J Food Sci Nutr.* **57/3-4**: 151-158.

38. Nilsson, A. C., E. M. Ostman, *et al.* (2008a). Effect of cereal test breakfasts differing in glycemic index and content of indigestible carbohydrates on daylong glucose tolerance in healthy subjects." *Amer J Clin Nutr.* **87/3**: 645-654.
39. Nilsson, A. C., E. M. Ostman, *et al.* (2008b). Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast." *J Nutr.* **138/4**: 732-739.
40. Haber, G. B., K. W. Heaton, *et al.* (1977). Depletion and disruption of dietary fibre, effects on satiety, plasma-glucose, and serum-insulin." *Lancet.* 679-682.
41. Rosen, L. A. H., L. O. B. Silva, *et al.* (2009). Endosperm and whole grain rye breads are characterized by low post-prandial insulin response and a beneficial blood glucose profile. *Nutr J.* **25/8**: 42.
42. Rosen, L. A., E. M. Östman, *et al.* (2011). Effects of cereal breakfasts on postprandial glucose, appetite regulation and voluntary energy intake at a subsequent standardized lunch; focusing on rye products. *Nutr J.* **19/10**: 7.

43. Trowell HC, Southgate DAT, Wolever TMS, Leeds AR, Gassull MA, Jenkins DJA. (1976). Dietary Fibre redefined. *Lancet*. **307/7966**: 967.
44. Raninen K, Lappi J, Mykkanen H, Poutanen K. (2011). Type of dietary Fibre reflects the physiological functionality – comparison of grain Fibre, inulin and polydextrose. *Nutr Abstr Rev*. **1**: 9–21.
45. Eastwood MA, Morris ER. (1992). Physical properties of dietary Fibre that influence physiological function: a model for polymers along the gastrointestinal tract. *Am J Clin Nutr*. **55**: 436–442.
46. Guillon F, Champ M. (2000). Structural and physical properties of dietary fibres and consequences of processing on human physiology. *Food Res Int*. **33**: 233–245.
47. Slavin JL, Savarino V, Paredes-Diaz A, Fotopoulos G. (2009). A review of the role of soluble Fibre in health with specific reference to wheat dextrin. *J Int Med Res*. **37/1**: 1-17.
48. Weickert, M.O. & Pfeiffer, A.F. (2008). Metabolic effects of dietary Fibre consumption and prevention of diabetes. *J Nutr*. **138**: 439-442.

49. Weickert, M.O., Möhlig, M., Schöfl, C., Arafat, A.M., Otto, B., Viehoff, H., Koebnick, C., Kohl, A., Spranger, J. & Pfeiffer, A.F. (2006). Cereal Fibre improves whole-body insulin sensitivity in overweight and obese women. *Diabetes Care*. **29**: 775-780.
50. Schulze, M.B., Schulz, M., Heidemann, C., Schienkiewitz, A., Hoffmann, K. & Boeing, H. (2007). Fibre and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. *Arch Intern Med*. **167**: 956-965.
51. de Munter, J.S., Hu, F.B., Spiegelman, D., Franz, M. & van Dam, R.M. (2007). Whole grain, bran, and germ intake and risk of type 2 diabetes: a prospective cohort study and systematic review. *PLoS Med*. **4**: e261.
52. Vuksan V, Rogovik AL, Jovanovski E, Jenkins AL. (2009). Fibre facts: benefits and recommendations for individuals with type 2 diabetes. *Curr Diab Rep*. **9/5**: 405-11.
53. Papathanasopoulos A, Camilleri M. (2010). Dietary Fibre supplements: effects in obesity and metabolic syndrome and relationship to gastrointestinal functions. *Gastroenterology*. **138/1**: 65-72.
54. Granfeldt Y, Nyberg L, Björck I. (2008). Muesli with 4 g oat beta-glucans lowers glucose and insulin responses after a bread meal in healthy subjects. *Eur J Clin Nutr*. **62/5**: 600-7.

55. Juvonen KR, Salmenkallio-Marttila M, Lyly M, Liukkonen KH, Lähteenmäki L, Laaksonen DE, Uusitupa MI, Herzig KH, Poutanen KS, Karhunen LJ. (2011). Semisolid meal enriched in oat bran decreases plasma glucose and insulin levels, but does not change gastrointestinal peptide responses or short-term appetite in healthy subjects. *Nutr Metab Cardiovasc Dis.* **21**: 748–756.
56. Tapola N, Karvonen H, Niskanen L, Mikola M, Sarkkinen E. (2005). Glycemic responses of oat bran products in type 2 diabetic patients. *Nutr Metab Cardiovasc Dis.* **15/4**: 255-61.
57. Juntunen KS, Laaksonen DE, Autio K, Niskanen LK, Holst JH, Savolainen KH, Liukkonen K-H, Poutanen KS & Mykkänen HM. (2003). Structural differences between rye and wheat bread but not total fiber content may explain the lower postprandial insulin response to rye bread *Am J Clin Nutr.* **78**: 957-964.
58. Karhunen LJ, Juvonen KR, Flander SM, Liukkonen KH, Lähteenmäki L, Siloaho M, Laaksonen DE, Herzig KH, uusitupa MI, Poutanen KS. (2010). A psyllium fiber-enriched meal strongly attenuates postprandial gastrointestinal peptide release in healthy young adults. *J Nutr.* **140**: 737-744.
59. Ellis, P. R., F. M. Dawoud, *et al.* (1991). Blood glucose, plasma insulin and sensory responses to guar-containing wheat breads: effects of molecular weight and particle size of guar gum. *Br J Nutr.* **66/3**: 363-379.

60. Golay, A., H. Schneider, *et al.* (1995). "The effect of a liquid supplement containing guar gum and fructose on glucose-tolerance in non-insulin-dependent diabetic-patients." *Nutr Met Cardiovascular Dis.* **5/2**: 141-148.
61. Pastors, J. G., P. W. Blaisdell, *et al.* (1991). Psyllium Fibre reduces rise in postprandial glucose and insulin concentrations in patients with non-insulin-dependent diabetes. *Am J Clin Nutr.* **53/6**: 1431-1435.
62. Elin Östmana E., Rossia E., Larssonc H., Brighentib F., Björck I. (2006). Glucose and insulin responses in healthy men to barley bread with different levels of (1→3;1→4)-β-glucans; predictions using fluidity measurements of in vitro enzyme digests. *J Cereal Sci.* **43/2**: 230–235.
63. Tappy L, Gügolz E, Würsch P. (1996). Effects of breakfast cereals containing various amounts of beta-glucan Fibres on plasma glucose and insulin responses in NIDDM subjects. *Diabetes Care.* **19/8**: 831-4.
64. Kim H, Stote KS, Behall KM, Spears K, Vinyard B, Conway JM. (2009). Glucose and insulin responses to whole grain breakfasts varying in soluble Fibre, beta-glucan: a dose response study in obese women with increased risk for insulin resistance. *Eur J Nutr.* **48/3**: 170-5.

65. Weickert, M.O., Möhlig, M., Koebnick, C., Holst, J.J., Namsolleck, P., Ristow, M., Osterhoff, M., Rochlitz, H., Rudovich, N., Spranger, J. & Pfeiffer, A.F. (2005). Impact of cereal fibre on glucose-regulating factors. *Diabetologia*. **48**: 2343-2353.
66. Nilsson, A.C., Ostman, E.M., Granfeldt, Y. & Bjorck, I.M. (2008). Effect of cereal test breakfasts differing in glycemic index and content of indigestible carbohydrates on daylong glucose tolerance in healthy subjects. *Am J Clin Nutr*. **87**: 645-654.
67. Weickert, M.O. & Pfeiffer, A.F. (2009). Low-glycemic index vs high-cereal Fibre diet in type 2 diabetes. *Jama*. **301**: 1538.
68. Brennan CS. (2005). Dietary fibre, glycaemic response, and diabetes. *Mol Nutr Food Res*. **49/6**: 560-70.
69. Sels JP, De Bruin H, Camps MH, Postmes TJ, Menheere P, Wolfenbuttel BH, Kruseman AC. (1992). Absence of guar efficacy in complex spaghetti meals on postprandial glucose and C-peptide levels in healthy control and non-insulin-dependent diabetes mellitus subjects. *Horm Metab Res Suppl*. **26**: 52-8.
70. D.J., Kendall, C.W., McKeown-Eyssen, G., Josse, R.G., Silverberg, J., Booth, G.L., Vidgen, E., Josse, A.R., Nguyen, T.H., Corrigan, S., Banach, M.S., Ares, S., Mitchell, S.

(2008). Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. *Jenkins, JAMA*. **23**: 2742-53.

71. Weickert, M.O. (2012). What dietary modification best improves insulin sensitivity and why? *Clin Endocrinol*. **77/4**: 508-12.
72. Nilsson AC, Ostman EM, Holst JJ, Björck IM. (2008). Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast. *J Nutr*. **138/4**: 732-9.
73. Nilsson AC, Ostman EM, Granfeldt Y, Björck IM. (2008). Effect of cereal test breakfasts differing in glycemic index and content of indigestible carbohydrates on daylong glucose tolerance in healthy subjects. *Am J Clin Nutr*. **87/3**: 645-54.
74. Nilsson A, Ostman E, Preston T, Björck I (2008). Effects of GI vs content of cereal fibre of the evening meal on glucose tolerance at a subsequent standardized breakfast. *Eur J Clin Nutr*. **62/6**: 712-20.

75. Rosén LA, Ostman EM, Björck IM. (2011). Effects of cereal breakfasts on postprandial glucose, appetite regulation and voluntary energy intake at a subsequent standardized lunch; focusing on rye products. *Nutr J.* **10**: 7.
76. de Natale C, Annuzzi G, Bozzetto L, Mazzarella R, Costabile G, Ciano C, Riccardi G, Rivellese AA. (2009). Effects of a plant-based high-carbohydrate/high-Fibre diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. *Diabetes Care.* **32**: 2168–2173.
77. Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy SM, Brinkley LJ. (2000). Beneficial effects of high dietary Fibre intake in patients with type 2 diabetes mellitus. *N Engl J Med.* **342**: 1392-8.
78. Jenkins DJ, Kendall CW, McKeown-Eyssen G, *et al.* (2008). Effect of a low glycemic index or a high-cereal Fibre diet on type 2 diabetes: a randomized trial. *JAMA.* **300**: 2742-53.
79. Wolever TM, Gibbs AL, Mehling C, *et al.* (2008). The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. *Am J Clin Nutr.* **87**: 114-25.

80. Weickert, M.O., Arafat, A.M., Blaut, M., Alpert, C., Becker, N., Leupelt, V., Rudovich, N., Mohlig, M. & Pfeiffer, A.F. (2011). Changes in dominant groups of the gut microbiota do not explain cereal-Fibre induced improvement of whole-body insulin sensitivity. *Nutr Metab (Lond)*. **8**: 90.
81. Pereira, M.A., Jacobs, D.R., Jr., Pins, J.J., Raatz, S.K., Gross, M.D., Slavin, J.L. & Seaquist, E.R. (2002). Effect of whole grains on insulin sensitivity in overweight hyperinsulinemic adults. *Am J Clin Nutr*. **75**: 848-855.
82. Robertson, M.D., Currie, J.M., Morgan, L.M., Jewell, D.P. & Frayn, K.N. (2003). Prior short-term consumption of resistant starch enhances postprandial insulin sensitivity in healthy subjects. *Diabetologia*. **46**: 659-665.
83. Robertson, M.D., Bickerton, A.S., Dennis, A.L., Vidal, H. & Frayn, K.N. (2005). Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. *Am J Clin Nutr*. **82**: 559-567.
84. Johnston, K.L., Thomas, E.L., Bell, J.D., Frost, G.S. & Robertson, M.D. (2010). Resistant starch improves insulin sensitivity in metabolic syndrome. *Diabet Med*. **27**: 391-397.

85. Schwab U, Louheranta A, Törrönen A, Uusitupa M. (2006). Impact of sugar beet pectin and polydextrose on fasting and postprandial glycemia and fasting concentrations of serum total and lipoprotein lipids in middle-aged subjects with abnormal glucose metabolism. *Eur J Clin Nutr.* **60**: 1073–1080.
86. Sorensen M, Johansen OE. (2010). Idiopathic reactive hypoglycaemia – Prevalence and effect of fibre on glucose excursions. *Scan J Clin Lab Invest.* **70**: 385–391.
87. Marciani L, Gowland PA, Spiller RC, Manoj P, Moore RJ, Young P, Fillery-Travis AJ. (2001). Effect of meal viscosity and nutrients on satiety, intragastric dilution, and emptying assessed by MRI. *Am J Physiol Gastrointest Liver Physiol.* **280/6**: G1227-33.
88. Darwiche G, Björgell O, Almér LO. (2003). The addition of locust bean gum but not water delayed the gastric emptying rate of a nutrient semisolid meal in healthy subjects. *BMC Gastroenterol.* **6/3**: 12.
89. Sanaka M, Yamamoto T, Anjiki H, Nagasawa K, Kuyama Y. (2007). Effects of agar and pectin on gastric emptying and post-prandial glycaemic profiles in healthy human volunteers. *Clin Exp Pharmacol Physiol.* **34/11**: 1151-5.
90. Dikeman CL, Fahey GCJ. (2006). Viscosity as related to dietary Fibre: a review. *Crit Rev Food Sci Nutr.* **46**: 649–663.

91. Leclerc, C., M. Champ, *et al.* (1994). Role of viscous guar gums in lowering the glycemic response after a solid meal. *Amer J Clin Nutr.* **59/4**: 914-921.
92. Slaughter, S. L., P. R. Ellis, *et al.* (2002). "The effect of guar galactomannan and water availability during hydrothermal processing on the hydrolysis of starch catalysed by pancreatic [alpha]-amylase." *Biochim. Biophys. Acta. General Subjects* **1571/1**: 55-63.
93. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. (2001). Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *N Engl J Med.* **345**: 790–797.
94. Livesey G, Taylor R, Hulshof T, Howlett J. (2008). Glycemic response and health—a systematic review and meta-analysis: relations between dietary glycemic properties and health outcomes. *Am J Clin Nutr.* **87(suppl)**: 258S–68S.
95. Lappi J, Kolehmainen M, Mykkänen H, Poutanen K. (2012). Do large intestinal events explain the protective effects of whole grain foods against type 2 diabetes? *Crit Rev Food Sci Nutr.* In press.

96. Vitaglione P, Napolitano A, Fogliano V. (2008). Cereal dietary fibre: a natural functional ingredient to deliver phenolic compounds into the gut. *Trends Food Sci Tech.* **19**: 451–463.

97. Weickert, M.O., Roden, M., Isken, F., Hoffmann, D., Nowotny, P., Osterhoff, M., Blaut, M., Alpert, C., Gögebakan, O., Bumke-Vogt, C., Mueller, F., Machann, J., Barber, T.M., Petzke, K.J., Hierholzer, J., Hornemann, S., Kruse, M., Illner, A.K., Kohl, A., Loeffelholz, C.V., Arafat, A.M., Möhlig, M. & Pfeiffer, A.F. (2011). Effects of supplemented isoenergetic diets differing in cereal Fibre and protein content on insulin sensitivity in overweight humans. *Am J Clin Nutr.* **94**: 459-471.

98. Krebs, M., Krssak, M., Bernroider, E., Anderwald, C., Brehm, A., Meyerspeer, M., Nowotny, P., Roth, E., Waldhausl, W. & Roden, M. (2002). Mechanism of amino acid-induced skeletal muscle insulin resistance in humans. *Diabetes.* **51**: 599-605.

99. Tremblay, F., Krebs, M., Dombrowski, L., Brehm, A., Bernroider, E., Roth, E., Nowotny, P. (2005). Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. *Diabetes.* **54/9**: 2674-84.

100. Um, S.H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., (2004). Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature.* **431/7005**: 200-5.

101. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le PD, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J (2010). A human gut microbial gene catalogue established by metagenomic sequencing *Nature*. **464**: 59-65.
102. Diamant M, Blaak EE, de Vos WM (2011). Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? *Obes Rev*. **12/4**: 272-81.
103. Arumugam M, Raes J, Pelletier E, Le PD, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T (2011). Enterotypes of the human gut microbiome. *Nature*. **473/7346**: 174-80.

104. Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, Yu P, Zhao C, Li L, Zhou A, Wang J, Moore JE, Millar BC, Xu J. (2010). Molecular characterisation of the faecal microbiota in patients with type II diabetes *Curr Microbiol.* **61**: 69-78.
105. Boesten RJ, de Vos WM. (2008). Interactomics in the human intestine: Lactobacilli and Bifidobacteria make a difference *J Clin Gastroenterol.* **42/3**: S163-S167.
106. Turrone F, Marchesi JR, Foroni E, Gueimonde M, Shanahan F, Margolles A, van SD, Ventura M. (2009). Microbiomic analysis of the bifidobacterial population in the human distal gut *ISME J.* **3**: 745-751.
107. Delzenne NM and Cani PD (2011). Gut microbiota and the pathogenesis of insulin resistance *Curr Diabetes Rep.* **11/3**: 154-9.
108. Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Dore J, Henegar C, Rizkalla S, Clement K. (2010). Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. *Diabetes.* **59**: 3049-3057.
109. Cani PD, Delzenne NM (2011). The gut microbiome as therapeutic target. *Pharmacol Ther.* **130**: 202-212.

110. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI.(2001). Molecular analysis of commensal host-microbial relationships in the intestine *Science*. **291**: 881-884.

111. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM. (2012). Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. *Diabetes*. **61/2**: 364-71.

112. Vrieze A, van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stoes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. (2012). Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome. *Gastroenterology*. **143/4**: 913-6.

113. Gibson GR, Roberfroid MB. (1995). Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J Nutr*. **125/6**: 1401-12.

114. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, Wolvers D, Watzl B, Szajewska H, Stahl B, Guarner F, Respondek F, Whelan K, Coxam V, Davicco

- MJ, Leotoing L, Wittrant Y, Delzenne NM, Cani PD, Neyrinck AM, Meheust A. (2010) Prebiotic effects: metabolic and health benefits. *Br J Nutr.* **104/2**: S1-63.
115. Delzenne NM, Cani PD (2011). Interaction between obesity and the gut microbiota: relevance in nutrition. *Annu Rev Nutr.* **31**: 15-31.
116. Delzenne NM, Neyrinck AM, Bäckhed F, Cani PD (2011). Targeting gut microbiota in obesity: effects of prebiotics and probiotics. *Nat Rev Endocrinol.* **7/11**: 639-46.
117. Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, Possemiers S, Van Holle A, François P, de Vos WM, Delzenne NM, Schrenzel J, Cani PD. (2011). Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. *Diabetes.* **60/11**: 2775-86.
118. Cani PD, Lecourt E, Dewulf EM, Sohet FM, Pachikian BD, Naslain D, De BF, Neyrinck AM, Delzenne NM. (2009). Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. *Am J Clin Nutr.* **90**: 1236-1243.
119. Luo J, Rizkalla SW, Alamowitch C, Boussairi A, Blayo A, Barry JL, Laffitte A, Guyon F, Bornet FR, Slama G. (1996). Chronic consumption of short-chain fructooligosaccharides

by healthy subjects decreased basal hepatic glucose production but had no effect on insulin-stimulated glucose metabolism. *Am J Clin Nutr.* **63/6**: 939-45.

120. Giacco R, Clemente G, Luongo D, Lasorella G, Fiume I, Brouns F, Bornet F, Patti L, Cipriano P, Rivellese AA, Riccardi G. (2004). Effects of short-chain fructo-oligosaccharides on glucose and lipid metabolism in mild hypercholesterolaemic individuals. *Clin Nutr.* **23/3**: 331-40.
121. Parnell JA, Reimer RA. (2009). Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. *Am J Clin Nutr.* **89/6**: 1751-9.
122. Antal M, Regöly-Mérei A, Biró L, Arató G, Schmidt J, Nagy K, Greiner E, Lásztity N, Szabó C, Péter S, Martos E. (2008). Effects of oligofructose containing diet in obese persons. *Orv Hetil.* **149/42**: 1989-95.
123. Fao/Who. (2002). Guidelines for the evaluation of probiotics in food. Joint FAO/WHO working group report on drafting for the evaluation of probiotics in food. London, Ontario, Canada

124. Moroti C, Souza Magri LF, de Rezende Costa M, Cavallini DC, Sivieri K. (2012). Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. *Lipids Health Dis.* **11**: 29.
125. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. (2012). Probiotic yogurt improves antioxidant status in type 2 diabetic patients. *Nutr.* **28**: 539-543.
126. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V, Akbarian-Moghari A. (2011). Effect of probiotic yogurt containing *Lactobacillus acidophilus* and *Bifidobacterium lactis* on lipid profile in individuals with type 2 diabetes mellitus. *J Dairy Sci.* **94**: 3288-3294.
127. Chang BJ, Park SU, Jang YS, Ko SH, Joo NM, Kim SI, Kim CH, Chang DK. (2011). Effect of functional yogurt NY-YP901 in improving the trait of metabolic syndrome. *Eur J Clin Nutr.* **65**: 1250-1255.
128. Schaafsma G, Meuling WJ, van Dokkum W, Bouley C. (1998). Effects of a milk product, fermented by *Lactobacillus acidophilus* and with fructo-oligosaccharides added, on blood lipids in male volunteers. *Eur J Clin Nutr.* **52**: 436-440.

129. Laitinen K, Poussa T, Isolauri E. (2009). Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial. *Br J Nutr.* **101**: 1679-1687.
130. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg RM, Moller K, Svendsen KD, Jakobsen M, Pedersen BK. (2010). Effects of *Lactobacillus acidophilus* NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. *Br J Nutr.* **104**: 1831-1838.
131. Granfeldt YE, Bjorck IM. (2011) A bilberry drink with fermented oatmeal decreases postprandial insulin demand in young healthy adults. *Nutr J.* **10**: 57.
132. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermudez-Humaran LG, Smirnova N, Berge M, Sulpice T, Lahtinen S, *et al.* (2011). Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. *EMBO Mol Med.* **3**: 559-572.
133. Amar J, Serino M, Lange C, Chabo C, Iacovoni J, Mondot S, Lepage P, Klopp C, Mariette J, Bouchez O, *et al.* (2011). Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. *Diabetologia.* **54**: 3055-3061.

134. Andersson U, Branning C, Ahrne S, Molin G, Alenfall J, Onning G, Nyman M, Holm C. (2010). Probiotics lower plasma glucose in the high-fat fed C57BL/6J mouse. *Benef Microbes*. **1**: 189-196.
135. Chen JJ, Wang R, Li XF, Wang RL. (2011). *Bifidobacterium longum* supplementation improved high-fat-fed-induced metabolic syndrome and promoted intestinal Reg I gene expression. *Exp Biol Med* (Maywood). **236**: 823-831.
136. Hession, M., Rolland, C., Kulkarni, U., Wise, A. & Broom, J. (2009). Systematic review of randomized controlled trials of low-carbohydrate vs. low-fat/low-calorie diets in the management of obesity and its comorbidities. *Obes Rev*. **10**: 36-50.
137. Gosby, A.K., Conigrave, A.D., Lau, N.S., Iglesias, M.A., Hall, R.M., Jebb, S.A., Brand-Miller, J., Caterson, I.D., Raubenheimer, D. & Simpson, S.J. (2011). Testing protein leverage in lean humans: a randomised controlled experimental study. *PLoS One*. **6**: e25929.
138. Westerterp-Plantenga MS, Lemmens SG, Westerterp KR. (2012). Dietary protein - its role in satiety, energetics, weight loss and health. *Br J Nutr*. **108/2**: S105-12

139. Mehrabani HH, Salehpour S, Amiri Z, Farahani SJ, Meyer BJ, Tahbaz F. (2012). Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in overweight and obese women with polycystic ovary syndrome: a randomized controlled intervention study. *J Am Coll Nutr.* **31/2**: 117-25.
140. Pi-Sunyer, F.X. (2005). Weight loss in type 2 diabetic patients. *Diabetes Care.* **28**: 1526-1527.
141. Manders RJ, Little JP, Forbes SC, Candow DG. (2012). Insulinotropic and muscle protein synthetic effects of branched-chain amino acids: potential therapy for type 2 diabetes and sarcopenia. *Nutrients* **4/11**: 1664-78
142. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP. (2009). A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab.* **9/4**: 311-26.
143. Michaliszyn SF, Sjaarda LA, Mihalik SJ, Lee S, Bacha F, Chace DH, De Jesus VR, Vockley J, Arslanian SA. (2012). Metabolomic profiling of amino acids and β -cell function relative to insulin sensitivity in youth. *J Clin Endocrinol Metab.* **97/11**: E2119-24

134. Newgard BC (2012). Interplay between lipids and branched chain amino acids in development of insulin resistance. *Cell Metab.* **15**: 606-614.

144. Linn, T., Santosa, B., Gronemeyer, D., Aygen, S., Scholz, N., Busch, M. & Bretzel, R.G. (2000). Effect of long-term dietary protein intake on glucose metabolism in humans. *Diabetologia.* **43**: 1257-1265.

145. Zanchi NE, Guimarães-Ferreira L, Siqueira-Filho MA, Gabriel Camporez JP, Nicastro H, Seixas Chaves DF, Campos-Ferraz P, Lancha AH Jr, de Oliveira Carvalho CR. (2012). The possible role of leucine in modulating glucose homeostasis under distinct catabolic conditions. *Med Hypotheses.* **79/6**: 883-8.

146. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP (2009). *Cell Metab.* **9**: 311-326.

147. Larsen, T.M., Dalskov, S.M., van Baak, M., Jebb, S.A., Papadaki, A., Pfeiffer, A.F., Martinez, J.A., Handjieva-Darlenska, T., Kunesova, M., Pihlsgard, M., Stender, S., Holst, C., Saris, W.H. & Astrup, A. (2010). Diets with high or low protein content and glycemic index for weight-loss maintenance. *N Engl J Med.* **363**: 2102-2113.

148. Gögebakan, O., Kohl, A., Osterhoff, M.A., van Baak, M.A., Jebb, S.A., Papadaki, A., Martinez, J.A., Handjieva-Darlenska, T., Hlavaty, P., Weickert, M.O., Holst, C., Saris, W.H., Astrup, A. & Pfeiffer, A.F. (2011). Effects of weight loss and long-term weight maintenance with diets varying in protein and glycemic index on cardiovascular risk factors: the diet, obesity, and genes (DiOGenes) study: a randomized, controlled trial. *Circulation*. **124**: 2829-2838.
149. Möhlig, M., Freudenberg, M., Bobbert, T., Ristow, M., Rochlitz, H., Weickert, M.O., Pfeiffer, A.F. & Spranger, J. (2006). Acetylsalicylic acid improves lipid-induced insulin resistance in healthy men. *J Clin Endocrinol Metab*. **91**: 964-967.
150. Sluijs, I., Beulens, J.W., van der, A.D., Spijkerman, A.M., Grobbee, D.E. & van der Schouw, Y.T. (2010). Dietary intake of total, animal, and vegetable protein and risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-NL study. *Diabetes Care*. **33**: 43-48.
151. Lagiou, P., Sandin, S., Lof, M., Trichopoulos, D., Adami, H.O. & Weiderpass, E. (2012). Low carbohydrate-high protein diet and incidence of cardiovascular diseases in Swedish women: prospective cohort study. *Br Med J*. **344**: e4026.

152. Polonsky KS, Sturis J, and Bell GI. (1996). Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. *N Engl J Med.* **334**: 777-783.
153. van Loon LJ, Kruijshoop M, Menheere PP, Wagenmakers AJ, Saris WH, and Keizer HA. (2003) Amino acid ingestion strongly enhances insulin secretion in patients with long-term type 2 diabetes. *Diabetes Care.* **26**: 625-630.
154. Newsholme P, Brennan L, Rubi B, and Maechler P. (2005). New insights into amino acid metabolism, beta-cell function and diabetes. *Clin Sci (Lond).* **108**: 185-194.
155. Blachier F, Leclercq Meyer V, Marchand J, Woussen Colle MC, Mathias PC, Sener A, and Malaisse WJ. (1989). Stimulus-secretion coupling of arginine-induced insulin release. Functional response of islets to L-arginine and L-ornithine. *Biochim Biophys Acta.* **1013**: 144-151.
156. Floyd JC, Jr., Fajans SS, Knopf RF, and Conn JW. (1963). Evidence that insulin release is the mechanism for experimentally induced leucine hypoglycemia in man. *J Clin Invest.* **42**: 1714-1719.
157. Lajoix AD, Reggio H, Charde T, Peraldi-Roux S, Tribillac F, Roye M, Dietz S, Broca C, Manteghetti M, Ribes G, Wollheim CB, and Gross R. (2001). A neuronal isoform of nitric

- oxide synthase expressed in pancreatic beta-cells controls insulin secretion. *Diabetes*. **50**: 1311-1323.
158. Malaisse WJ, Plasman PO, Blachier F, Herchuelz A, and Sener A. (1991). Stimulus-secretion coupling of arginine-induced insulin release: significance of changes in extracellular and intracellular pH. *Cell Biochem Funct*. **9**: 1-7.
159. Pipeleers DG, Schuit FC, in't Veld PA, Maes E, Hooghe-Peters EL, Van de Winkel M, and Gepts W. (1985). Interplay of nutrients and hormones in the regulation of insulin release. *Endocrinology*. **117**: 824-833.
160. Schwanstecher C, Meyer M, Schwanstecher M, and Panten U. (1998). Interaction of N-benzoyl-D-phenylalanine and related compounds with the sulphonylurea receptor of beta-cells. *Br J Pharmacol*. **123**: 1023-1030.
161. Sener A, Hutton JC, and Malaisse WJ. (1981). The stimulus-secretion coupling of amino acid-induced insulin release. Synergistic effects of L-glutamine and 2-keto acids upon insulin secretion. *Biochim Biophys Acta*. **677**: 32-38.
162. Xu G, Kwon G, Cruz WS, Marshall CA, and McDaniel ML. (2001). Metabolic regulation by leucine of translation initiation through the mTOR-signaling pathway by pancreatic beta-cells. *Diabetes*. **50**: 353-360.

163. Salehi A, Gunnerud U, Muhammed SJ, Ostman E, Holst JJ, Björck I, Rorsman P. (2012). The insulinogenic effect of whey protein is partially mediated by a direct effect of amino acids and GIP on β -cells. *Nutr Metab.* **9/1**: 48.
164. Sener A, and Malaisse WJ. (2002). The stimulus-secretion coupling of amino acid-induced insulin release. Insulinotropic action of L-alanine. *Biochim Biophys Acta.* **1573**: 100-104.
165. Dean PM, and Matthews EK. (1970). Glucose-induced electrical activity in pancreatic islet cells. *J Physiol.* **210**: 255-264.
166. Brennan L, Shine A, Hewage C, Malthouse JP, Brindle KM, McClenaghan N, Flatt PR, and Newsholme P. (2002). A nuclear magnetic resonance-based demonstration of substantial oxidative L-alanine metabolism and L-alanine-enhanced glucose metabolism in a clonal pancreatic beta-cell line: metabolism of L-alanine is important to the regulation of insulin secretion. *Diabetes.* **51**: 1714-1721.
167. Dunne MJ, Yule DI, Gallacher DV, and Petersen OH. (1990). Effects of alanine on insulin-secreting cells: patch-clamp and single cell intracellular Ca^{2+} measurements. *Biochim Biophys Acta.* **1055**: 157-164.

168. Kofod H, Lernmark A, and Hedekov CJ. (1986). Potentiation of insulin release in response to amino acid methyl esters correlates to activation of islet glutamate dehydrogenase activity. *Acta Physiol Scand*. **128**: 335-340.
169. Floyd JC, Jr., Fajans SS, Conn JW, Knopf RF, and Rull J. (1966). Stimulation of insulin secretion by amino acids. *J Clin Invest*. **45**: 1487-1502.
170. Floyd JC, Jr., Fajans SS, Pek S, Thiffault CA, Knopf RF, and Conn JW. (1970). Synergistic effect of essential amino acids and glucose upon insulin secretion in man. *Diabetes*. **19**: 109-115.
171. Floyd JC, Jr., Fajans SS, Conn JW, Thiffault C, Knopf RF, and Guntsche E. (1968). Secretion of insulin induced by amino acids and glucose in diabetes mellitus. *J Clin Endocrinol Metab*. **28**: 266-276.
172. Pallotta JA, and Kennedy PJ. (1968). Response of plasma insulin and growth hormone to carbohydrate and protein feeding. *Metabolism*. **17**: 901-908.
173. Rabinowitz D, Merimee TJ, Maffezzoli R, and Burgess JA. (1966). Patterns of hormonal release after glucose, protein, and glucose plus protein. *Lancet*. **2**: 454-456.

174. Nuttall FQ, Gannon MC, Wald JL, and Ahmed M. (1985). Plasma glucose and insulin profiles in normal subjects ingesting diets of varying carbohydrate, fat, and protein content. *J Am Coll Nutr.* **4**: 437-450.
175. Gannon MC, Nuttall FQ, Grant CT, Ercan-Fang S, and Ercan-Fang N. (1998). Stimulation of insulin secretion by fructose ingested with protein in people with untreated type 2 diabetes. *Diabetes Care.* **21**: 16-22.
176. Gannon MC, Nuttall FQ, Lane JT, and Burmeister LA. (1992). Metabolic response to cottage cheese or egg white protein, with or without glucose, in type II diabetic subjects. *Metabolism.* **41**: 1137-1145.
177. Nuttall FQ, Mooradian AD, Gannon MC, Billington C, and Krezowski P. (1984). Effect of protein ingestion on the glucose and insulin response to a standardized oral glucose load. *Diabetes Care.* **7**: 465-470.
178. van Loon LJ, Kruijshoop M, Verhagen H, Saris WH, and Wagenmakers AJ. (2000). Ingestion of protein hydrolysate and amino acid-carbohydrate mixtures increases postexercise plasma insulin responses in men. *J Nutr.* **130**: 2508-2513.

179. van Loon LJ, Saris WH, Verhagen H, and Wagenmakers AJ. (2000). Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. *Am J Clin Nutr.* **72**: 96-105.
180. Manders RJ, Koopman R, Beelen M, Gijsen AP, Wodzig WK, Saris WH, and van Loon LJ. (2008). The muscle protein synthetic response to carbohydrate and protein ingestion is not impaired in men with longstanding type 2 diabetes. *J Nutr.* **138**: 1079-1085.
181. Manders RJ, Koopman R, Sluijsmans WE, van den Berg R, Verbeek K, Saris WH, Wagenmakers AJ and van Loon LJ. (2006). Co-ingestion of a protein hydrolysate with or without additional leucine effectively reduces postprandial blood glucose excursions in Type 2 diabetic men. *J Nutr.* **136**: 1294-1299.
182. Manders RJ, Praet SF, Meex RC, Koopman R, de Roos AL, Wagenmakers AJ, Saris WH, and van Loon LJ. (2006). Protein hydrolysate/leucine co-ingestion reduces the prevalence of hyperglycemia in type 2 diabetic patients. *Diabetes Care.* **29**: 2721-2722.
183. Gunnerud UJ, Heinzle C, Holst JJ, Ostman EM, Björck IM. (2012). Effects of pre-meal drinks with protein and amino acids on glycemic and metabolic responses at a subsequent composite meal *PLoS One.* **7/9**: e44731.

184. Michaliszyn SF, Sjaarda LA, Mihalik SJ, Lee S, Bacha F, Chace DH, De Jesus VR, Vockley J, Arslanian SA. (2012). Metabolomic Profiling of Amino Acids and β -Cell Function Relative to Insulin Sensitivity in Youth. *J Clin Endocrinol Metab.* **11**: E2119-24.
185. Manders RJ, Wagenmakers AJ, Koopman R, Zorenc AH, Menheere PP, Schaper NC, Saris WH, and van Loon LJ. (2005). Co-ingestion of a protein hydrolysate and amino acid mixture with carbohydrate improves plasma glucose disposal in patients with type 2 diabetes. *Am J Clin Nutr.* **82**: 76-83.
186. Gannon MC, Nuttall JA, Damberg G, Gupta V, and Nuttall FQ. (2001). Effect of protein ingestion on the glucose appearance rate in people with type 2 diabetes. *J Clin Endocrinol Metab.* **86**: 1040-1047.
187. Storlien, L. H., Jenkins, A. B., Chisholm, D. J., Pascoe, W. S., Khouri, S. and Kraegen, E. W. (1991). Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. *Diabetes.* **40**: 280-289.
188. Lovegrove, J. A., Lovegrove, S. S., Lesauvage, S. V., Brady, L. M., Saini, N., Minihane, A. M. and Williams, C. M. (2004). Moderate fish-oil supplementation reverses low-platelet, long-chain n \hat{A} -3 polyunsaturated fatty acid status and reduces plasma

- triacylglycerol concentrations in British Indo-Asians. *The American Journal of Clinical Nutrition*. **79**: 974-982.
189. Rustan, A. C., Nenseter, M. S. and Drevon, C. A. (1997). Omega-3 and Omega-6 Fatty Acids in the Insulin Resistance Syndrome. *Annals of the New York Academy of Sciences*. **827**: 310-326.
 190. Adams, J. M., Pratipanawatr, T., Berria, R., Wang, E., DeFronzo, R. A., Sullards, M. C. and Mandarino, L. J. (2004). Ceramide Content Is Increased in Skeletal Muscle From Obese Insulin-Resistant Humans. *Diabetes*. **53**: 25-31.
 191. Strackowski, M., Kowalska, I., Nikolajuk, A., Dzienis-Strackowska, S., Kinalska, I., Baranowski, M., Zendzian-Piotrowska, M., Brzezinska, Z. and Gorski, J. (2004). Relationship Between Insulin Sensitivity and Sphingomyelin Signaling Pathway in Human Skeletal Muscle. *Diabetes*. **53**: 1215-1221.
 192. Xu, X., Bittman, R., Duportail, G., Heissler, D., Vilcheze, C. and London, E. (2001). Effect of the Structure of Natural Sterols and Sphingolipids on the Formation of Ordered Sphingolipid/Sterol Domains (Rafts). *J Biol Chem*. **276**: 33540-33546.
 193. Gao, D., Griffiths, H. R. and Bailey, C. J. (2009). Oleate protects against palmitate-induced insulin resistance in L6 myotubes. *Br. J. Nutr.* **102**: 1557-1563.

194. Gao D, Pararasa C, Dunston CR, Bailey CJ, Griffiths HR (2012). Palmitate promotes monocyte atherogenicity via de novo ceramide synthesis. *Free Rad. Biol. Med.* **53**: 796-806

195. Scalfi, L., Coltorti, A. and Contaldo, F. (1991). Postprandial thermogenesis in lean and obese subjects after meals supplemented with medium-chain and long-chain triglycerides. *Ame. J. Clin. Nutr.* **53**: 1130-1133.

196. Li, D., Xu, T., Takase, H., Tokimitsu, I., Zhang, P., Wang, Q., Yu, X. and Zhang, A. (2008). Diacylglycerol-induced improvement of whole-body insulin sensitivity in type 2 diabetes mellitus: A long-term randomized, double-blind controlled study. *Clin. Nutr. (Edinburgh, Scotland)*. **27**: 203-211.

197. Zambon, S., Friday, K., Childs, M., Fujimoto, W., Bierman, E. and Ensinnck, J. (1992). Effect of glyburide and omega 3 fatty acid dietary supplements on glucose and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. *Amer J Clin Nutr.* **56**: 447-454.

198. West, S., Hecker, K., Mustad, V., Nicholson, S., Schoemer, S., Wagner, P., Hinderliter, A., Ulbrecht, J., Ruey, P. and Kris-Etherton, P. (2005). Acute effects of monounsaturated fatty

acids with and without omega-3 fatty acids on vascular reactivity in individuals with type 2 diabetes. *Diabetologia*. **48**: 113-122.

199. Brady, L. M., Lovegrove, S. S., Lesauvage, S. V., Gower, B. A., Minihane, A.-M., Williams, C. M. and Lovegrove, J. A. (2004). Increased n⁶ polyunsaturated fatty acids do not attenuate the effects of long-chain n³ polyunsaturated fatty acids on insulin sensitivity or triacylglycerol reduction in Indian Asians. *Ame J Clin Nutr*. **79**: 983-991
200. Kelley DS, Adkins Y, Woodhouse LR, Swislocki A, Mackey BE, Siegel D. (2012). Docosahexaenoic acid supplementation improved lipocentric but not glucocentric markers of insulin sensitivity in hypertriglyceridemic men. *Metab Syndr Relat Disord*. **10/1**: 32-8
201. Li, S.-C., Liu, Y.-H., Liu, J.-F., Chang, W.-H., Chen, C.-M. and Chen, C. Y. O. Almond consumption improved glycemic control and lipid profiles in patients with type 2 diabetes mellitus. *Metabolism: clinical and experimental*. **60**: 474-479
202. Madigan, C., Ryan, M., Owens, D., Collins, P. and Tomkin, G. H. (2000). Dietary unsaturated fatty acids in type 2 diabetes: higher levels of postprandial lipoprotein on a linoleic acid-rich sunflower oil diet compared with an oleic acid-rich olive oil diet. *Diabetes Care*. **23**: 1472-1477.

203. Jans A, Konings E, Goossens GH, Bouwman FG, Moors CC, Boekschoten MV, *et al.* (2012). PUFAs acutely affect triacylglycerol-derived skeletal muscle fatty acid uptake and increase postprandial insulin sensitivity. *Amer J Clin Nutr.* **95/4**: 825-36.
204. Thomsen, C., Storm, H., Holst, J. J. and Hermansen, K. (2003). Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. *Amer J Clin Nutr.* **77**: 605-611.
205. Sloth, B., Due, A., Larsen, T. M., Holst, J. J., Heding, A. and Astrup, A. (2009). The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period. *Br J Nutr.* **101**: 1846-1858.
206. Paniagua JA, de la Sacristana AG, Sánchez E, Romero I, Vidal-Puig A, Berral FJ, Escribano A, Moyano MJ, Pérez-Martínez P, López-Miranda J, Pérez-Jiménez F. (2007). A MUFA-Rich Diet Improves Postprandial Glucose, Lipid and GLP-1 Responses in Insulin-Resistant Subjects. *J Ame Coll Nutr.* **26**: 434-444.
207. Manning, P. J., Sutherland, W. H., Hendry, G., de Jong, S. A., McGrath, M. and Williams, S. M. (2004). Changes in Circulating Postprandial Proinflammatory Cytokine

Concentrations in Diet-Controlled Type 2 Diabetes and the Effect of Ingested Fat. *Diabetes Care*. **27**: 2509-2511.

208. Piers, L. S., Walker, K. Z., Stoney, R. M., Soares, M. J. and O'Dea, K. (2003). Substitution of saturated with monounsaturated fat in a 4-week diet affects body weight and composition of overweight and obese men. *Br J Nutr*. **90**: 717-727.
209. McCargari, L. J., Innis, S. M., Bowron, E., Leichter, J., Dawson, K., Toth, E. and Wall, K. M. (1998). Effect of enteral nutritional products differing in carbohydrate and fat on indices of carbohydrate and lipid metabolism in patients with NIDDM. *Mol. Cell Biochem*. **188**: 81-89.
210. Christiansen, E., Schnider, S., Palmvig, B., Tauber-Lassen, E. and Pedersen, O. (1997). Intake of a Diet High in Trans Monounsaturated Fatty Acids or Saturated Fatty Acids: Effects on postprandial insulinemia and glycemia in obese patients with NIDDM. *Diabetes Care*. **20**: 881-887.
211. Lefevre, M., Lovejoy, J. C., Smith, S. R., DeLany, J. P., Champagne, C., Most, M. M., Denkins, Y., de Jonge, L., Rood, J. and Bray, G. A. (2005). Comparison of the acute response to meals enriched with cis- or trans-fatty acids on glucose and lipids in overweight individuals with differing FABP2 genotypes. *Metab Clin Exper*. **54**: 1652-1658.

212. Lopez, S., Bermudez, B., Ortega, A., Varela, L. M., Pacheco, Y. M., Villar, J., Abia, R. and Muriana, F. J. Effects of meals rich in either monounsaturated or saturated fat on lipid concentrations and on insulin secretion and action in subjects with high fasting triglyceride concentrations. *Amer J Clin Nutr.* **93**: 494-499.
213. Lerman-Garber I, Ichazo-Cerro S, Zamora-González J, Cardoso-Saldaña G, Posadas-Romero C. Effect of a high-monounsaturated fat diet enriched with avocado in NIDDM patients. *Diabetes Care.* **4**: 311-5.
214. Devaraj, S., Wang-Polagruto, J., Polagruto, J., Keen, C. L. and Jialal, I. (2008). High-fat, energy-dense, fast-foodâ€style breakfast results in an increase in oxidative stress in metabolic syndrome. *Metab. Clin. Experl.* **57**: 867-870.
215. Rivellese AA, Maffettone A, Iovine C, Di Marino L, Annuzzi G, Mancini M, Riccardi G. (1996). Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. *Diabetes Care.* **11**: 1207-13.
216. Thompson, AK., Minihaane, AM. and Williams, CM. (2011). Trans fatty acids, insulin resistance and diabetes. *Eur J Clin Nutr.* **65**: 553-564.

217. Gerss J, K. W. (2009). The questionable association of vitamin E supplementation and mortality--inconsistent results of different meta-analytic approaches. *Cell Mol Biol (Noisy-le-grand)*. **55**: 1111-1120.
218. Page, G. L. J., Laight, D. and Cummings, M. H. (2011). Thiamine deficiency in diabetes mellitus and the impact of thiamine replacement on glucose metabolism and vascular disease. *International Journal of Clinical Practice*. **65**: 684-690.
219. Mitri, J., Muraru, M. D. and Pittas, A. G. (2011). Vitamin D and type 2 diabetes: a systematic review. *Eur J Clin Nutr*. **65**: 1005-1015.
220. Stirban, A., Negrean, M., Stratmann, B., Gawlowski, T., Horstmann, T., Götting C., Kleesiek, K., Mueller-Roesel, M., Koschinsky, T., Uribarri, J., Vlassara, H. and Tschoepe, D. (2006). Benfotiamine Prevents Macro- and Microvascular Endothelial Dysfunction and Oxidative Stress Following a Meal Rich in Advanced Glycation End Products in Individuals With Type 2 Diabetes. *Diabetes Care*. **29**: 2064-2071.
221. Stirban, A., Negrean, M., Stratmann, B., Götting C., Salomon, J., Kleesiek, K. and Tschoepe, D. (2007). Adiponectin Decreases Postprandially Following a Heat-Processed Meal in Individuals With Type 2 Diabetes. *Diabetes Care*. **30**: 2514-2516.

222. Altschul, R., Hoffer, A. and Stephen, J. (1955). Influence of nicotinic acid on serum cholesterol in man. *Arch Biochem Biophys.* **54**: 558-559.
223. Plaisance, E. P., Mestek, M. L., Mahurin, A. J., Taylor, J. K., Moncada-Jimenez, J. and Grandjean, P. W. (2008). Postprandial triglyceride responses to aerobic exercise and extended-release niacin. *Amer J Clin Nutr.* **88**: 30-37.
224. Goldberg, R. B. and Jacobson, T. A. (2008). Effects of Niacin on Glucose Control in Patients With Dyslipidemia. *Mayo Clinic Proc.* **83**: 470-478.
225. Bays, H., Shah, A., Dong, Q., McCrary Sisk, C. and Maccubbin, D. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. *Int. J. Clin Practice.* **65**: 436-445.
226. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med.* **365(24)**: 2255-67
227. Geohas, J., Daly, A., Juturu, V., Finch, M. and Komorowski, J. (2007). Chromium Picolinate and Biotin Combination Reduces Atherogenic Index of Plasma in Patients with

Type 2 Diabetes Mellitus: A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial. *Amer J Medl Sci* **333**: 145-153.

228. Muscogiuri, G., Sorice, G. P., Prioletta, A., Policola, C., Casa, S. D., Pontecorvi, A. and Giaccari, A. Will vitamin D reduce insulin resistance? Still a long way to go. *Amer J Clin Nutr.* **93**: 672-673.
229. Nikooyeh, B., Neyestani, T. R., Farvid, M., Alavi-Majd, H., Houshiarrad, A., Kalayi, A., Shariatzadeh, N., Gharavi, A. a., Heravifard, S., Tayebinejad, N., Salekzamani, S. and Zahedirad, M. (2011). Daily consumption of vitamin D or vitamin D calcium “fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial. *Amer J Clin Nutr.* **93**: 764-771.
230. Jorde, R. and Figenschau, Y. (2009). Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. *Eur J Nutr.* **48**: 349-354.
231. Tai, K., Need, A. G., Horowitz, M. and Chapman, I. M. (2008). Glucose tolerance and vitamin D: Effects of treating vitamin D deficiency. *Nutr. (Burbank, Los Angeles County, Calif.).* **24**: 950-956

232. O'Sullivan, A., Balducci, D., Paradisi, F., Cashman, K. D., Gibney, M. J. and Brennan, L. Effect of supplementation with vitamin D3 on glucose production pathways in human subjects. *Mol Nutr Food Res.* **55**: 1018-1025.
233. Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield JL, Ramachandran A, Riddle MC, Rydén LE, Zinman B, Afzal R, Yusuf S, Gerstein HC; TIDE Trial Investigators. (2012). Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. *Diabetologia.* **55**: 36-45.
234. Akbar S, Bellary S and Griffiths HR. (2011) Dietary antioxidant interventions in type 2 diabetes patients: a meta-analysis. *Br J. Diabetes Vascular Dis.* **11/2**: 62-6
235. Evans, M., Anderson, R. A., Smith, J. C., Khan, N., Graham, J. M., Thomas, A. W., Morris, K., Deely, D., Frenneaux, M. P., Davies, J. S. and Rees, A. (2003). Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus. *Eur. J.. Clin. Inv.* **33**: 231-238.
236. Carroll, M. F. and Schade, D. S. (2003). Timing of Antioxidant Vitamin Ingestion Alters Postprandial Proatherogenic Serum Markers. *Circulation.* **108**: 24-31.

237. Nappo, F., Esposito, K., Cioffi, M., Giugliano, G., Molinari, A. M., Paolisso, G., Marfella, R. and Giugliano, D. (2002). Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: Role of fat and carbohydrate meals. *J Amer Coll Cardiology*. **39**: 1145-1150.
238. Neri, S., Signorelli, S. S., Torrisi, B., Pulvirenti, D., Mauceri, B., Abate, G., Ignaccolo, L., Bordonaro, F., Cilio, D., Calvagno, S. and Leotta, C. (2005). Effects of antioxidant supplementation on postprandial oxidative stress and endothelial dysfunction: A single-blind, 15-day clinical trial in patients with untreated type 2 diabetes, subjects with impaired glucose tolerance, and healthy controls. *Clin Therap*. **27**: 1764-1773.
239. Masterjohn C, Mah E, Guo Y, Koo SI, Bruno RS. (2012). Gamma-Tocopherol abolishes postprandial increases in plasma methylglyoxal following an oral dose of glucose in healthy, college-aged men. *J Nutr Bioch* **23/3**: 292-8.
240. Cefalu W and Hu FB. (2004). Role of Chromium in Human Health and in Diabetes. *Diabetes Care*. **27/11**: 2741-2751.
241. Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, Feng J. (1997). Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. *Diabetes*. **46/11**: 1786-91.

242. Cheng N, Zhu X, Shi H, Wu W, Chi J, Cheng J, Anderson RA. (1999). Follow-up survey of people in China with type 2 diabetes mellitus consuming supplemental chromium. *Trace Elements Exp Res.* **12**: 55-60.
243. Frauchiger MT, Wenk C, Colombani PC. (2004). Effects of acute chromium supplementation on postprandial metabolism in healthy young men. *J Am Coll Nutr.* **23/4**: 351-7.
244. Khan LA, Alam AM, Ali L, Goswami A, Hassan Z, Sattar S, Banik NG, Khan AK. (1999). Serum and urinary magnesium in young diabetic subjects in Bangladesh. *Am J Clin Nutr.* **69/1**: 70-3.
245. Sales CH, Pedrosa LF, Lima JG, Lemos TM, Colli C. (2011). Influence of magnesium status and magnesium intake on the blood glucose control in patients with type 2 diabetes. *Clin Nutr.* **30/3**: 359-64.

246. Roth HP, Kirchgessner M. (1981). Zinc and insulin metabolism. *Biol Trace Elem Res.* **3**: 13-32.
247. Park JH, Grandjean CJ, Hart MH *et al.* (1986). Effect of pure zinc deficiency on glucose tolerance and insulin and glucagon levels. *Am J Physiol.* **251**: E273±E278.
248. Brun JF, Guinrand-Hugret R, Fons C *et al.* (1995). Effects of oral zinc gluconate on glucose effectiveness and insulin sensitivity in humans. *Biol Trace Elem Res.* **47**: 385±391.
249. Kinlaw WB, Levine AS, Morley JE *et al.* (1983). Abnormal zinc metabolism in type II diabetes mellitus. *Am J Med.* **75**: 273±277.
250. Chan MD, Liou SJ, Lin PY *et al.* (1998). Effects of zinc supplementation on the plasma glucose level and insulin activity in genetically obese (ob/ob) mice. *Biol Trace Elem Res.* **61**: 303±311.

251. Chen MD, Song YM, Lin PY. (2000). Zinc effects on hyper-glycemia and hypoleptinemia in streptozotocin-induced diabetic mice. *Horm Metab Res.* **32**: 107-109.
252. Gunasekara P, Hettiarachchi M, Liyanage C, Lekamwasam S. (2011). Effects of zinc and multimineral vitamin supplementation on glycemic and lipid control in adult diabetes. *Diabetes Metab Syndr Obes.* **26/4**: 53-60.
253. Hwang IK, Go VL, Harris DM, Yip I, Song MK. (2002). Effects of arachidonic acid plus zinc on glucose disposal in genetically diabetic (ob/ob) mice. *Diabetes Obes. Metab.* **4/2**: 124-31.
254. Hanhineva, K Torronen, R Bondia-Pons, I Pekkinen, J Kolehmainen, M Mykkanen, H Poutanen, K (2012). Impact of Dietary Polyphenols on Carbohydrate Metabolism. *Int J Mol Sci* **11**: 1365-1402.
255. Brasnyo, P Molnar, GA Mohas, M Marko, L Laczy, B Cseh, J Mikolas, E Szijarto, IA Merei, A Halmai, R Meszaros, LG Sumegi, B Wittmann, I (2011). Veratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients *Br J Nutr.* **106/3**: 383.

256. Kar, P Laight, D Rooprai, HK Shaw, KM Cummings, M (2009). Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity *Diabetic Med.* **26/5**: 526-531.
257. Serracclara, A Hawkins, F Perez, C Dominguez, E Campillo, JE Torres, MD (1998). Hypoglycemic action of an oral fig-leaf decoction in type-I diabetic patients *Diabetes Res Clin Pract.* **39/1**: 19-22.
258. Lehtonen, HM Jarvinen, R Linderborg, K Viitanen, M Venojarvi, M Alanko, H Kallio, H (2010). Postprandial hyperglycemia and insulin response are affected by sea buckthorn (*Hippophae rhamnoides ssp turkestanica*) berry and its ethanol-soluble metabolites *Eur J Clin Nutr.* **64/12**: 1465-1471.
259. Torronen, R Sarkkinen, E Tapola, N Hautaniemi, E Kilpi, K Niskanen, L (2010). Berries modify the postprandial plasma glucose response to sucrose in healthy subjects *Br J Nutr* **103/8**: 1094.

260. Visen, P Saraswat, B Visen, A Roller, M Bily, A Mermet, C He, K Bai, NIS Lemaire, B Lafay, S Ibarra, A (2009). Acute effects of *Fraxinus excelsior* L. seed extract on postprandial glycemia and insulin secretion on healthy J Ethnopharmacol. **126/2**: 226-232.
261. Grassi, D Lippi, C Necozone, S Desideri, G Ferri, C (2005). Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Amer J Clin Nutr. **81/3**: 611-614.
262. Grassi, D Desideri, G Necozone, S Lippi, C Casale, R Properzi, G Blumberg, JB Ferri, C (2008). Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark J. Nutr. **138/ 9**: 1671-1676.
263. Muniyappa, R Hall, G Kolodziej, TL Karne, RJ Crandon, SK Quon, MJ (2008). Cocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension Amer J Clin Nutr. **88/6**: 1685-1696.

264. Iso H, Date C, Wakai K, Fukui M, Tamakoshi A. (2006). The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. *Ann Intern Med.* **144/8**: 554-62.
265. Fukino Y, Ikeda A, Maruyama K, Aoki N, Okubo T and Iso H. (2008). Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. *Eur J Clin Nutr* **62**: 953–960.
266. Rebello SA, Chen CH, Naidoo N, Xu W, Lee J, Chia KS, Tai ES, van Dam RM. (2011). Coffee and tea consumption in relation to inflammation and basal glucose metabolism in a multi-ethnic Asian population: a cross-sectional study. *Nutr J.* **2**: 10:61.
267. Steptoe A; Gibson EL. (2007). Vuononvirta R; Hamer M; Wardle J; Rycroft JA; Martin JF; Erusalimsky JD. The effects of chronic tea intake on platelet activation and inflammation: a double-blind placebo controlled trial. *Atherosclerosis.* **193/2**: 277-82.

268. De Bacquer D; Clays E; Delanghe J; De Backer G. (2006). Epidemiological evidence for an association between habitual tea consumption and markers of chronic inflammation. *Atherosclerosis*. **189/2**: 428-35.
269. Maki T, Pham NM, Yoshida D, Yin G, Ohnaka K, Takayanagi R, Kono S. (2010). The relationship of coffee and green tea consumption with high-sensitivity C-reactive protein in Japanese men and women. *ClinChem Lab Med*. **48/6**: 849-54.
270. Sae-tan S, Grove KA, Lambert JD. (2011). Weight control and prevention of metabolic syndrome by green tea. *Pharmacol Res* **64**: 146– 154.
271. Tsuneki, H Ishizuka, M Terasawa, M Wu, J-B Sasaoka, T and Kimura I. (2004). Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans *BMC Pharmacol*. **4**: 18.
272. Josic J, Olsson AT, Wickeberg J, Lindstedt S, Hlebowicz J. (2010). Does green tea affect postprandial glucose, insulin and satiety in healthy subjects: a randomized controlled trial. *Nutr J*. **9**: 63.

273. Louie JC, Atkinson F, Petocz P, Brand-Miller JC. (2008). Delayed effects of coffee, tea and sucrose on postprandial glycemia in lean, young, healthy adults. *Asia Pac Clin Nutr.* **17/4:** 657-62.
274. Brown, AL Lane, J Coverly, J Stocks, J Jackson, S Stephen, A Bluck, L Coward, A Hendrickx, H. (2009). Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial *Br J Nutr* **101/6:** 886-894.
275. Fukino Y, Shimbo M, Aoki N, Okubo T, Iso H. (2005). Randomized controlled trial for an effect of green tea consumption on insulin resistance and inflammation markers. *J Nutr Sci Vitaminol (Tokyo).* **51/5:** 335-42.
276. Nagao, T Meguro, S Hase, T Otsuka, K Komikado, M Tokimitsu, I Yamamoto, T Yamamoto, KA (2009). Catechin-rich Beverage Improves Obesity and Blood Glucose Control in Patients With Type 2 Diabetes Obesity. **17/2:** 310-317.

277. Maruyama K, Iso H, Sasaki S, Fukino Y. (2009). The Association between Concentrations of Green Tea and Blood Glucose Levels. *J Clin BiochemNutr.* **44/1**: 41-5.

278. Bryans, JA Judd, PA Ellis, PR (2007). The effect of consuming instant black tea on postprandial plasma glucose and insulin concentrations in healthy humans. *J Amer Coll Nutr* **26/5**: 471-477.

279. van Dam RM, Hu FB. (2005). Coffee Consumption and Risk of Type 2 Diabetes A Systematic Review *JAMA.* **294**: 97-104.

280. Tunncliffe JM, Shearer J. (2008). Coffee, glucose homeostasis, and insulin resistance: physiological mechanisms and mediators. *Appl Physiol Nutr Metab.* **33/6**: 1290-300.

281. Floegel A, Pischon T, Bergmann MM, Teucher B, Kaaks R, Boeing H. (2012). Coffee consumption and risk of chronic disease in European Prospective Investigation into Cancer and Nutrition (EPIC)-Germany study. *Am J Clin Nutr* **95/4**: 901-8.

282. Williams CJ, Fargnoli JL, Hwang JJ, van Dam RM, Blackburn GL, Hu FB, Mantzoros CS. (2008). Coffee consumption is associated with higher plasma adiponectin concentrations in

women with or without type 2 diabetes: a prospective cohort study. *Diabetes Care*. **31/3**: 504–507.

283. Wedick NM, Brennan AM, Sun Q, Hu FB, Mantzoros CS, van Dam RM. (2011). Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. *Nutr. J.* **10**: 93
284. van Dam RM. (2006). Coffee and type 2 diabetes: from beans to beta-cells. *Nutr Metab Cardiovasc Dis.* **16/1**: 69-77.
285. Johnston, KL Clifford, MN Morgan, LM (2003). Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. *Amer J Clin Nutr.* **78/4**: 728-733.
286. Moisey LL, Robinson LE, Graham TE. (2010). Consumption of caffeinated coffee and a high carbohydrate meal affects postprandial metabolism of a subsequent oral glucose tolerance test in young, healthy males. *Br J Nutr.* **103/6**: 833-41.

287. Moisey LL, Kacker S, Bickerton AC, Robinson LE, Graham TE. (2008). Caffeinated coffee consumption impairs blood glucose homeostasis in response to high and low glycemic index meals in healthy men *Am J Clin Nutr.* **87**: 1254–61.
288. Jenkins, D.J. Kendall, C.W. Josse, A.R. Salvatore, S. Brighenti, F. Augustin, L.S. *et al.* (2006). Almonds decrease postprandial glycemia, insulinemia, and oxidative damage in healthy individuals. *J Nutr.* **136**: 2987-92.
289. Josse, A.R. Kendall, C.W. Augustin, L.S. Ellis, P.R. and Jenkins. D.J. (2007). Almonds and postprandial glycemia--a dose-response study. *Metabolism.* **56**: 400-4.
290. Kendall, C.W. Esfahani, A. Josse, A.R. Augustin, L.S. Vidgen, E. and Jenkins. D.J. (2011). The glycemic effect of nut-enriched meals in healthy and diabetic subjects. *Nutr Metab Cardiovasc Dis.* **21/1**: S34-9.
291. Kendall, C.W. Josse, A.R. Esfahani, A. and Jenkins. D.J. (2011). The impact of pistachio intake alone or in combination with high-carbohydrate foods on post-prandial glycemia. *Eur J Clin Nutr.* **65**: 696-702.

292. Cohen A.E. and Johnston. C.S. (2011). Almond ingestion at mealtime reduces postprandial glycemia and chronic ingestion reduces hemoglobin A(1c) in individuals with well-controlled type 2 diabetes mellitus. *Metabolism*. **60**: 1312-7.
293. Mori, A.M. Considine, R.V. and Mattes. R.D. (2011). Acute and second-meal effects of almond form in impaired glucose tolerant adults: a randomized crossover trial. *Nutr Metab*. **8/1**: 6.
294. Kendall, C.W. Josse, A.R. Esfahani, A. and Jenkins. D.J. (2010). Nuts, metabolic syndrome and diabetes. *Br J Nutr*. **104**: 465-73.
295. Jenkins DJ, Kendall CW, Banach MS, Srichaikul K, Vidgen E, Mitchell S, Parker T, Nishi S, Bashyam B, de Souza R, Ireland C, Josse RG. (2011). Nuts as a replacement for carbohydrates in the diabetic diet. *Diabetes Care*. **34**: 1706-11.
296. Goni, I Valdivieso, L Garcia-Alonso, A (2000). Nori seaweed consumption modifies glycemic response in healthy volunteers *Nutr Res*. **20/10**: 1367-1375.
297. Dascalu, J.L. Sievenpiper, A.L. Jenkins, M.P. Stavro, L.A. Leiter, J.T. Arnason, *et al.* (2007). Five batches representative of Ontario-grown American ginseng root produce

comparable reductions of postprandial glycemia in healthy individuals. *Can J Physiol Pharmacol.* **85**: 856-64.

298. Vuksan, V. Sievenpiper, J.L. Koo, V.Y. Francis, T. Beljan-Zdravkovic, U. Xu, Z. *et al.* (2000a). American ginseng (*Panax quinquefolius* L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. *Arch Intern Med.* **160**: 1009-13.
299. Vuksan, V. Sievenpiper, J.L. Wong, J. Xu, Z. Beljan-Zdravkovic, U. Arnason, J.T. *et al.* (2001). American ginseng (*Panax quinquefolius* L.) attenuates postprandial glycemia in a time-dependent but not dose-dependent manner in healthy individuals. *Am J Clin Nutr.* **73**: 753-8.
300. Vuksan, V. Stavro, M.P. Sievenpiper, J.L. Koo, V.Y. Wong, E. Beljan-Zdravkovic, U. *et al.* (2000b). American ginseng improves glycemia in individuals with normal glucose tolerance: effect of dose and time escalation. *J Am Coll Nutr.* **19**: 738-44.
301. Vuksan, V. Stavro, M.P. Sievenpiper, J.L. Beljan-Zdravkovic, U. Leiter, L.A. Josse, R.G. *et al.* (2000c). Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. *Diabetes Care.* **23**: 1221-6.

302. Sievenpiper, J.L. Arnason, J.T. Leiter, L.A. and Vuksan. V. (2004). Decreasing, null and increasing effects of eight popular types of ginseng on acute postprandial glycemic indices in healthy humans: the role of ginsenosides. *J Am Coll Nutr.* **23**: 248-58.
303. Sievenpiper, J.L. Arnason, J.T. Leiter, L.A. and Vuksan. V. (2003). Variable effects of American ginseng: a batch of American ginseng (*Panax quinquefolius* L.) with a depressed ginsenoside profile does not affect postprandial glycemia. *Eur J Clin Nutr.* **57**: 243-8.
304. Sievenpiper, J.L. Arnason, J.T. Leiter, L.A. and Vuksan. V. (2003). Null and opposing effects of Asian ginseng (*Panax ginseng* C.A. Meyer) on acute glycemia: results of two acute dose escalation studies. *J Am Coll Nutr.* **22**: 524-32.
305. Reay, J.L. Scholey, A.B. Milne, A. Fenwick, J. and Kennedy. D.O. (2009). *Panax ginseng* has no effect on indices of glucose regulation following acute or chronic ingestion in healthy volunteers. *Br J Nutr.* **101**: 1673-8.
306. Reay, J.L. Kennedy, D.O. and Scholey. A.B. (2006). The glycaemic effects of single doses of *Panax ginseng* in young healthy volunteers. *Br J Nutr.* **96**: 639-42.

307. Sievenpiper, J.L. Sung, M.K. Di Buono, M. Seung-Lee, K. Nam, K.Y. Arnason, J.T. *et al.* (2006). Korean red ginseng rootlets decrease acute postprandial glycemia: results from sequential preparation- and dose-finding studies. *J Am Coll Nutr.* **25**: 100-7.
308. De Souza, L.R. Jenkins, A.L. Sievenpiper, J.L. Jovanovski, E. Rahelic, D. and Vuksan. V. (2011). Korean red ginseng (*Panax ginseng* C.A. Meyer) root fractions: differential effects on postprandial glycemia in healthy individuals. *J Ethnopharmacol.* **137**: 245-50.
309. Vuksan, V Sung, MK Sievenpiper, JL Stavro, PM Jenkins, AL Di Buono, M Lee, KS Leiter, LA Nam, KY Arnason, JT Choi, M Naeem, A (2008). Korean red ginseng (*Panax ginseng*) improves glucose and insulin regulation in well-controlled, type 2 diabetes: Results of a randomized, double-blind, placebo-controlled study of efficacy and safety *Nutr Metab Cardiovascular Dis.* **18/1**: 46-56.
310. Vuksan, V. Xu, Z. Jenkins, A.L. Beljan-Zdravkovic, U. Sievenpiper, J.L. Leiter, L.A. *et al.* (2000d). American ginseng improves long-term glycemic control in type 2 diabetes: double-blind placebo controlled crossover trial (abstract). *Diabetes.* **49/1**: A:95.

311. Vuksan, V. Sievenpiper, J.L. Sung, M.K. Di Buono, M. Stavro, M.P. Jenkins, A.L. *et al.* (2003). Safety and efficacy of Korean red ginseng intervention (SAEKI): results of a double-blind, placebo-controlled crossover trial in type 2 diabetes. *Diabetes*. **52/1**: A:137.
312. Sotaniemi, E.A. Haapakoski, E. and Rautio. A. (1995). Ginseng therapy in non-insulin-dependent diabetic patients. *Diabetes Care*. **18**: 1373-5.
313. Markey, O McClean, CM Medlow, P Davison, GW Trinick, TR Duly, E Shafat, A (2011). Effect of cinnamon on gastric emptying, arterial stiffness, postprandial lipemia, glycemia, and appetite responses to high-fat breakfast *Cardiovascular Dis*. **10**: 78.
314. Heacock, PM Hertzler, SR Williams, JA Wolf, BW (2004). Effects of a medical food containing an herbal alpha-glucosidase inhibitor on postprandial glycemia and insulinemia in healthy adults *J Amer Dietetic Ass*. **105/1**: 65-71.
315. Collene, AL Hertzler, SR Williams, JA Wolf, BW (2005). Effects of a nutritional supplement containing *Salacia oblonga* extract and insulinogenic amino acids on postprandial glycemia, insulinemia, and breath hydrogen responses in healthy adults *Nutr*. **21/7-8**: 848-854.

316. Williams, JA Choe, YS Noss, MJ Baumgartner, CJ Mustad, VA (2007). Extract of *Salacia oblonga* lowers acute glycemia in patients with type 2 diabetes. *Amer J Clin Nutr.* **86/1**: 124-130.

317. Matsuda, H., Yoshikawa, M., Morikawa, T., Tanabe, G., Muraoka, O. (2005). Antidiabetogenic constituents from *Salacia* species. *J Trad Med.* **22/1**: 145-153.

318. Clegg, ME Pratt, M Meade, CM Henry, CJK. (2011). The addition of raspberries and blueberries to a starch-based food does not alter the glycaemic response. *Br J Nutr.* **106/3**: 335-338.

319. Josic, J Olsson, AT Wickeberg, J Lindstedt, S Hlebowicz, J (2010). Does green tea affect postprandial glucose, insulin and satiety in healthy subjects: a randomized controlled trial *Nutr J.* **9**: 63.

320. Duffy, V. B., & Sigman-Grant, M. (2004). Position of the American Dietetic Association. Use of nutritive and non-nutritive sweeteners. *Journal of the American Dietetic Association* **104**: 255–275

321. Fitch C, Keim KS. (2012). Academy of Nutrition and Dietetics. Position of the Academy of Nutrition and Dietetics: use of nutritive and nonnutritive sweeteners. *J Acad Nutr Diet.* **112/5**: 739-58.

322. Fernstrom JD, Munger SD, Sclafani A, de Araujo IE, Roberts A, Molinary S. (2012). Mechanisms for sweetness. *J Nutr.* **142/6**: 1134S-41S.

323. Fujita Y, Wideman RD, Speck M, Asadi A, King DS, Webber TD, Haneda M, Kieffer TJ. (2009). Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo. *Am J Physiol Endocrinol Metab.* **296**: E473-9.

324. Härtel B, Graubau HL, Schneider B. (1993). The influence of sweetener solutions on the secretion of insulin and the blood glucose level. *Ernährungsumschau.* **40**: 152-5.

325. Mezitis NH, Maggio CA, Koch P, Quidooos A, Allison DB, Pi-Sunyer FX. (1996). Glycemic effect of a single high oral dose of the novel sweetener sucralose in patients with diabetes. *Diabetes Care.* **19**: 1004-5.

326. Roberts A. (1999). Sucralose and diabetes. *Food Food Ingrid Jpn.* **182**: 49-55.

327. Grotz VL, Henry RF, McGill JB, Prince MJ, Shamoon H, Trout JR, Pi-Sunyer FX. (2003). Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. *J Am Diet Assoc.* **103**: 1607–12.
328. Maki KC, Curry LL, Reeves MS, Toth PD, McKenney JM, Farmer MV, Schwartz SL, Lubin BC, Boileau AC, Dicklin MR, Carakostas MC, Tarka SM. (2008). Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. *Food Chem Toxicol.* **46/7**: S47-53.
329. Anton SD, Martin CK, Han H, Coulon S, Cefalu WT, Geiselman P, Williamson DA. (2010). Effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels. *Appetite.* **55/1**: 37-43.
330. Raben A, Møller BK, Flint A, Vasilaris TH, Christina Møller A, Juul Holst J, Astrup A. (2011). Increased postprandial glycaemia, insulinemia, and lipidemia after 10 weeks' sucrose-rich diet compared to an artificially sweetened diet: a randomised controlled trial. *Food Nutr Res.* **55**: doi: 10.3402/fnr.v55i0.5961.

331. Brown RJ, Walter M, Rother KI. (2012). Effects of DietSoda on Gut Hormones in Youths With Diabetes Diabetes Care. **35**: 959-964.
332. Gardner C, Wylie-Rosett J, Gidding SS, Steffen LM, Johnson RK, Reader D, Lichtenstein AH. (2012). American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Disease in the Young; American Diabetes AssociationNonnutritive sweeteners: current use and health perspectives: a scientific statement from the American Heart Association and the American Diabetes Association.Diabetes Care. **35/8**: 1798-808.
333. Torsdottir and Andersson. H. (2009). Effect on the postprandial glycaemic level of the addition of water to a meal ingested by healthy subjects and type 2 (non-insulin-dependent) diabetic patients. Diabetologia. **32**: 231-5.
334. Gregersen, S. Rasmussen, O. Winther, E. and Hermansen. K. (1990). Water volume and consumption time: influence on the glycemic and insulinemic responses in non-insulin-dependent diabetic subjects. Am J Clin Nutr. **52**: 515-8.

335. Carlsson S, Hammar N, Grill V. (2005). Alcohol consumption and type 2 diabetes. Meta-analysis of epidemiological studies indicates a U-shaped relationship *Diabetologia*. **48**: 1051–1054.
336. Kiechl S, Willeit J, Poewe W, Egger G, Oberhollenzer F, Muggeo M, Bonora E (1996). Insulin sensitivity and regular alcohol consumption: large, prospective, cross-sectional population study (Bruneck study). *Br Med J*. **313**: 1040–1044.
337. Facchini F; Chen YD; Reaven GM. (1994). Light-to-moderate alcohol intake is associated with enhanced insulin sensitivity. *Diabetes Care*. **17/2**: 115-9.
338. Kroenke CH, Chu NF, Rifai N, Spiegelman D, Hankinson SE, Manson JE, Rimm EB (2003). A cross-sectional study of alcohol consumption patterns and biologic markers of glycemic control among 459 women. *Diabetes Care*. **26**: 1971–1978.
339. Schroder H, Marrugat J, Fito M, Weinbrenner T, Covas MI. (2006). Alcohol consumption is directly associated with circulating oxidized low-density lipoprotein. *Free Radic Biol Med*. **40/8**: 1474-81.

340. Rajpathak SN, Freiberg MS, Wang C, Wylie-Rosett J, Wildman RP, Rohan TE, Robinson JG, Liu S, Wassertheil-Smoller S. (2010). Alcohol consumption and the risk of coronary heart disease in postmenopausal women with diabetes: Women's Health Initiative Observational Study. *Eur J Nutr.* **4**: 211-8.
341. Joosten MM, Beulens JW, Kersten S, Hendriks HF. (2008). Moderate alcohol consumption increases insulin sensitivity and ADIPOQ expression in postmenopausal women: a randomised, crossover trial. *Diabetologia.* **51**: 1375–1381.
342. Brand-Miller, J. C, Fatima, K. ; Middlemiss, C. ; Bare, M. ; Liu, V. ; Atkinson, F. ; Petocz, P. (2007). Effect of alcoholic beverages on postprandial glycemia and insulinemia in lean, young, healthy adults. *Amer J Clin Nutr.* **85/6**: 1545–1551.
343. Godley R, Brown RC, Williams SM, Green TJ. (2009). Moderate alcohol consumption the night before glycaemic index testing has no effect on glycaemic response. *Eur J Clin Nutr.* **63**: 692-94.

344. Pravdova E; Macho L; Fickova M. (2009) Alcohol intake modifies leptin, adiponectin and resistin serum levels and their mRNA expressions in adipose tissue of rats. *Endocrine Reg.* **43/3**: 117-25.
345. Liljeberg HGM & Björck IME. (1998). Delayed gastric emptying rate may explain improved glycaemia in healthy subjects to a starchy meal with added vinegar. *Eur. J. Clin. Nutr.* **52**: 368–371.
346. Darwiche G, Stman EM, Liljeberg HGM, Kallinen N, Björgell O, Björck IME & Almer L-O. (2001). Measurements of the gastric emptying rate by use of ultrasonography: studies in humans using bread with added sodium propionate. *Am J Clin. Nutr.* **74**: 254–258.
347. Ostman E, Granfeldt Y, Persson L, Björck I. (2005). Vinegar supplementation lowers glucose and insulin responses and increases satiety after a bread meal in healthy subjects. *Eur J Clin Nutr.* **59/9**: 983-8.
348. Liatis S, Grammatikou S, Poulia KA, Perrea D, Makrilakis K, Diakoumopoulou E, Katsilambros N. (2010). Vinegar reduces postprandial hyperglycaemia in patients with

type II diabetes when added to a high, but not to a low, glycaemic index meal. *Eur J Clin Nutr.* **64/7**: 727-32.

349. Mettler S, Schwarz I, Colombani PC. (2009). Additive postprandial blood glucose-attenuating and satiety-enhancing effect of cinnamon and acetic acid. *Nutr Res.* **29/10**: 723-7.
350. Hlebowicz J, Lindstedt S, Björgell O, Höglund P, Almér LO, Darwiche G. (2008). The botanical integrity of wheat products influences the gastric distention and satiety in healthy subjects. *Nutr J.* **27**: 7-12.
351. Cooper AJ, Forouhi NG, Ye Z, Buijsse B, Arriola L, Balkau B, Barricarte A, Beulens JW, Boeing H, Büchner FL, Dahm CC, de Lauzon-Guillain B, Fagherazzi G, Franks PW, Gonzalez C, Gioni S, Kaaks R, Key TJ, Masala G, Navarro C, Nilsson P, Overvad K, Panico S, Ramón Quirós J, Rolandsson O, Roswall N, Sacerdote C, Sánchez MJ, Slimani N, Sluijs I, Spijkerman AM, Teucher B, Tjønneland A, Tumino R, Sharp SJ, Langenberg C, Feskens EJ, Riboli E, Wareham NJ; The InterAct Consortium. (2012). Fruit and vegetable intake and type 2 diabetes: EPIC-InterAct prospective study and meta-analysis. *Eur J Clin Nutr.* **66/10**: 1082-92.
352. Thomas T, Pfeiffer, AFH. (2012). Foods for the prevention of diabetes: how do they work? *Diabetes Metab. Res Rev.* **2**: 25-49.

Table 1: Carbohydrates and carbohydrate foods and postprandial glycaemic control in healthy or diabetic individuals.

Reference	Design	Test products	Control	Study subjects	Duration	Glucose	Insulin
Larsen et al. 2000	Randomized crossover	Breakfast (CHO 50 g) Cooked polished rice: NP, TP, PP	WB	9 (6M/3F), T2DM, BMI = 26.6	3 h	iAUC: NP, TP, PP < control	iAUC: NP, TP, PP < control
Hallström et al. 2011	Randomized crossover	Breakfast(CHO50g) EAWB, EAWB-LA, WB	WB	14 (7F/7M), healthy, BMI = 22.2	3 h	iAUC (120 min): EAWB, EAWB-LA < WB	iAUC (120 min) ns
Granfeldt et al. 1995	Randomized crossover	Breakfast (CHO 50g) raw rolled oats (muesli), boiled rolled oats (porridge), boiled intact oat, boiled intact wheat	WB	9 M, healthy, 65-70 years, BMI 26.1	3 h	iAUC (90 min): muesli, porridge ns; intact oat, wheat < control	iAUC (90 min): muesli, porridge ns; intact oat, wheat < control
Granfeldt et al. 2000	Randomized crossover	Breakfast (CHO 50g) Oat flakes; thin roasted, thin roasted/steamed, thick raw, thick roasted, thick steamed Barley flakes: thin, thick steamed	WB	10 (5M/5F), healthy, BMI 21.0	3 h	iAUC (120 min): Oat - thick roasted steamed < control; thick raw < thin roasted/steamed Barley - ns	iAUC 120 min Oat - thick steamed and thick roasted < control Barley - ns
Frid et al. 2005	Randomized crossover	Breakfast (CHO 50g) WB: whey, lactose and lean ham Standardized Lunch (CHO 45g) Mashed potatoes/meatballs: whey, lactose and lean ham	WB with ham + lactose	14 (6M/8F), T2DM, BMI 26.2	4 h after breakfast 3 h after lunch	iAUC: Breakfast – ns Lunch - whey < control	iAUC: Breakfast - whey > control Lunch - whey > control
Nilsson et al. 2007	Randomized crossover	Breakfast (CHO 25g) Glc Drink: whey (W), Lys, Thr (2AA), Leu, Ile and Val (3AA), Lys, Thr, Leu, Ile, Val (5AA)	Glc	12 (6M/6F) healthy, BMI = 22.4	2 h	iAUC 90 min W and AA5 < control	iAUC 90 min W and AA3 > control
Järvi et	Random	Breakfast (CHO 53-57		1: 10 (5M/5F),	4 h	iAUC (120	iAUC (120

al. 1995	mizedC rossove r	E%) 1 Durum: Low-GI pasta, High-GI 2 Cereal/Bean: Low- GI, High-GI		T2DM, BMI = 26.7 2: 10 (2M/8F) T2DM, BMI = 27.0		min): pasta < bread; Cereal/Bea n low-GI < high-GI	min): pasta < bread; Cereal/Bean low-GI < high-GI
Robert and Ismail 2012	Rando mizedC rossove r	Breakfast Individual foods (CHO 25g): rice, pancake, flatbread, noodles Mixed meals (CHO 28- 32g): coconut milk rice, pancake/chicken curry, flat bread/dhal curry, fried noodles/chicken and prawn	Glc	10 (6M/4F), T2DM, BMI 28.1	3 h	iAUC: all foods < control; flatbread > rice, pancake pancake with chicken > pancake	
Wheeler et al. 1990	Rando mizedC rossove r Double- blind	Breakfast Glc (50g), HSH5875 ¹ , HSH6075 ¹	Glc	T2DM, n=6, BMI 31.7; T1DM, n=6, BMI 23.2 and non-diabetic (NGT) n=6, BMI 24.4	5 h	iAUC (5 h): NGT < DM2 and DM1 all meals; HSH-meals < Glc	iAUC (5 h): HSH-meals < Glc for NGT and DM2
d'Emden et al. 1987	Rando mizedC rossove r	Breakfast (CHO50g) Breads: white (WB), semolina (SB), white spaghetti (WS), whole meal, brown spaghetti (BS)		10 (3M/7F), T2DM, BMI 30.9	3 h	iAUC: WB, SB > WS, BS; WB vs. SB & WS vs. BS ns	iAUC: WB vs. SB, ns; WS < BS
Liljeberg et al. 1992	Rando mizedC rossove r	Breakfast (CHO 50g) Breads: WK, RK, OK, BK, scalded BK (SBK), barley flour (BF)	WB	10 (5M/5F), healthy, BMI normal	3 h	iAUC: WK, RK, BK and SBK < control	iAUC: all kernel bread < control
Panlasi gui & Thompson 2006	Rando mizedC rossove r	Breakfast (CHO 50g) intact brown rice, milled brown rice	WB	10 (3M/7F), healthy; 9 (5M/4F), T2DM	3 h	iAUC: both groups milled > intact	
Haber et al. 1977	Rando mizedC rossove r	Breakfast (CHO 60g) Apples: quartered/cored, Purée (fibre- disrupted), Juice (fibre- free)		10 (5M/5F), healthy	3 h	iAUC: ns	iAUC: juice > apples IIP: juice > purée > apples
Leclerc et al. 1994	Rando mizedC rossove r	Breakfast (CHO 60 E%) Glc: HV-GG, LV-GG Pre-gelatinized Starch (S): HV, LV		6 (3M/3F), healthy	3 h	iAUC (90 min): SHV < SLV SLV < Glc- LV	iAUC (90 min): both HV < LV SLV < Glc- LV

Ellis et al. 1991	Randomized crossover	Breakfast (CHO 75g) WB + GG flour: high (M150), medium (M90), low (M60) M _W WB + granulated GG: coarse, medium, fine particle size	WB	17 (14M/3F), healthy, BMI 22.8	2 h		iAUC: control > all test bread products
Golay et al. 1995	Randomized crossover	Breakfast (CHO 52 E%) Standard Formula: soy/milk protein, sunflower/palm oil, maltodextrin/ sucrose; Diabetic Formula: milk protein, rape-seed oil, partially hydrolysed starch/fructose Diabetic Formula: + hydrolyzed GG		6 (3M/3F), T2DM, BMI 30.4	4 h	iAUC: diabetic formula + guar < standard	iAUC: diabetic formula < standard
Pastors et al. 1991	Randomized crossover	Breakfast (CHO 53 E%) preceded by Placebo, Psyllium	Placebo	18 (6M/12F), T2DM	5 h	iAUC: ns	iAUC: Psyllium < Placebo
Rosén et al. 2009	Randomized crossover	Breakfast (CHO 40 g) white WP, ERB, ERP, WGRB, WGRB+LA, WGRP, bran RB	WB	12 (9M/3F), healthy, BMI= 23.1	3 h	iAUC (120 min): control > ERB, ERP, WGRB-LA, WGRP	iAUC (120 min): Control > ERB, ERP, WGRB, WGRB-lac,
Rosén et al. 2011	Randomized crossover	Breakfast (CHO 50 g) ERB, ERB-LA, WGRB, WGRB-LA, boiled RK, boiled WK	WB	10 (5M/5F), healthy, BMI = 22.6	4.5 h	IGP: control > ERB-LA, RK, WK, WGRB, WGRB-LA,	IIP: control > all test products

iAUC, integrated area under the curve; AUC, area under the curve; CHO, carbohydrate; DF, dietary fiber;

NP, non-parboiled; TP, traditionally parboiled; PP, pressure parboiled; B, boiled, EA, elevated amylose;

HV/LV, high/low viscosity; AA, amino acid; GG, guar gum; LA, lactic acid; WB, white bread, WP, wheat

porridge; ERB, endosperm rye bread; ERP, endosperm rye porridge; WGRB, wholegrain rye bread;

WGRP, wholegrain rye porridge; RK, rye kernel; WK, wheat kernel; OK, oat kernel; BK, barley kernel;

T1DM, type 1 diabetes; T2DM, type 2 diabetes; Glc, glucose; IGP, Incremental Glucose Peak; IIP,

Incremental Insulin Peak; HSH, hydrogenated starch hydrolysates; BMI, body mass index (given as mean

in kg m⁻²),¹ HSH5875 (maltitol 60%, sorbitol 7% and reduced maltooligosaccharides 33%), HSH 6075

(reduced maltooligosaccharides 78%, sorbitol 14% and maltitol 8%).

Table 2: Dietary fibre and postprandial glycaemic control in diabetic individuals.

Reference	Design	Fibre type / fibre source	Control	Study subjects	Duration	Glucose (Glc)	Insulin (Ins)
Maki et al. 2009	Randomised Crossover DB	Breakfast (CHO 75 g) (HPMC 1, 2, 4 or 8 g)	Cellulose	39 (18M/21F), IGT, BMI ≥ 27	2 h	iAUC: HPMC 4 and 8 g < control	iAUC: HPMC 2, 4 and 8 g < control
Kim et al. 2009	Randomised Crossover	Breakfast (CHO ~ 62 g) β -glucan (barley) 0, 2.5, 5, 7.5, 10 g		17 (F); NGT, increased risk for IR, BMI ~33.2	3 h	10 g < 0, 2.5, 5 g at peak 30 min; AUC, NS	10 g < 0, 2.5, 5, 7.5 g at 30, 60 min; AUC: 10 g < 0, 5 g (LR)
Jenkins et al. 2008	Randomised Controlled SB	Breakfast (Biscuits, CHO 50 g) PolyGlycopleX (PGX) 70% glucomannan, 30% xanthan 10 g	Control (0 g)	9 (3M/6F), T2DM, BMI 28.8	3 h	PGX < control 30, 60, 90, 120, 150, 180 min	-
Nazare et al. 2009	Randomised Crossover SB	Breakfast (CHO ~ 72 g) β -glucan (oats) 5 g	Control (0 g)	12 (M), BMI 27.5, fasting insulin 49	6 h	AUC (120-360 min): 5 g > 0 g	AUC: (120-360 min), 5 g > 0 g
Chearskul et al. 2007	Crossover Controlled SB	Purified glucomannan 1 g with 200 mL water 30 min before 75 g oral Glc	White Rice Flour (1g)	20 (10M/10F), T2DM, BMI (M 25.1, F 27.4)	2 h	Glc increase, glucomannan < placebo 1 to 2h	Ins: NS
Flamang et al. 2006	Randomised, Crossover DB	Breakfast (crispy bar, CHO 50 g) GG 8.4 g	Control 1) DF 0 g 2) DF < 5 g	60 (41M/9F), T2DM, BMI 30.2,	4 h	30, 45, 60, 90, 120 min: GG < control; 240 min: GG > control (1 only) ; AUC: GG < control	30, 45, 60, 90, 120, 180 min GG < control Min; AUC : GG < Control
Tapola et al. 2005	Randomised Controlled	Breakfast 1) OBF, CHO 12.5 g, DF 19.5 g (β -glucan 9.4 g); OBC CHO 12.5 g, DF 6.3 g (β -glucan 3.0 g); 2) CHO 6.1 g, DF 9.5	Glc	12 (7M/5F), T2DM	2 h	1) OBF/OBC < gluc (15, 30, 45 min) OBF/OBC > Glc (90 min); AUC (0-60 min, 0-120	

		g (β -glucan 4.6g)				min): OBF < Glc; AUC (0-60 min): OBC < Glc; 2) OBF < Glc at 30, 45, 60 min; OBF > Glc at 120 min; AUC (0-60 min, 0-120 min): OBF < Glc	
Rendell et al. 2005	Crossover DB	Breakfast prowash barley meal (CHO 20 g, DF 23 g, soluble 10 g); oatmeal (CHO 44 g, DF 7 g, soluble 3 g); LMR (CHO 35 g)	LMR	18 (12M/6F), T2DM, BMI 33	3 h	Prowash < oatmeal, replacer at 30, 60 min iAUC: prowash < oatmeal, replacer	Prowash < oatmeal, replacer at 30, 60 min iAUC: prowash < oatmeal, replacer
Jenkins et al. 2002	Randomized Crossover Open-label	Breakfast (CHO 50 g) WB (DF 2.6 g); oat bran cereal (DF 10.3 g, 3.7 g β -glucan); high β -glucan cereal (14.9 g, 7.3 g β -glucan); - high β -glucan bar (DF 17.7 g, β -glucan 6.2 g)	WB	16 (10M/6F), T2DM, BMI 29	3 h	high β -glucan cereal, bar < WB, oat bran at 60, 90, 120 min; AUC, high β -glucan cereal, bar < WB, oat bran	-
Tappy et al. 1996		Breakfast cereals (CHO 35 g) β -glucan 4.0, 6.0, 8.4 g	Continental Breakfast	8, T2DM		Glc increase, 8.4, 6.0, 4.0 g β -glucan < control AUC: linear inverse β -glucan	Ins increase 8.4, 6.0, 4.0 g β -glucan < control
Guévin et al. 1996		Breakfast (DF 10 g and 20 g) soluble:insoluble ratios 1:4 vs. 2:3		8, T2DM/ hypertriglyceridemic	4 h	iAUC: 20 g < 10 g soluble insol ratio, NS	iAUC: 20 g < 10 g soluble insol ratio, NS
Gatenby et al. 1996	Randomized Crossover	Breakfast (CHO 75 g) GG (low, med., high MWt) 7.6 g GG/ meal	Control Meal	14, T2DM		Glc increase, GG < control	Ins increase, GG < control
Braaten et al. 1994		Porridge meals (Farina); isolated β -glucan, oat gum; - native β -glucan, oat bran; farina meal	Farina Meal	T2DM	3 h	oat bran, gum < control	oat bran, gum < control
Sels et al. 1992		Spaghetti meal (CHO 51 %); - T. aestivum; T. durum wheat with/without		6, T2DM		iAUC: GG vs. no GG, ns IGP lower at 60 and 90 min	

		wheat with/without 20 g % GG				60 and 90 min after GG T. aestivum	
Libren ti et al. 1992	Rando mized Cross- over	Breakfast soya fiber 7 g; purified cellulose 7 g - ingested before standard breakfast		8, T2DM		Glycemic profiles, soya < cellulose AUC: soya fibre < cellulose	Ins profile, ns
Pastor s et al. 1991	Rando mized Crossov er Controll ed	Breakfast (CHO 73 g) psyllium 6.8 g (in 240 ml of water) vs. placebo before breakfast	Placebo	18 (6 M/12 F), T2DM, overweight / obese	5 h	psyllium < placebo up to 90 min; AUC, ns	psyllium < placebo up to 90 min; AUC, psyllium < placebo
Torsd ottir et al. 1991	Rando mized Crossov er	Breakfast (CHO 48 %) meals with/ without sodium alginate 5.0 g (algae-isolate, 75% soluble)	Fibre- free meal	7(M), T2DM, BMI 25.6		alginate < fibre free at 105 min	alginate < fibre free at 15, 60, 90 min
Del Toma et al. 1988	Rando mized Crossov er	low fibre (LF); high soluble fibre (HSF); high insoluble fibre (HIF)		10, T2DM		HSF < LF, HIF LF vs. HIF, NS	HSF < LF, HIF LF vs. HIF, NS
Del Toma et al. 1988	Rando mized crossov er	Lunch (CHO 45 %) LF (6.7 g, sol. 2.0 g); HF (32.9 g, sol. 14.3 g)		13 (8 M/5F), T2DM, BMI 27	3 h	HF < LF at 30, 45, 60, 90 min	HF vs. LF, NS
Tsai et al. 1987	Rando mized Crossov er	Breakfast, (CHO 48.5 %) noodles with/without soy 10 g	Fibre- free Meal	7 (3 M/4F), T2DM/ obese	4 h	Soy < fibre-free at 180, 240 min	Soy vs. fibre-free , NS
Mclvo r et al. 1985		Breakfast high-CHO HF (HCF) bar consumed alone or with meals	Placebo Bar absorbab le CHO and GG	20, T2DM		HCF < placebo (early PP period); bars with HCF < placebo (90 to 240 min)	
Hagan der et al. 1984		Breakfast HF and LF		8, T2DM	3 h	Glc increase/decrease, HF < LF; iAUC: HF < LF	
Jenkin s et al. 1976	Rando mized Crossov er	Test meals, CHO 106 g; control; control + GG 16 g, pectin 10 g		1) 8, T2DM (non-insulin-requiring) 2) 3, T2DM (insulin-		1) Glc decrease, GG + pectin > control from 30 to 90 min 2) Glc decrease, GG+pectin >	1) Ins decrease, GG+pectin > control from 30 to 120 min

				dependent)		control	
Weickert et al. 2005	Randomised Crossover SB	Insoluble cereal fibre extracts from oat and wheat, and resistant starch, baked in white bread	WB	14F, healthy	24 h	Reduced AUC glucose in a second meal test in all interventions vs. control	ns difference between diets, trend to lower AUC insulin
Weickert et al. 2006	Randomised Crossover SB	Insoluble cereal fibre extract from oat, baked in white bread	WB	17F, overweight /obese	72 h		Improved whole-body IS vs. control, EHC
Weickert et al. 2011 (1)	Randomised Crossover SB	HCF diet supported by twice daily supplements	Healthy (ADA) HP MF/ Protein + supplements	111, overweight / obese/ metabolic syndrome	18 wks		Improved whole-body IS vs. HP, EHC NS IS (HOMA-IR)
Robertson et al. 2003	Randomised Crossover	RS	Waxy Maize Starch	10, healthy	24 h		Estimated IS (SI oral); iAUC C-peptide/insulin
Robertson et al. 2005	Randomised Crossover	RS	Rapidly digestible starch	10, healthy	4 wks		Increased IS using EHC
Johnston et al. 2010	Randomised Parallel SB	RS	Rapidly digestible starch	20, healthy	12 wks		Increased IS using EHC
Nilsson et al. 2008	Randomised Crossover	Barley or kernel breakfast	WB	12, healthy	1 d	Improved iAUC glucose	Improved iAUC insulin
Pereira et al. 2002	Randomised Crossover	Diet containing whole grains	Refined Grain Diet	11 overweight / obese hyper-insulinemic adults	6 wks		Improved whole-body IS vs.refined grain diet, EHC
Chandalia et al. 2000	Randomised Crossover	HF diet (24 vs 50 g/d) oats, lima beans, sweet potatoes), no supplements	Healthy (ADA)	17 (16M/1F), T2DM, 45-70 y	6 wks	improved glycemic control (plasma glucose, urinary glucose, HbA1c)	decreased hyper-insulinemia (plasma insulin)
Jenkins et al.	Randomised	HCF diet (27-32 g/d vs 25-27 g/d)	Low GI	210 (128M/82F)	6 m	HbA1c reduced in	

2008	Parallel	whole grain bread, brown rice, whole wheat cereals), T2DM, 60 y, BMI 31		low GI vs. HCF	
Wolever et al. 2008	Randomized Parallel	Low GI vs. low CHO (21 vs 36 vs 23 g/d) branbuds cereals, rye pumpernickel bread, beans	High GI	162, T2DM, 35-75 y, BMI 24-40	1 y	HbA1c NS DF PPG reduced (low GI diet)	
Sorensen & Johansen 2010	Randomized Crossover	FOS dissolved in water 20 g/d (31-40 g/d from the diet)		12 (6M/6F), IRH, 41-75 y, BMI 20-29	2 wks	supplemental dietary fibre reduced glucose excursions in IRH	
de Natale et al 2009	Randomized Crossover	HCF diet (53 vs 15 g/d) whole grain cereals legumes, veg.	LC-high MUFA Diet	18 (12M/6F), 59 y, T2DM, BMI 27	4 wks	PPG reduced	PP insulin response reduced
Schwab et al 2006	Randomized Parallel	Sugar beet pectin +16 g/d (24-30 g/d fibre from the diet)	PDX Drink	66 (29M/37F), T2DM 10 IGT, IFG, 53 y, BMI 28	12 wks	ns fasting glucose	

DB, double blind; SB, single blind; HPMC, hydroxypropylmethylcellulose; EHC, euglycemic hyperinsulinaemic clamp; IS, insulin sensitivity; HOMA-IR, homeostasis model assessment for insulin resistance; LMR, liquid meal replacer; IFG impaired fasting glucose; IGT, impaired glucose tolerance; IRH, idiopathic reactive hypoglycemia; NGT normal glucose tolerance; LR, linear response, OBF, oat bran flower; OBC, oat bran crisp; L(H)F, low (high) fibre, L(H)IF, low (high) insoluble fibre, L(H)SF, low (high) soluble fibre, MF, moderate fibre; HP, high protein; iAUC, integrated area under the curve; AUC, area under the curve; CHO, carbohydrate; DF, dietary fibre; RS, resistant starch; GG, guar gum; WB, white bread; NS, no significant effect; T2DM, type 2 diabetes; Glc, glucose; IGP, Incremental Glucose Peak; IIP, Incremental Insulin Peak; BMI, body mass index (kg m^{-2} ; expressed as mean unless otherwise specified).

Table 3: Non digestible carbohydrates with prebiotic properties on blood parameters related to glucose homeostasis

Reference	Design	Subjects	Source	Control	Duration	Outcome measures	Outcome
Lu et al. 2004	Randomized Crossover	15 (9F/6M), T2DM, 60±2 y, BMI 28.1±0.9	Bread/Muffins with arabinoxylan (14%) 15.1 g/d arabinoxylan	arabinoxylan 0%	6 wks	fasting and 2h Glc, insulin, urinary Glc HbA _{1c} , plasma insulin	decrease in fasting glycemia, decrease in post-OGTT glycemia&insulinemia
Garcia et al. 2006	Randomized Crossover SB	11 (7F/4M), IGT, 60 y; BMI 31	WB supplemented with arabinoxylan (15 g) 15 g/d	WB	6 wks	fasting serum Glc, insulin	fasting serum glucose was significantly lower than placebo
Garcia et al. 2007	Randomized Crossover SB	11 (7F/4M), IGT, 55.5 y, BMI 30.1	WB supplemented with arabinoxylan (15 g) 21 vs. 36 vs. 23 g/d	WB	6 wks	PPG and PPI	lower postprandial responses in serum glucose and insulin after a liquid meal challenge test in supplemented group
Parnell et al. 2009	Randomized Crossover DB Placebo-controlled	48 overweight/obese, 20-70 y, BMI >25	Supplement 21 g/d oligofructose	Maltodextran	12 wks	Serum Glc and insulin	decrease in body weight, decrease in caloric intake, increase GIP ns fasting glucose, insulin, GLP-1 PYY, leptin <i>After MTT</i> decreased glycemia, decreased insulin, increased AUC for PYY, ns AUC for GLP-1, ns GIP
Luo et al. 2000	Crossover DB	10 94F/6M) T2DM	Short-chain fructans 20g/d with coffee, tea or yogurt	Sucrose 20g/d	4 wks	fasting Glc, fasting insulin, ITT	NS for caloric intake, body weight, glucose, insulin, hepatic glucose production, insulin-stimulated glucose metabolism
Daubioul et al. 2005	Randomized Crossover DB	7M overweight with non-alcoholic steatohepatitis 37-66 y, BMI 29	Oligofructose 16 g/d with breakfast and dinner	Maltodextran	8 wks	fasting Glc, fasting insulin	decrease in fasting insulin, NS for fasting glycaemia

DB, double blind; SB, single blind; T2DM, type 2 diabetes; Glc, glucose; PPG postprandial glycaemia; PPI, postprandial insulinaemia; WB, white bread, NS, non-significant change, BMI, body mass index (kg m^{-2} ; expressed as mean unless otherwise specified).

Table 4: Dietary fatty acids and postprandial glycaemic control

Reference	Design	Subjects	Source	Daily Intake	Duration	Outcome measures	Outcome
Scalfi et al. 1991	Randomized Crossover	6 Lean: 28 ± 1.5 y, BMI 23.1 ± 0.7 ; 6 Obese: BMI 35.1 ± 3.7 , 47.1 y, Italy	FA length: MCT oil C6:0 2%, C8:0 56%, C10:0 40%, and C12 2% est. with glycerol LCT = corn oil	Test Meal: 15% protein, 58 g; 55% CHO, 194 g; and 30% fat, 38g	6 h	iAUC, indirect calorimetric for RMR, glucose oxidase method and immunoassay for insulin	resting metabolic rate decreased when LCT were replaced by MCT; incremental Glc AUC lower in lean but not obese subjects after MCT, NS for chain length on insulin or free fatty acids
Zambon et al. 1992	Randomized Crossover	10M, T2DM; 64 ± 2 y; BMI 28.6 ± 1 , USA	n-3 capsules	8 g/d	8 wks	iAUC plasma Glc and insulin	decreased IR to meal with fish oils in presence of glyburide compared to drug alone. NS for HDL and triglycerides
Lerman-Garber et al. 1994	Randomized Crossover	12F, T2DM, Mexico	Avocados high source of MUFA	n/a	4 wks	blood samples pre- and post	glycemic control was similar with both diets. MUFA diet was associated with a greater decrement in plasma triglycerides (20 vs. 7% in the high CHO diet).
Rivellese et al. 1996	Placebo DB Parallel	16, T2DM, 35-75 y, BMI 24-40, Italy	Fish oil supplements EPA/DHA	2.7 g/d for 2 m then 1.7 g/d for 4 m	6 m	euglycemic hyper-insulinemic clamp	NS for fish oil on insulin stimulated Glc uptake. reduction in TG but not Glc after intervention.

Christianse n et al. 1997	Randomized Crossover	16 (7 post- menopausal F/9M), free- living obese T2DM, 55 ± 3y BMI 33.5±1.2, Denmark	Saturated FA diet, cis-MUFA diet, trans-MUFA diet	20 g/d (31- 40 g/d from the diet)	6 wks	incremental serum insulin, fasting and 2h plasma Glc, insulin and C- peptide	decreased serum insulin and C- peptide following cis-MUFA (NS for control) compared with trans-MUFA and saturated FA diets. NS for fasting levels of serum lipids (total cholesterol, TG, phospholipid, and nonesterified fatty acids) or lipoproteins of HDL, VLDL, LDL and apolipoprotein B
McCargar et al. 1998	Randomized Prospective	32 T2DM Canada	CHO and Fat Ensure with Fat or Glucerna	n/a	4 wks	PPG	PP rise in blood Glc was lower on MUFA diet. NS for fasting plasma Glc, fructosamine, TG and cholesterol levels
Madigan et al. 2000	Randomized Crossover	11M T2DM, HbA1c 5.7 ± 0.8%, 56.0 ± 2.5 y, Ireland	isocaloric diet, high MUFA (olive) or PUFA (sunflower). Meal: High-fat breakfast, 50 g Glc load (30 min). WB fried in oil 1,100 kcal, 55% fat	30 mL/daily	8 h	Fasting Glc and Insulin	plasma cholesterol, LDL, chylomicron Apo B48 & Apo B100 , PP chylomicron, VLDL Apo B48 & B100 higher on the linoleic acid diet. Fasting Glc/ insulin higher after PUFA compared to MUFA.
Piers et al. 2003	Randomized Crossover	8M, obese/ overweight	Total E from SFA, MUFA & PUFA 24, 13 and 3 % on SFA diet; 11, 22 and 7 % on MUFA diet. In selected foods.	4 wks	5 h	Fasting Glc and Insulin	lower weight -2.1 ±0.3 kg & fat mass -2.6 ± 0.6 kg on MUFA vs. SFA rich diet. Blood Glc - 0.04±0.6 mM (SFA) &-0.15 ± 0.53mM (MUFA); insulin +0.2±3.68 (SFA) & -0.66±2.44 (MUFA)
Thomsen et al. 2003	Randomized Crossover	12, T2DM, overweight, 64±4 y, BMI 27.9 ± 5.3, HbA1c 6.9± 0.8%, Denmark	Control: Soup CHO 50 g, Control + 100 g butter, Control + 80 g olive oil		8 h	iAUC	iAUC: lower for olive oil vs. control, NS for fat-induced insulin, plasma TG and chylomicron TG highest after butter, HDL decreased after butter but NS after olive oil. GLP-1 responses highest after olive oil
Brady et	Randomised	29, T2DM,	Moderate (olive	6 wk daily	8 h	iAUC	NS for fasting or PP plasma

al. 2004	Parallel DB	48 +2yr; BMI= 26 Fasting Glc = 5.3 mM, Asian UK	oil) or high (corn oil) n-6 PUFA oils. Test breakfast : energy (3904 kJ), fat (49 g) CHO (109 g) protein (18 g)	supplement of n-3 LC-PUFA fish oil (4.0 g); EPA + DHA (2.5 g) in combination			triacyl-glycerol or apo B48 for moderate and high intervention groups after fish-oil treatment. Over entire study period: reduction in fasting plasma TG (20%). AUC and iAUC: reduction in PP TG
Manning et al. 2004	Randomized Crossover	18, T2DM (2 -60 m) non-smokers, 61 ± 10 y, BMI 28.5 ± 4.4 fGlc 6.8 ± 1.7 mmol/l, HbA _{1c} 6.5 ± 0.6%, Canada	meals of starch +/- SFA or MUFA		6 h	FBG mM, insulin pM	NS for PPG and PPI after fatty meals, CHO increased PPG and PPI, FFA and TG increased in fat diets at 4h and 6h. IL-6 decreased after 1h and TNF-α decreased after 4 and 6h in all diets
West et al. 2004	Randomized Crossover DB	18, T2DM (duration 4.4 ±1.6 y), HbA _{1c} 7.2%, 55.1±2 y, fGlc = 7.69 ± 0.35 mM, fl = 12 ± 1.5 uU/ml, BMI 29.2, US	Test meal: n-3 PUFA, prepared in 473 mL skimmed milk, flavourings designed to mask the characteristic aroma and flavours of the oils	50 g fat from three blends of unsaturated fatty acids	4 h		correlation between PP change in flow-mediated dilation and PP increase (absolute change) in TG for MUFA alone were as follows: r=-0.50, p<0.05 for the MUFA meal; r=0.49, p=0.052 for the EPA/DHA meal; and r=0.49, p=0.046 for the ALA meal. NS for meal composition on Glc levels
Lefevre et al. 2005	Crossover	Overweight, FABP Ala54 homozygous or Thr54 carriers, US	Breakfast: provided 40% of their daily energy requirement and containing 50% of energy as fat		8 h	PPG	NS for PPG between diets but Thr54 allele increased PPG, fractional TG synthesis rates were higher after trans fats in Thr54 carriers only
Paniagua et al. 2007	Prospective Crossover	overweight , family history of	Breakfast isocaloric : virgin olive oil		Single meal effect	FBG, Homa-IR, iAUC for insulin and Glc	MUFA decreased fGlc and increased IS, PPI and PPG, iAUC decreased with MUFA vs.

		obesity and T2DM, BMI > 25 Kg/m ² , WC (M/F) > 102/ 88, HBA1c < 6.5%, IR after OGTT, Spain	compared high CHO or high in saturated fat (SAT)				isocaloric CHO rich breakfast, GLP-1 increased with MUFA and SAT; HDL cholesterol increased with MUFA (fasting and PP), fasting proinsulin and stimulated proinsulin NS for MUFA diet
Deveraj et al. 2008	Randomized Crossover	11 metabolic syndrome, US	Breakfast: AHA vs. SFA. Control: breakfast E 914, protein 14.1%, CHO 36%,fat 50%		2h & 8 h		Glc levels significantly increased compared to pre-meal after both meals i.e. NS
Li et al, 2008	Controlled Parallel, DB	127, T2DM 40-65 y, China	diacylglycerol (DG) compared to triacylglycerol (TG)	25 g/day oil for 120 d		fasting measurements taken at days 0, 60, 120, No PP study	reduced body weight, BMI, waist circumference, HOMA-IR, serum insulin and leptin levels in DAG vs. TG vs. baseline, serum Glc improved in patients with higher Glc at baseline in the DG, NS for liver/kidney function and FA in serum phospholipids
De Natale et al. 2009	Randomized Crossover	18, T2DM, 59 ± 5 y, BMI 27 ± ; A1C 6.9 ± 0.7%	isoenergetic diet, low CHO and high MUFA vs. high CHO, High fibre	For 4 wks	6 h	mM, glycaemic variability and IAUC	Increased Glc following fibre vs. MUFA diets at 2h & 3 h, increased lipids, triacylglycerols following fibre vs. MUFA diets, NS for cholesterol, plasma Glc & insulin higher 6 h after thigh CHO/high fibre meal vs. high MUFA meal
Sloth et al. 2009	Randomized	131, 8-week weight loss diet, Denmark	High MUFA, low GI MUFA , moderate -fat (35-45 E%) high in MUFA with low GI, low fat (20-30 E%),		6 m	PPG, PPI	Decreased PPG and PPPI on MUFA or low fat vs. control/western diet, NS for fasting insulin, pancreatic polypeptide, peptide YY, glucagon-like peptide-1 and glucagon-like peptide-2 lowered after weight loss diet

			control (35 E%)				
Li et al. 2011	Randomized Crossover	20 (9M,11F) T2DM, China 58 years, BMI=26kg/m ²	fibre, MUFA and PUFA in almonds	NCEP step II diet with or without 60g almonds	12 wks	fl, fBG, IR	almond diet had lower levels of fasting Glc, insulin and homeostasis model assessment of insulin resistance index, respectively, decreased total cholesterol, LDL, LDL/HDL
Lopez et al. 2011	Crossover		MUFA vs. SFA vs. no fat in enriched meals. Test meal no fat isocaloric meal	14.9% SFA, 81.0% MUFA, 4.1% PUFA (olive oil); 65.3% SFA, 31.3% MUFA, and 3.4% PUFA (butter)	8h	PPI	high-fat meals significantly increased TG, nonesterified fatty acids, and insulin and PP indexes of β cell function. However, PP indexes of IS decreased and were attenuated with MUFA relative to SFA
Jans et al. 2012	Randomized Crossover SB	10M obese (IR), Holland	PUFA vs. MUFA vs. SFA, 3 high-fat mixed meals (2.6 MJ), which were high in SFAs, MUFA, or PUFA	2.6MJ high fat mixed meal	6 hours	Fasting and PP skeletal muscle FA, skeletal muscle biopsy, AUC	AUC (Glc and insulin): significantly higher for SFA vs. PUFA, TG-derived FAs lower in the PP phase after PUFA meal c.f. other meals, fractional synthetic rate of the TG, DG, and phospholipid pool was higher after the MUFA meal vs. SFA
Kelley et al. 2012	Placebo-controlled Parallel	14-17M hypertriglyceride mic	DHA without EPA vs. control	3 g/d vs. 0 g/d supplement	90 d	Fasting plasma Glc and insulin, PPG, PPI, AUC Matsuda index	increased fasting plasma Glc with DHA. NS for indices of fasting IR, PPI and PPG. AUC: NS increased Glc in placebo (2.7%). NS for both groups. DHA decreased several lipocentric markers of IR,

							including circulating non-esterified fatty acids, small, dense LDL particles and TG/HDL ratio, NS for placebo
--	--	--	--	--	--	--	---

DB, double blind; NS, no significant effect; IR, insulin response; T2DM, type 2 diabetes; AUC, area under the curve; CHO, carbohydrate; F, female; M, male; FA, fatty acid; PUFA, polyunsaturated fatty acid; MUFA, monounsaturated fatty acid; SFA, saturated fatty acid; Glc, glucose; fGlc, fasting glucose, WC, waist circumference; IR, insulin resistant; IS, insulin sensitivity ; TG, triglycerides; HDL, high-density lipoprotein; VLDL very low-density lipoprotein; LDL, low-density lipoprotein; PPG postprandial glycaemia; RMR, resting metabolic rate; PPI, postprandial insulinaemia; BMI, body mass index (kg m^{-2} ; expressed as mean unless otherwise specified).

Table 5: Dietary vitamins and minerals and postprandial control

Reference	Design	Subjects	Source	Daily intake	Duration	Outcome measures	Outcome
Neri et al. 2005	Controlled SB	46, T2DM, 41±3 y, BMI 24±2, USA	Vitamin E, vitamin C and N-acetyl cysteine	8 g/d	8 wks	iAUC plasma Glc and insulin	Only measured at baseline
Frauchiger et al. 2004	Randomized Crossover SB	13M, healthy, non-smoking, 23.8-25.6y, BMI 22-23	Test meals (75g CHO) WB with added chromium	Placebo vs. 400 µg vs. 800 µg	8 h	Glc tolerance test, AUC plasma insulin	30% - 36% reduction in capillary Glc AUC with 400 µg Cr in 10 responders
Anderson et al. 1997	Randomized Crossover DB	180 (M/F), T2DM	Normal diet supplemented with chromium picolinate	Placebo vs. 200 µg/d vs. 1000 µg/d	4 m	HbA _{1c} fasting Glc and insulin; 2 h Glc and insulin	HbA _{1c} , fasting, 2h Glc and insulin significantly reduced in patients supplemented with Cr for 4 months
Cheng et al. 1999	Follow-up survey	833, T2DM	Supplementation (500 µg/d) with chromium picolinate	500 µg/d	10 m	fasting and PPG	fasting Glc and PPG improved in >90% of subjects, and similar improvements occurred after 1–10 months. Fasting Glc level and PPG lowered in 1 month and remained significantly lower in the following 9 months.

DB, double blind; SB, single blind; Cr, chromium; NS, no significant effect; IR, insulin response; WB, white bread;

T2DM, type 2 diabetes; Glc, glucose; HDL, high-density lipoprotein; PPG postprandial glycaemia; BMI, body mass

index (kg m⁻²; expressed as mean unless otherwise specified).

Table 6: Effect of phytochemical rich sources (cocoa, plant extracts) on postprandial glycaemia

Reference	Design	Subjects	Source	Daily intake	Duration	Outcome measures	Outcome
Grassi et al. 2008	Randomized Crossover DB	19 (11M/8F), IGT (no diabetes), 44.8±8.0 y, BMI < 30	Dark chocolate bar (epicatechin, catechin, procyanidin) Control: WC	100 g/d	15 d	OGTT, AUC, lipids, CRP, endothelial function	decreased HOMA, increased QUICKI, PPG (p<0.0001)
Grassi et al. 2005	Randomized Crossover DB	15 (7M/8F), healthy, 44.8±8.0 y	Dark chocolate bar (epicatechin, catechin, procyanidin) Control: WC	100 g/d	15 d	OGTT, AUC, lipids, CRP, endothelial function	decreased HOMA, increased QUICKI, PPG (p<0.0001)
Muniyappa et al. 2008	Randomized Crossover DB	20 (7M/13F), 13 White, 7 African Americans, mild-moderate hypertension 21-65 y	Flavanol-rich cocoa drink (epicatechin, catechin, procyanidin)	300 ml/d contains ~900 mg flavanols/d	2 wks	Glc clamp, metabolites, endothelial function, BP	NS for IR
Kar et al. 2009	Randomized Crossover DB	32 (16M/16F), T2DM, 61.8±6.36 y, BMI 31.2±5.92	Grape seed extract (flavonoids, other phenolics)	600 mg/d	4 wks	HOMA-IR, fructosamine, endothelial function, CRP	decreased fructosamine, NS for HOMA-IR
Serraclara et al 1998	Randomized Crossover DB	10 (6M/4F), IDMM, 22-38 y BMI 20.8±3.0	Fig supplement (flavonoids, other phenolics) Control: non-sweet commercial tea control	53 vs. 15 g/d	1 m	2h PP lipids	decreased plasma Glc
Lehtonen et al 2010	Randomized Parallel	10, healthy, 20-34 y, BMI 19.8-26.9	Sea buckthorn extract in yogurt (flavanol glycosides)		6 h	OGTT, AUC	decreased plasma Glc/insulin

Torronen et al. 2010	Randomized Crossover	12 (2M/10F), Healthy, 25-69 y BMI 25.4±2.9	Berry puree (flavonoid, other phenolics) Control: carbohydrate drink	150 g	3 h	15, 30 min plasma Glc	decreased plasma Glc
Goni et al. 2000	Crossover	12F, healthy, 22.08±1.44 y, BMI 2.19±2.78	Nori alga with WB	3 g	2 h	OGTT, AUC	Decrease in PPG
Markey et al. 2011	Randomized Crossover SB	9 (3M/6F), healthy, 26.2±3 y, BMI 22.4±2.5	High-fat meal supplemented with cinnamon or placebo	3 g	360 min	OGTT, AUC Arterial stiffness, BP	NS for PPG

DB, double blind; SB, single blind; WC white chocolate; NS, no significant effect; IR, insulin response; WB, white bread; T2DM, type 2 diabetes; Glc, glucose; HDL, high-density lipoprotein; PPG postprandial glycaemia; IGT, impaired glucose tolerance; BMI, body mass index (kg m^{-2} ; expressed as mean unless otherwise specified) iAUC, integrated area under the curve; AUC, area under the curve; CHO, carbohydrate; DF, dietary fibre; OGTT, oral glucose tolerance test; HOMA-IR, homeostasis model assessment for insulin resistance; CRP c-reactive protein.

Table 7: Effect of ginseng on postprandial glycaemia

Reference	Design	Subjects	Source	Daily intake	Duration	Outcome measures	Outcome
Sievenpiper et al. 2003	Randomized Controlled Crossover	11 (8M/3F), 29±3 y, BMI 28.5±2.1; 11 (6M/5F), 27±3 y, BMI 26.9±1.4	Asian Ginseng	1) 0, 1, 2, 3 g; 2) 0, 3, 6, 9 g	120 min	OGTT	decreases in PPG American c.f. Asian
Sievenpiper et al. 2003	Randomized, Crossover SB	12 (6M/6F), 31±3 y, BMI 28±2	American Ginseng	6 g	120 min	OGTT, iAUC	NS for AG on iAUC Glc
Sievenpiper et al. 2004	Randomized, Multiple-Crossover DB	12 (6M/6F), healthy, 34 ±3 y, BMI 25.8±1.2, Canadian	American, American-wild, Asian, Asian-red, Siberian, Vietnamese-wild, Sanchi and Japanese-rhizome, Ginsengs (alkaloids, ginsenosides)	3 g	120 min	OGTT	American Ginseng and Vietnamese Ginseng decreased 90 min PPG; Asian Ginseng increased peak-PPG and AUC-PG; American-wild Ginseng increased 120 min PPG and Siberian Ginseng increased 90 min PPG, 120-min-PG, and AUC-PG.
Sievenpiper et al. 2006	Randomized Crossover DB	7 (3M/4F), healthy, 32±4 y, BMI 24±2; 12 (9M/3F), healthy, 29 ±3 y, BMI 22.5 ±1	Korean Ginseng (ginsenosides, alkaloids)	0g (placebo) and 6 g KRG-rootlets, -body, and -H2O extract	120 min	OGTT, AUC	decrease in PPG
Dascalu et al. 2007	Randomized Crossover Placebo controlled	12 (5M/7F), healthy, 26.5 ±2 y, BMI 23.96 ±3.41, Canadian	American ginseng (5 farms), whole, dried and ground root	9 g, 40 min before 75 g OGTT, placebo 500 mL water	2 h	OGTT	1 mM reduction peak Glc, 28% reduction iAUC, 24% reduction iAUC insulin. NS for 2 batches
Reay et al 2006	Balanced-Crossover DB Placebo-controlled,	1) 30 healthy, BMI 22.6±5.46, 2) 27 healthy, BMI 1.89±4.46, UK	Asian Panax Ginseng Extract (G115)	1) placebo, 200 or 400mg 2) placebo, 200 mg placebo and	2h	OGTT	1) decreased Glc at 60, 90, 120 mins 2) decreased Glc at 60 min for ginseng vs placebo. Higher Glc for ginseng and glucose compared to

				Glc (25 g) and 200 mg 30 mins before and Glc (25 g)			glucose alone.
Reay et al. 2009	Cross-over DB placebo-controlled,	1) 24 healthy, BMI 33.3±10.4 2) 18 healthy, BMI 41.5±9.7, UK	1) Asian Panax Ginseng Extract (G115); 2) Asian Panax ginseng extract Cheong Kwan Jang	200 mg/d	57 d	HbA1c, plasma insulin, blood Glc	Ns for HbA1c
Sotaniemi et al. 1995	DB placebo-controlled	36 T2DM, 60±6 y, 59±7 y, 57±9 y, Finland	Ginseng	100 mg or 200 mg	8 wks	Fasting blood Glc, HbA1c	100 mg decreased fasting Glc 8.3 to 7.7 (p<0.05), 200 mg reduced HbA1c from 6.5 to 6.0 (p<0.05). NS for Glc, insulin, C-peptide over OGTT (75 g)
Tetsutani et al.	Not specified	34 T2DM	Korean Red Ginseng	3 - 4.5 g /d	4 m	HbA1c	Reduction in HbA1c
Vuksan et al. 2000	Randomized Crossover placebo controlled	10 (6M/4F), non-diabetic 41± 13 y, BMI 24.8 ± 3.5	American Ginseng, ground root, encapsulated (500 mg)	0, 3, 6 or 9 g	120 min	OGTT, AUC	All AG doses reduced AUC and IIG (3g, 26.6%; 6g, 29.3%; 9g, 38.5%). AG taken at different times did not influence PPG
Vuksan et al. 2000	Randomized Crossover SB placebo controlled	10 (6M/4F), T2DM, 63±2 y, BMI 27.7±1.5, Canadian	American Ginseng encapsulated, ground root (500 mg)	0, 3, 6, or 9 g	120 min	OGTT, AUC	3,6 or 9 g significantly reduced iAUC (19.7, 15.3 and 15.9%). NS for time of administration
Vuksan et al. 2000	Randomised Crossover placebo controlled	1) 9 T2DM, 62± 7 y, BMI 29±5 2) 10 healthy, 34±7 y, BMI 25.6±3	American ginseng	3 g	120 min	OGTT	1) reduction (19%) in iAUC 40 minutes before the Glc challenge, reduction (22%, p<0.05) when given glucose; 2) reduction (18%) in iAUC 40 minutes before the Glc challenge, NS when given together.
Vuksan et al. 2001	Randomized Crossover DB	10 (6M/4F), IDMM, 63±2 y, BMI 27.7±1.5	American Ginseng, Ontario-grown ground root encapsulated	0, 3, 6, or 9 g	120 min	OGTT	decreased PPG
Vuksan et al. 2001	Randomized Crossover SB placebo controlled,	12 healthy, 42 ±7 y, BMI 24.1 ± 1.1, Canadian	American Ginseng, dried and ground root encapsulated (500 mg)	0, 1, 2, or 3 g	120 min	OGTT	Decreased PPG (final 45 min) 1, 2, or 3 g ginseng c.f. placebo; decreased AUC (final hour) when administered 40 min c.f. 20, 10, or 0 min before the challenge
Vuksan et al. 2006	Randomized Crossover SB	19 (11M/8F), well-controlled	Korean Red Ginseng, root with meal (ginsenosides	2 g/meal=6 g/day	12 wks	OGTT, AUC	decrease in PPG

		T2DM, 64±2 y, BMI 28.9±1.4	alkaloids)				
De Souza et al. 2011	Randomized Crossover	13 (6M/7F), healthy, 28±10 y, BMI 24.1±3	Korean Red Ginseng with standard meal (ginsenosides alkaloids)	3g of KRG-body, rootlets or placebo	120 min	OGTT, AUC	27% decrease in glycaemic response
Heacock et al. 2008	Randomized Crossover	39 (15M/24F), healthy, 25.7±0.9 y, BMI 23.7±0.4	Beverage 480 mL (14 g fat, 82 g, CHO 20 g protein) with <i>S. oblonga</i> extract (salacinolkotalanol)	0, 500, 700, or 1,000 mg of <i>S. oblonga</i> extract	2 h	Finger prick	decrease in PPG/PPI
Collene et al. 2004	Randomized Crossover	43 (20M/23F), healthy, 23.5±0.6 y, BMI 23.9±0.4, 29 Caucasian, 1 African American, 8 Asian, 1 Latino	Control Beverage (C) 480 mL (14 g fat, 82 g CHO, 20 g protein), C plus phenylalanine and leucine (3.5 g, A); C plus <i>S. oblonga</i> extract (1000 mg, S), Control plus S and AA	1000 mg of <i>S. oblonga</i> extract	3 h	OGTT, AUC	decrease in PPG
Williams et al. 2007	Randomized Crossover DB	66 (53M/13F), T2DM, 61.3±1.2 y, BMI 28.8±0.4, 1 American Indian/Alaskan, 7 African American, 58 Caucasian	<i>S. oblonga</i> extract	240 mg and 480 mg	3 h	OGTT, AUC	decrease in PPG/PPI

DB, double blind; SB, single blind; IDMM, insulin-dependent diabetes mellitus NS, no significant effect; IR, insulin response;

WB, white bread; T2DM, type 2 diabetes; Glc, glucose; HDL, high-density lipoprotein; PPG postprandial glycaemia; IGT,

impaired glucose tolerance; BMI, body mass index (kg m^{-2} ; expressed as mean unless otherwise specified) iAUC, integrated

area under the curve; AUC, area under the curve; CHO, carbohydrate; DF, dietary fibre; OGTT, oral glucose tolerance test;

HOMA-IR, homeostasis model assessment for insulin resistance; CRP c-reactive protein.

Table 8: Effect of phytochemical rich sources (nuts and beverages) on postprandial glycaemia

Reference	Design	Subjects	Source	Daily intake	Duration	Outcome measures	Outcome
Josse et al. 2007		9 (7M/2F), healthy, 27.8±6.9 y BMI 22.9±3.6	50 g CHO from white bread +/- almonds phenolics, flavonoids, sterols	30, 60, 90 g almonds	120 min	OGTT, AUC	decreased PPG, lower serum cholesterol
Cohen et al. 2011	Randomized Crossover	1) 13 (2M/11F), healthy, 53.3±3 y; 2) 7 (4M/3F), T2DM, 66.3±3 y	test meal (bagel, juice, and butter) with or without almonds phenolics, flavonoids, sterols	28 g/d	120 min	OGTT, AUC	decreased PPG compared to T2DM; NS for iAUC insulin or 30 min GLP-1
Cohen et al. 2011	Randomized Parallel, Pilot	13 T2DM, 66±3.3 years, BMI 32.6±2.3 Control BMI 36.7±3.6	Almonds Control: cheese sticks	1 oz, 5 d/week	acute	HbA1c on fasting venous blood	HbA1c: -4% vs. +1%, p = 0.045 to T2DM
Kendall et al. 2011	Randomized Crossover	10, healthy, 48.3±6.4 years, BMI: 28±4.8	Pistachio consumed with/without WB (50 g CHO)	28,56 or 84 g	120 min		lower relative glyceamic response vs. WB
Mori et al. 2011	Randomized Crossover	14 IGT, 18-60y	75 g CHO matched breakfast (orange juice and cream of wheat) containing vehicle, whole almonds, almond butter, defatted almond flour or almond oil phenolics, flavonoids, sterols	42.5 g	acute	OGTT, AUC	decreased PPG

Jenkins et al. 2006	Crossover	15 healthy, 26.3±8.6 years, BMI 23.4±3.4	WB (50g CHO), WB and 60 g almonds, parboiled rice and mashed potatoes, these last 2 were balanced for fat (butter), protein (cheese)	60 g	240 mins	iAUC	insulin iAUC lower for almond and rice compared to potato.
Kendall et al. 2011	Randomized Crossover	14 healthy, 36 ±4 y, BMI: 21.8 + 0.6) 10 T2DM 68±2 years, BMI: 26.5±0.5	WB (50 g CHO) with or without 30, 60, 90 g mixed nuts	30, 60, 90 g	120 mins		1) 30, 60, 90 g reduced the GR by 11.2 + 11.6%, 29.7 + 12.2 and 53.5 + 8.5%; 2) 30, 60, 90 reduced the GR by 6.6 + 8.8%, 16.6 + 9.3 and 30.8 + 7.6
Brown et al; 2009	Randomized Crossover	46M, obese/ Overweight, 40-65 y	Green Tea, purified extract, > 97% epigallocatechingallate	Lactose	8 wks	OGTT, AUC HOMO, fasting Glc/insulin	no change in insulin sensitivity/ secretion or Glc tolerance
Josic et al; 2010	Randomized Crossover	14(7M/7F), healthy, 27 ± 3, BMI 22.3 ± 3.4	Green Tea, beverage + breakfast, flavan-3-ols	Water + breakfast	120 mins	OGTT	no Glc/insulin lowering, increased satiety
Bryans et al; 2007	Randomized Crossover	16(4M/8F), healthy, 35.5 ± 1.5 y, BMI 23.8 ± 0.7	Black tea, beverage, flavan-3-ols, theaflavins	Water, caffeine, Glc	120 mins	OGTT	late phase plasma Glcresponse/ elevated insulin
Johnston et al; 2003	Randomized Crossover	9, healthy, 26 ± 3.2 y, BMI < 25	Coffee, beverage (caffeinated/ decaffeinated chlorogenic acid caffeine	Water	3 h	OGTT	increased Glc/insulin; delayed GI glucose absorption
Nagao et al; 2009	Controlled DB	1) 23(15M/8F), T2DM (no ins.), 64.9 ± 1.6 y, BMI 25.6 ± 0.8 2) 20(10M/10F) 62.8 ± 2.2 y, BMI 24.0 ± 0.9	Green tea, (catechin rich) beverage, flavan-3-ols	Low-catechin beverage	12 wks	plasma glucose, insulin HbA1c	Increased insulin, waist circumference, & adiponectin

DB, double blind; SB, single blind; IDMM, insulin-dependent diabetes mellitus, NS, no significant effect; IR, insulin response; WB, white bread; T2DM, type 2 diabetes; Glc, glucose; HDL, high-density lipoprotein; PPG postprandial glycaemia; IGT, impaired glucose tolerance; BMI, body mass index (kg m^{-2} ; expressed as mean unless otherwise specified) iAUC, integrated area under the curve; AUC, area under the curve; CHO, carbohydrate; DF, dietary fibre; OGTT, oral glucose tolerance test; HOMA-IR, homeostasis model assessment for insulin resistance; CRP c-reactive protein.

Table 9: Effect of miscellaneous food sources (water and low-calorie sweeteners) on postprandial glycaemia

Reference	Design	Subjects	Source	Daily intake	Duration	Outcome measures	Outcome
Torsdottir et al. 1989	Randomized Crossover Controlled	7, healthy, 23-31y, BMI: 21.0-29.4; 20, T2DM well controlled: 46-67 y, BMI 21.5-31.8, Poorly controlled 44-71 y, BMI 19.2-27.6	Water, test meal: boiled potatoes, beef, fried in margarine (415 kcal, 55 EN% CHO, 2.8 fibre) with or without water	300 mL	180 min	iAUC	iAUC increase in Glc, 68% for healthy, 40% for well controlled DM2, NS for poorly controlled DM2, time to glucose peak: NS in HV, 58 (water) min vs. 69 in well controlled DM2, NS in poorly controlled DM2
Nehrling et al. 1985	Randomized Placebo-controlled Parallel DB	32 T1DM, 31 T2DM, mean 18-65 y	Aspartame, with meal	0.9 g x 3 for 18 wks		Fasting Glc/insulin, PPG and HbA1c	NS for fasting Glc, 2h PPG or HbA1c
Okuno et al. 1986	Crossover	7, healthy, 46.7 y	Aspartame or Glc 100 g	Single dose 500 mg	180 min		Small, but significant decrease in Glc (mean in healthy 7 mg/dl, 14-28 mg in 3 subgroups of DM). NS for insulin or glucagon
Okuno et al. 1998	Not blinded Not randomized	9 T2DM (hospitalized), mean 57 y, mean duration of diabetes 5 y	Aspartame, in jelly cake given as dessert, No control Group	125 mg for 2 wks	180 min	OGTT	NS for OGTT after 2 weeks, total cholesterol, HDL or triglycerides
Grotz et al 2003	Randomized Double blind Placebo-controlled	128, T2DM	Sucralose	667mg/d for 13 wks		Fasting Glc HbA1c serum C-peptide levels	NS fasting Glc, HbA1c or serum C-peptide levels
Mezitis et al 1996	Double blind Crossover	13, T1DM; 13, T2DM	Sucralose	Single dose 1000mg		IAUC Serum C-peptide levels	NS for IAUC or serum C-peptide levels

Raben et al 2011	Randomised Placebo-Controlled Parallel	33, healthy, 20-50y; BMI 25-30, 12 sucrose group, 11 sweeteners group	Foods and drinks Containing Sucrose (~2g/kg BW) or artificial sweeteners in the diet	10 weeks		Fasting Glc/insulin, IAUC PPG and HbA1c	NS for fasting Glc, 2h PPG or HbA1c
------------------	--	---	--	----------	--	---	-------------------------------------

DB, double blind; NS, no significant effect; T2DM, type 2 diabetes; T1DM, type 1 diabetes; Glc, glucose; HDL, high-density lipoprotein; PPG postprandial glycaemia; BMI, body mass index (kg m^{-2} ; expressed as mean unless otherwise specified) iAUC, integrated area under the curve; OGTT, oral glucose tolerance test.

Figure 1




Figure 1: Potential for dietary factors to reduce blood glucose levels and impact on β -cell function and associated biomarkers. GSIS, glucose-stimulated insulin secretion.

Figure 2




Figure 2: Overview of proposed mechanisms by which glucose and leucine stimulate insulin secretion. GK, glucokinase; PDC, pyruvate dehydrogenase complex; PC, pyruvate carboxylase; TCA, tricarboxylic acid; α -KG, α -ketoglutarate; AT, aminotransferase; BCKDH, branched-chain a-keto-acid dehydrogenase; GDH, glutamate dehydrogenase; KIC, a-ketoisocaproate. Adapted from van Loon *et al*; Current Opinion in Clinical Nutrition and Metabolic Care, 2012 15: 71-77